No	O
formal	O
drug	O
interaction	O
studies	O
of	O
Aranesp	O
?	O
have	O
been	O
performed	O
.	O

Hypertensive	O
crises	O
have	O
resulted	O
when	O
sympathomimetic	B-drug
amines	I-drug
have	O
been	O
used	O
concomitantly	O
within14	O
days	O
following	O
use	O
of	O
monoamine	B-drug
oxidase	I-drug
inhibitors	I-drug
.	O

DIDREX	B-drug
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
CNS	B-drug
stimulants	I-drug
.	O

Amphetamines	B-drug
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
antihypertensives	B-drug
.	O

Amphetamines	B-drug
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B-drug
antidepressants	I-drug
.	O

Urinary	O
alkalinizing	B-drug
agents	I-drug
increase	O
blood	O
levels	O
and	O
decrease	O
excretion	O
of	O
amphetamines	B-drug
.	O

Urinary	O
acidifying	B-drug
agents	I-drug
decrease	O
blood	O
levels	O
and	O
increase	O
excretion	O
of	O
amphetamines	B-drug
.	O

No	O
drugs	B-drug
are	O
known	O
to	O
interfere	O
with	O
the	O
conversion	O
of	O
fosphenytoin	B-drug
to	O
phenytoin	B-drug
.	O

Conversion	O
could	O
be	O
affected	O
by	O
alterations	O
in	O
the	O
level	O
of	O
phosphatase	O
activity	O
,	O
but	O
given	O
the	O
abundance	O
and	O
wide	O
distribution	O
of	O
phosphatases	B-drug
in	O
the	O
body	O
it	O
is	O
unlikely	O
that	O
drugs	B-drug
would	O
affect	O
this	O
activity	O
enough	O
to	O
affect	O
conversion	O
of	O
fosphenytoin	B-drug
to	O
phenytoin	B-drug
.	O

Drugs	B-drug
highly	O
bound	O
to	O
albumin	B-drug
could	O
increase	O
the	O
unbound	O
fraction	O
of	O
fosphenytoin	B-drug
.	O

Although	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
could	O
result	O
in	O
clinically	O
significant	O
effects	O
,	O
caution	O
is	O
advised	O
when	O
administering	O
Cerebyx	B-drug
with	O
other	O
drugs	B-drug
that	O
significantly	O
bind	O
to	O
serum	B-drug
albumin	I-drug
.	O

The	O
pharmacokinetics	O
and	O
protein	O
binding	O
of	O
fosphenytoin	B-drug
,	O
phenytoin	B-drug
,	O
and	O
diazepam	B-drug
were	O
not	O
altered	O
when	O
diazepam	B-drug
and	O
Cerebyx	B-drug
were	O
concurrently	O
administered	O
in	O
single	O
submaximal	O
doses	O
.	O

The	O
most	O
significant	O
drug	O
interactions	O
following	O
administration	O
of	O
Cerebyx	B-drug
are	O
expected	O
to	O
occur	O
with	O
drugs	B-drug
that	O
interact	O
with	O
phenytoin	B-drug
.	O

Phenytoin	B-drug
is	O
extensively	O
bound	O
to	O
serum	O
plasma	O
proteins	B-drug
and	O
is	O
prone	O
to	O
competitive	O
displacement	O
.	O

Phenytoin	B-drug
is	O
metabolized	O
by	O
hepatic	B-drug
cytochrome	I-drug
P450	I-drug
enzymes	O
and	O
is	O
particularly	O
susceptible	O
to	O
inhibitory	O
drug	O
interactions	O
because	O
it	O
is	O
subject	O
to	O
saturable	O
metabolism	O
.	O

Inhibition	O
of	O
metabolism	O
may	O
produce	O
significant	O
increases	O
in	O
circulating	O
phenytoin	B-drug
concentrations	O
and	O
enhance	O
the	O
risk	O
of	O
drug	O
toxicity	O
.	O

Phenytoin	B-drug
is	O
a	O
potent	O
inducer	O
of	O
hepatic	O
drug	O
-	O
metabolizing	O
enzymes	O
.	O

The	O
most	O
commonly	O
occurring	O
drug	O
interactions	O
are	O
listed	O
below	O
:	O
-	O
Drugs	B-drug
that	O
may	O
increase	O
plasma	O
phenytoin	B-drug
concentrations	O
include	O
:	O
acute	O
alcohol	O
intake	O
,	O
amiodarone	B-drug
,	O
chboramphenicol	O
,	O
chlordiazepoxide	B-drug
,	O
cimetidine	B-drug
,	O
diazepam	B-drug
,	O
dicumarol	B-drug
,	O
disulfiram	B-drug
,	O
estrogens	B-drug
,	O
ethosuximide	B-drug
,	O
fluoxetine	B-drug
,	O
H2-antagonists	O
,	O
halothane	B-drug
,	O
isoniazid	B-drug
,	O
methylphenidate	B-drug
,	O
phenothiazines	B-drug
,	O
phenylbutazone	B-drug
,	O
salicylates	B-drug
,	O
succinimides	B-drug
,	O
sulfonamides	B-drug
,	O
tolbutamide	B-drug
,	O
trazodone	B-drug

.	O

-	O
Drugs	B-drug
that	O
may	O
decrease	O
plasma	O
phenytoin	B-drug
concentrations	O
include	O
:	O
carbamazepine	B-drug
,	O
chronic	O
alcohol	O
abuse	O
,	O
reserpine	B-drug

.	O

-	O
Drugs	B-drug
that	O
may	O
either	O
increase	O
or	O
decrease	O
plasma	O
phenytoin	B-drug
concentrations	O
include	O
:	O
phenobarbital	B-drug
,	O
vaiproic	O
acid	O
,	O
and	O
sodium	B-drug
valproate	I-drug
.	O

Similarly	O
,	O
the	O
effects	O
of	O
phenytoin	B-drug
on	O
phenobarbital	B-drug
,	O
valproic	B-drug
acid	I-drug
and	O
sodium	O
plasma	O
valproate	B-drug
concentrations	O
are	O
unpredictable	O

.	O

-	O
Although	O
not	O
a	O
true	O
drug	O
interaction	O
,	O
tricyclic	B-drug
antidepressants	I-drug
may	O
precipitate	O
seizures	O
in	O
susceptible	O
patients	O
and	O
Cerebyx	B-drug
dosage	O
may	O
need	O
to	O
be	O
adjusted	O

.	O

-	O
Drugs	B-drug
whose	O
efficacy	O
is	O
impaired	O
by	O
phenytoin	B-drug
include	O
:	O
anticoagulants	B-drug
,	O
corticosteroids	B-drug
,	O
coumarin	B-drug
,	O
digitoxin	B-drug
,	O
doxycycline	B-drug
,	O
estrogens	B-drug
,	O
furosemide	B-drug
,	O
oral	B-drug
contraceptives	I-drug
,	O
rifampin	B-drug
,	O
quinidine	B-drug
,	O
theophylline	B-drug
,	O
vitamin	B-drug
D.	O

Monitoring	O
of	O
plasma	O
phenytoin	B-drug
concentrations	O
may	O
be	O
helpful	O
when	O
possible	O
drug	O
interactions	O
are	O
suspected	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
Phenytoin	B-drug
may	O
decrease	O
serum	O
concentrations	O
of	O
14	O
.	O

It	O
may	O
also	O
produce	O
artifactually	O
low	O
results	O
in	O
dexamethasone	B-drug
or	O
metyrapone	O
tests	O
.	O

Phenytoin	B-drug
may	O
also	O
cause	O
increased	O
serum	O
concentrations	O
of	O
glucose	B-drug
,	O
alkaline	B-drug
phosphatase	I-drug
,	O
and	O
gamma	B-drug
glutamyl	I-drug
transpeptidase	I-drug
(	O
GGT	O
)	O
.	O

Care	O
should	O
be	O
taken	O
when	O
using	O
immunoanalytical	O
methods	O
to	O
measure	O
plasma	O
phenytoin	B-drug
concentrations	O
following	O
Cerebyx	B-drug
administration	O
.	O

Aminoglycosides	B-drug
The	O
mixing	O
of	O
piperacillin	B-drug
with	O
an	O
aminoglycoside	B-drug
in	O
vitro	O
can	O
result	O
in	O
substantial	O
inactivation	O
of	O
the	O
aminoglycoside	B-drug
.	O

Vecuronium	B-drug
When	O
used	O
in	O
the	O
perioperative	O
period	O
,	O
piperacillin	B-drug
has	O
been	O
implicated	O
in	O
the	O
prolongation	O
of	O
the	O
neuromuscular	O
blockade	O
of	O
vecuronium	B-drug
.	O

Caution	O
is	O
indicated	O
when	O
piperacillin	B-drug
is	O
used	O
perioperatively	O
.	O

In	O
one	O
controlled	O
clinical	O
study	O
,	O
the	O
ureidopenicillins	O
,	O
including	O
piperacillin	B-drug
,	O
were	O
reported	O
to	O
prolong	O
the	O
action	O
of	O
vecuronium	B-drug
.	O

Due	O
to	O
their	O
similar	O
mechanism	O
of	O
action	O
,	O
it	O
is	O
expected	O
that	O
the	O
neuromuscular	O
blockade	O
produced	O
by	O
any	O
of	O
the	O
non	B-drug
-	I-drug
depolarizing	I-drug
muscle	I-drug
relaxants	I-drug
could	O
be	O
prolonged	O
in	O
the	O
presence	O
of	O
piperacillin	B-drug
.	O

Probenecid	B-drug
The	O
oral	O
combination	O
of	O
probenecid	B-drug
before	O
intramuscular	O
injection	O
of	O
PIPRACIL	B-drug
produces	O
an	O
increase	O
in	O
piperacillin	B-drug
peak	O
serum	O
level	O
of	O
about	O
30	O
%	O
.	O

Anticoagulants	B-drug
Coagulation	O
parameters	O
should	O
be	O
tested	O
more	O
frequently	O
and	O
monitored	O
regularly	O
during	O
simultaneous	O
administration	O
of	O
high	O
doses	O
of	O
heparin	B-drug
,	O
oral	B-drug
anticoagulants	I-drug
,	O
or	O
other	O
drugs	B-drug
that	O
may	O
affect	O
the	O
blood	O
coagulation	O
system	O
or	O
the	O
thrombocyte	O
function	O
.	O

Methotrexate	B-drug
Piperacillin	I-drug
sodium	O
may	O
reduce	O
the	O
excretion	O
of	O
methotrexate	B-drug
.	O

Therefore	O
,	O
serum	O
levels	O
of	O
methotrexate	B-drug
should	O
be	O
monitored	O
in	O
patients	O
to	O
avoid	O
drug	O
toxicity	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
other	B-drug
penicillins	I-drug
,	O
the	O
administration	O
of	O
PIPRACIL	B-drug
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	B-drug
in	O
the	O
urine	O
using	O
a	O
copper	B-drug
-	O
reduction	O
method	O
.	O

It	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	O
glucose	B-drug
oxidase	I-drug
reactions	O
be	O
used	O
.	O

There	O
have	O
been	O
reports	O
of	O
positive	O
test	O
results	O
using	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
in	O
patients	O
receiving	O
piperacillin	B-drug
/	O
tazobactam	B-drug
injection	O
who	O
were	O
subsequently	O
found	O
to	O
be	O
free	O
of	O
Aspergillus	O
infection	O
.	O

Cross	O
-	O
reactions	O
with	O
non	O
-	O
Aspergillus	O
polysaccharides	B-drug
and	O
polyfuranoses	O
with	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
have	O
been	O
reported	O
.	O

Therefore	O
,	O
positive	O
test	O
results	O
in	O
patients	O
receiving	O
piperacillin	B-drug
should	O
be	O
interpreted	O
cautiously	O
and	O
confirmed	O
by	O
other	O
diagnostic	O
methods	O
.	O

Studies	O
in	O
vitro	O
show	O
that	O
caspofungin	B-drug
acetate	I-drug
is	O
not	O
an	O
inhibitor	O
of	O
any	O
enzyme	O
in	O
the	O
cytochrome	B-drug
P450	I-drug
(	O
CYP	B-drug
)	O
system	O
.	O

In	O
clinical	O
studies	O
,	O
caspofungin	B-drug
did	O
not	O
induce	O
the	O
CYP3A4	B-drug
metabolism	O
of	O
other	O
drugs	B-drug
.	O

Caspofungin	B-drug
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	B-drug
and	O
is	O
a	O
poor	O
substrate	O
for	O
cytochrome	B-drug
P450	I-drug
enzymes	O
.	O

Clinical	O
studies	O
in	O
healthy	O
volunteers	O
show	O
that	O
the	O
pharmacokinetics	O
of	O
CANCIDAS	B-drug
are	O
not	O
altered	O
by	O
itraconazole	B-drug
,	O
amphotericin	B-drug
B	I-drug
,	O
mycophenolate	B-drug
,	O
nelfinavir	B-drug
,	O
or	O
tacrolimus	B-drug
.	O

CANCIDAS	B-drug
has	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
itraconazole	B-drug
,	O
amphotericin	B-drug
B	I-drug
,	O
or	O
the	O
active	B-drug
metabolite	I-drug
of	O
mycophenolate	B-drug
.	O

CANCIDAS	B-drug
reduced	O
the	O
blood	O
AUC0	O
-	O
12	O
of	O
tacrolimus	B-drug
(	O
FK-506	B-drug
,	O
Prograf	O
span	O
class=	O
c4	B-drug
?	O
3	O
)	O
by	O
approximately	O
20	O
%	O
,	O
peak	O
blood	O
concentration	O
(	O
Cmax	O
)	O
by	O
16	O
%	O
,	O
and	O
12-hour	O
blood	O
concentration	O
(	O
C12hr	O
)	O
by	O
26	O
%	O
in	O
healthy	O
subjects	O
when	O
tacrolimus	B-drug
(	O
2	O
doses	O
of	O
0.1	O
mg	O
/	O
kg	O
12	O
hours	O
apart	O
)	O
was	O
administered	O
on	O
the	O
10th	O
day	O
of	O
CANCIDAS	B-drug
70	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
results	O
from	O
a	O
control	O
period	O
in	O
which	O
tacrolimus	B-drug
was	O
administered	O
alone	O
.	O

For	O
patients	O
receiving	O
both	O
therapies	O
,	O
standard	O
monitoring	O
of	O
tacrolimus	B-drug
blood	O
concentrations	O
and	O
appropriate	O
tacrolimus	B-drug
dosage	O
adjustments	O
are	O
recommended	O
.	O

In	O
two	O
clinical	O
studies	O
,	O
cyclosporine	B-drug
(	O
one	O
4	O
mg	O
/	O
kg	O
dose	O
or	O
two	O
3	O
mg	O
/	O
kg	O
doses	O
)	O
increased	O
the	O
AUC	O
of	O
caspofungin	B-drug
by	O
approximately	O
35	O
%	O
.	O

CANCIDAS	B-drug
did	O
not	O
increase	O
the	O
plasma	O
levels	O
of	O
cyclosporine	B-drug
.	O

There	O
were	O
transient	O
increases	O
in	O
liver	B-drug
ALT	O
and	O
AST	B-drug
when	O
CANCIDAS	B-drug
and	O
cyclosporine	B-drug
were	O
co	O
-	O
administered	O
.	O

A	O
drug	O
-	O
drug	O
interaction	O
study	O
with	O
rifampin	B-drug
in	O
healthy	O
volunteers	O
has	O
shown	O
a	O
30	O
%	O
decrease	O
in	O
caspofungin	B-drug
trough	O
concentrations	O
.	O

Patients	O
on	O
rifampin	B-drug
should	O
receive	O
70	O
mg	O
of	O
CANCIDAS	B-drug
daily	O
.	O

In	O
addition	O
,	O
results	O
from	O
regression	O
analyses	O
of	O
patient	O
pharmacokinetic	O
data	O
suggest	O
that	O
co	O
-	O
administration	O
of	O
other	O
inducers	O
of	O
drug	O
clearance	O
(	O
efavirenz	B-drug
,	O
nevirapine	B-drug
,	O
phenytoin	B-drug
,	O
dexamethasone	B-drug
,	O
or	O
carbamazepine	B-drug
)	O
with	O
CANCIDAS	B-drug
may	O
result	O
in	O
clinically	O
meaningful	O
reductions	O
in	O
caspofungin	B-drug
concentrations	O
.	O

It	O
is	O
not	O
known	O
which	O
drug	O
clearance	O
mechanism	O
involved	O
in	O
caspofungin	B-drug
disposition	O
may	O
be	O
inducible	O
.	O

When	O
CANCIDAS	B-drug
is	O
co	O
-	O
administered	O
with	O
inducers	O
of	O
drug	O
clearance	O
,	O
such	O
as	O
efavirenz	B-drug
,	O
nevirapine	B-drug
,	O
phenytoin	B-drug
,	O
dexamethasone	B-drug
,	O
or	O
carbamazepine	B-drug
,	O
use	O
of	O
a	O
daily	O
dose	O
of	O
70	O
mg	O
of	O
CANCIDAS	B-drug
should	O
be	O
considered	O

.	O

?	O

Diphenhydramine	B-drug
hydrochloride	I-drug
has	O
additive	O
effects	O
with	O
alcohol	B-drug
and	O
other	O
CNS	B-drug
depressants	I-drug
(	O
hypnotics	B-drug
,	O
sedatives	B-drug
,	O
tranquilizers	B-drug
,	O
etc	O
)	O
.	O

MAO	B-drug
inhibitors	I-drug
prolong	O
and	O
intensify	O
the	O
anticholinergic	B-drug
(	O
drying	O
)	O
effects	O
of	O
antihistamines	B-drug
.	O

May	O
interact	O
anticoagulants	B-drug
(	O
altered	O
hypo	O
-	O
prothrombinemic	O
effect	O
)	O
,	O
barbiturates	B-drug
,	O
rifampin	B-drug
and	O
other	O
inducers	O
of	O
hepatic	O
microsomal	B-drug
enzyme	I-drug
oxidation	O
system	O
(	O
decreased	O
effect	O
of	O
diethylstilbestrol	B-drug
)	O
,	O
corticosteroids	B-drug
(	O
increased	O
effect	O
of	O
corticosteroids	B-drug
)	O
.	O

Inhibitors	O
of	O
CYP3A4-Eplerenone	O
metabolism	O
is	O
predominantly	O
mediated	O
via	O
CYP3A4	B-drug
.	O

A	O
pharmacokinetic	O
study	O
evaluating	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
INSPRA	B-drug
100	O
mg	O
with	O
ketoconazole	B-drug
200	I-drug
mg	I-drug
BID	O
,	O
a	O
potent	O
inhibitor	O
of	O
the	O
CYP3A4	B-drug
pathway	O
,	O
showed	O
a	O
1.7-fold	O
increase	O
in	O
Cmax	O
of	O
eplerenone	B-drug
and	O
a	O
5.4-fold	O
increase	O
in	O
AUC	O
of	O
eplerenone	B-drug
.	O

INSPRA	B-drug
should	O
not	O
be	O
used	O
with	O
drugs	B-drug
described	O
as	O
strong	O
inhibitors	O
of	O
CYP3A4	B-drug
in	O
their	O
labeling	O
.	O

Administration	O
of	O
eplerenone	B-drug
with	O
other	O
CYP3A4	B-drug
inhibitors	O
(	O
e.g.	O
,	O
erythromycin	B-drug
500	I-drug
mg	I-drug
BID	O
,	O
verapamil	B-drug
240	I-drug
mg	I-drug
QD	O
,	O
saquinavir	B-drug
1200	O
mg	O
TID	O
,	O
fluconazole	B-drug
200	I-drug
mg	I-drug
QD	O
)	O
resulted	O
in	O
increases	O
in	O
Cmax	O
of	O
eplerenone	B-drug
ranging	O
from	O
1.4-	O
to	O
1.6-	O
fold	O
and	O
AUC	O
from	O
2.0-	O
to	O
2.9-	O
fold	O
.	O

ACE	B-drug
Inhibitors	I-drug
and	O
Angiotensin	B-drug
II	I-drug
Receptor	I-drug
Antagonists	I-drug
(	O
Congestive	O
Heart	O
Failure	O
Post	O
-	O
Myocardial	O
Infarction)-	O
In	O
EPHESUS	O
,	O
3020	O
(	O
91	O
%	O
)	O
patients	O
receiving	O
INSPRA	B-drug
25	O
to	O
50	O
mg	O
also	O
received	O
ACE	B-drug
inhibitors	I-drug
or	O
angiotensin	B-drug
II	I-drug
receptor	I-drug
antagonists	I-drug
(	O
ACEI	O
/	O
ARB	O
)	O
.	O

Rates	O
of	O
patients	O
with	O
maximum	O
potassium	O
levels	O
 	O
5.5	O
mEq	O
/	O
L	O
were	O
similar	O
regardless	O
of	O
the	O
use	O
of	O
ACEI	O
/	O
ARB	O
.	O

ACE	B-drug
Inhibitors	I-drug
and	O
Angiotensin	B-drug
II	I-drug
Receptor	I-drug
Antagonists	I-drug
(	O
Hypertension)-	O
In	O
clinical	O
studies	O
of	O
patients	O
with	O
hypertension	O
,	O
the	O
addition	O
of	O
INSPRA	B-drug
50	O
to	O
100	O
mg	O
to	O
ACE	B-drug
inhibitors	I-drug
and	O
angiotensin	B-drug
II	I-drug
receptor	I-drug
antagonists	I-drug
increased	O
mean	O
serum	O
potassium	O
slightly	O
(	O
about	O
0.09	O
-	O
0.13	O
mEq	O
/	O
L	O
)	O
.	O

In	O
a	O
study	O
in	O
diabetics	O
with	O
microalbuminuria	O
INSPRA	B-drug
200	O
mg	O
combined	O
with	O
the	O
ACE	O
inhibitor	O
enalapril	B-drug
10	I-drug
mg	I-drug
increased	O
the	O
frequency	O
of	O
hyperkalemia	O
(	O
serum	O
potassium	O
 	O
5.5	O
mEq	O
/	O
L	O
)	O
from	O
17	O
%	O
on	O
enalapril	B-drug
alone	O
to	O
38	O
%	O
.	O

Lithium	B-drug
-	O
A	O
drug	O
interaction	O
study	O
of	O
eplerenone	B-drug
with	O
lithium	B-drug
has	O
not	O
been	O
conducted	O
.	O

Lithium	O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B-drug
concomitantly	O
with	O
diuretics	B-drug
and	O
ACE	B-drug
inhibitors	I-drug
.	O

Serum	O
lithium	O
levels	O
should	O
be	O
monitored	O
frequently	O
if	O
INSPRA	B-drug
is	O
administered	O
concomitantly	O
with	O
lithium	B-drug
.	O

Nonsteroidal	B-drug
Anti	I-drug
-	I-drug
Inflammatory	I-drug
Drugs	I-drug
(	O
NSAIDs)-A	O
drug	O
interaction	O
study	O
of	O
eplerenone	B-drug
with	O
an	O
NSAID	B-drug
has	O
not	O
been	O
conducted	O
.	O

The	O
administration	O
of	O
other	O
potassium	B-drug
-	I-drug
sparing	I-drug
antihypertensives	I-drug
with	O
NSAIDs	B-drug
has	O
been	O
shown	O
to	O
reduce	O
the	O
antihypertensive	O
effect	O
in	O
some	O
patients	O
and	O
result	O
in	O
severe	O
hyperkalemia	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

Therefore	O
,	O
when	O
INSPRA	B-drug
and	O
NSAIDs	B-drug
are	O
used	O
concomitantly	O
,	O
patients	O
should	O
be	O
observed	O
to	O
determine	O
whether	O
the	O
desired	O
effect	O
on	O
blood	O
pressure	O
is	O
obtained	O
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
ifosfamide	B-drug
even	O
though	O
ifosfamide	B-drug
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	B-drug
,	O
including	O
other	B-drug
cytotoxic	I-drug
drugs	I-drug
.	O

No	O
drug	O
interactions	O
have	O
been	O
observed	O
with	O
the	O
Vitrasert	B-drug
Implant	O
.	O

There	O
is	O
limited	O
experience	O
with	O
use	O
of	O
retinal	O
tamponades	O
in	O
conjunction	O
with	O
the	O
Vitrasert	B-drug
Implant	O
.	O

Co	O
-	O
administration	O
of	O
BOTOX	O
?	O
and	O
aminoglycosides	B-drug
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e.g.	O
,	O
curare	B-drug
-	O
like	O
compounds	O
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B-drug
may	O
be	O
potentiated	O
.	O

The	O
effect	O
of	O
administering	O
different	O
botulinum	B-drug
neurotoxin	I-drug
serotypes	O
at	O
the	O
same	O
time	O
or	O
within	O
several	O
months	O
of	O
each	O
other	O
is	O
unknown	O
.	O

Excessive	O
neuromuscular	O
weakness	O
may	O
be	O
exacerbated	O
by	O
administration	O
of	O
another	O
botulinum	B-drug
toxin	I-drug
prior	O
to	O
the	O
resolution	O
of	O
the	O
effects	O
of	O
a	O
previously	O
administered	O
botulinum	B-drug
toxin	I-drug
.	I-drug

General	O
No	O
clinical	O
drug	O
interaction	O
studies	O
were	O
performed	O
.	O

No	O
evaluation	O
of	O
EXTRANEALs	O
effects	O
on	O
the	O
cytochrome	B-drug
P450	I-drug
system	O
was	O
conducted	O
.	O

As	O
with	O
other	O
dialysis	B-drug
solutions	I-drug
,	O
blood	O
concentrations	O
of	O
dialyzable	O
drugs	B-drug
may	O
be	O
reduced	O
by	O
dialysis	O
.	O

Dosage	O
adjustment	O
of	O
concomitant	O
medications	B-drug
may	O
be	O
necessary	O
.	O

In	O
patients	O
using	O
cardiac	B-drug
glycosides	I-drug
(	O
digoxin	B-drug
and	O
others	O
)	O
,	O
plasma	O
levels	O
of	O
calcium	B-drug
,	O
potassium	B-drug
and	O
magnesium	B-drug
must	O
be	O
carefully	O
monitored	O
.	O

Insulin	B-drug
A	O
clinical	O
study	O
in	O
6	O
insulin	O
-	O
dependent	O
diabetic	O
patients	O
demonstrated	O
no	O
effect	O
of	O
EXTRANEAL	B-drug
on	O
insulin	B-drug
absorption	O
from	O
the	O
peritoneal	O
cavity	O
or	O
on	O
insulins	O
ability	O
to	O
control	O
blood	O
glucose	O
when	O
insulin	B-drug
was	O
administered	O
intraperitoneally	O
with	O
EXTRANEAL	B-drug
.	O

However	O
,	O
appropriate	O
monitoring	O
of	O
blood	O
glucose	O
should	O
be	O
performed	O
when	O
initiating	O
EXTRANEAL	B-drug
in	O
diabetic	O
patients	O
and	O
insulin	B-drug
dosage	O
should	O
be	O
adjusted	O
if	O
needed	O
.	O

Heparin	B-drug
No	O
human	O
drug	O
interaction	O
studies	O
with	O
heparin	B-drug
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
heparin	B-drug
with	O
EXTRANEAL	B-drug
.	O

Antibiotics	B-drug
No	O
human	O
drug	O
interaction	O
studies	O
with	O
antibiotics	B-drug
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
evaluating	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
vancomycin	B-drug
,	O
cefazolin	B-drug
,	O
ampicillin	B-drug
,	O
ampicillin	B-drug
/	O
flucoxacillin	O
,	O
ceftazidime	B-drug
,	O
gentamicin	B-drug
,	O
and	O
amphotericin	B-drug
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
these	O
antibiotics	B-drug
with	O
EXTRANEAL	B-drug
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
Blood	O
Glucose	O
Blood	O
glucose	O
measurement	O
must	O
be	O
done	O
with	O
a	O
glucose	B-drug
-	O
specific	O
method	O
to	O
prevent	B-drug
maltose	B-drug
interference	O
with	O
test	O
results	O
.	O

Since	O
falsely	O
elevated	O
glucose	O
levels	O
have	O
been	O
observed	O
with	O
blood	O
glucose	O
monitoring	O
devices	O
and	O
test	O
strips	O
that	O
use	O
glucose	B-drug
dehydrogenase	I-drug
pyrroloquinolinequinone	O
(	O
GDH	B-drug
PQQ)-based	O
methods	O
,	O
GDH	B-drug
PQQ	O
-	O
based	O
methods	O
should	O
not	O
be	O
used	O
to	O
measure	O
glucose	O
levels	O
in	O
patients	O
administered	O
EXTRANEAL	B-drug
..	O

Serum	O
Amylase	O
An	O
apparent	O
decrease	O
in	O
serum	O
amylase	O
activity	O
has	O
been	O
observed	O
in	O
patients	O
administered	O
EXTRANEAL	B-drug
.	O

Preliminary	O
investigations	O
indicate	O
that	O
icodextrin	B-drug
and	O
its	O
metabolites	B-drug
interfere	O
with	O
enzymatic	O
-	O
based	O
amylase	B-drug
assays	O
,	O
resulting	O
in	O
inaccurately	O
low	O
values	O
.	O

This	O
should	O
be	O
taken	O
into	O
account	O
when	O
evaluating	O
serum	O
amylase	O
levels	O
for	O
diagnosis	O
or	O
monitoring	O
of	O
pancreatitis	O
in	O
patients	O
using	O
EXTRANEAL	B-drug
.	O

D.	O

Drug	B-drug
and	O
Laboratory	O
Test	O
Interactions	O
1	O
.	O

Accelerated	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
and	O
platelet	O
aggregation	O
time	O
;	O

increased	O
platelet	O
count	O
;	O

increased	O
factors	B-drug
II	I-drug
,	I-drug
VII	O
antigen	B-drug
,	O
VIII	O
antigen	B-drug
,	O
VIII	B-drug
coagulant	I-drug
activity	O
,	O
IX	O
,	O
X	O
,	O
XII	O
,	O
VII	O
-	O
X	O
complex	O
,	O
II	O
-	O
VII	O
-	O
X	O
complex	O
,	O
and	O
beta	B-drug
-	I-drug
thromboglobulin	I-drug
;	O

decreased	O
levels	O
of	O
anti	B-drug
-	I-drug
factor	I-drug
Xa	I-drug
and	O
antithrombin	B-drug
III	I-drug
,	O
decreased	O
antithrombin	B-drug
III	I-drug
activity	O
;	O

increased	O
levels	O
of	O
fibrinogen	B-drug
and	O
fibrinogen	O
activity	O
;	O

increased	O
plasminogen	O
antigen	O
and	O
activity	O
.	O

2	O
.	O

Increased	O
thyroid	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	O
hormone	O
levels	O
,	O
as	O
measured	O
by	O
protein	B-drug
-	I-drug
bound	I-drug
iodine	I-drug
(	O
PBI	O
)	O
,	O
T4	O
levels	O
(	O
by	O
column	O
or	O
by	O
radioimmunoassay	O
)	O
or	O
T3	O
levels	O
by	O
radioimmunoassay	O
.	O

T3	O
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
.	O

Free	O
T4	O
and	O
T3	B-drug
concentrations	O
are	O
unaltered	O
.	O

Patients	O
on	O
thyroid	B-drug
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	B-drug
hormone	I-drug
.	O

3	O
.	O

Other	O
binding	B-drug
proteins	I-drug
may	O
be	O
elevated	O
in	O
serum	O
,	O
i.e.	O
,	O
corticosteroid	B-drug
binding	I-drug
globulin	I-drug
(	O
CBG	B-drug
)	O
,	O
sex	B-drug
hormone	I-drug
-	I-drug
binding	I-drug
globulin	I-drug
(	O
SHBG	O
)	O
,	O
leading	O
to	O
increased	O
total	O
circulating	O
corticosteroids	B-drug
and	O
sex	O
steroids	O
,	O
respectively	O
.	O

Free	O
hormone	O
concentrations	O
may	O
be	O
decreased	O
.	O

Other	O
plasma	B-drug
proteins	I-drug
may	O
be	O
increased	O
(	O
angiotensinogen	B-drug
/	B-drug
renin	I-drug
substrate	I-drug
,	I-drug
alpha-1-antitrypsin	B-drug
,	I-drug
ceruloplasmin	B-drug
)	O
.	O

4	O
.	O

Increased	O
plasma	O
HDL	O
and	O
HDL2	O
cholesterol	B-drug
subfraction	O
concentrations	O
,	O
reduced	O
LDL	B-drug
cholesterol	I-drug
concentration	O
,	O
increased	O
triglyceride	O
levels	O
.	O

5	O
.	O

Impaired	O
glucose	O
tolerance	O
.	O

6	O
.	O

Reduced	O
response	O
to	O
metyrapone	O
test	O
.	O

General	O
In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
demonstrated	O
no	O
evidence	O
of	O
cytochrome	B-drug
P450-mediated	O
drug	O
interactions	O
that	O
are	O
likely	O
to	O
be	O
of	O
clinical	O
relevance	O
.	O

Anesthetics	B-drug
/	O
Sedatives	B-drug
/	O
Hypnotics	B-drug
/	O
Opioids	B-drug
Co	O
-	O
administration	O
of	O
PRECEDEX	B-drug
with	O
anesthetics	B-drug
,	O
sedatives	B-drug
,	O
hypnotics	B-drug
,	O
and	O
opioids	B-drug
is	O
likely	O
to	O
lead	O
to	O
an	O
enhancement	O
of	O
effects	O
.	O

Specific	O
studies	O
have	O
confirmed	O
these	O
effects	O
with	O
sevoflurane	B-drug
,	O
isoflurane	B-drug
,	O
propofol	B-drug
,	O
alfentanil	B-drug
,	O
and	O
midazolam	B-drug
.	O

No	O
pharmacokinetic	O
interactions	O
between	O
dexmedetomidine	B-drug
and	O
isoflurane	B-drug
,	O
propofol	B-drug
,	O
alfentanil	B-drug
,	O
and	O
midazolam	B-drug
have	O
been	O
demonstrated	O
.	O

However	O
,	O
due	O
to	O
possible	O
pharmacodynamic	O
interactions	O
,	O
when	O
co	O
-	O
administered	O
with	O
PRECEDEX	B-drug
,	O
a	O
reduction	O
in	O
dosage	O
of	O
PRECEDEX	B-drug
on	O
the	O
concomitant	O
anesthetic	B-drug
,	I-drug
sedative	O
,	O
hypnotic	B-drug
or	O
opioid	B-drug
may	O
be	O
required	O
.	O

Neuromuscular	B-drug
Blockers	I-drug
In	O
one	O
study	O
of	O
10	O
healthy	O
volunteers	O
,	O
administration	O
of	O
PRECEDEX	B-drug
for	O
45	O
minutes	O
at	O
a	O
plasma	O
concentration	O
of	O
1	O
(	O
one	O
)	O
ng	O
/	O
mL	O
resulted	O
in	O
no	O
clinically	O
meaningful	O
increases	O
in	O
the	O
magnitude	O
or	O
neuromuscular	O
blockade	O
associated	O
with	O
rocuronium	B-drug
administration	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
VELCADE	B-drug
.	O

In	O
vitro	O
studies	O
with	O
human	O
liver	O
microsomes	O
indicate	O
that	O
bortezomib	B-drug
is	O
primarily	O
a	O
substrate	O
for	O
cytochrome	B-drug
P450	I-drug
3A4	I-drug
,	O
2C19	O
,	O
and	O
1A2	O
.	O

Patients	O
who	O
are	O
concomitantly	O
receiving	O
VELCADE	B-drug
and	O
drugs	B-drug
that	O
are	O
inhibitors	O
or	O
inducers	O
of	O
cytochrome	B-drug
P450	I-drug
3A4	I-drug
should	O
be	O
closely	O
monitored	O
for	O
either	O
toxicities	O
or	O
reduced	O
efficacy	O
.	O

During	O
clinical	O
trials	O
,	O
hypoglycemia	O
and	O
hyperglycemia	O
were	O
reported	O
in	O
diabetic	O
patients	O
receiving	O
oral	B-drug
hypoglycemics	I-drug
.	O

Patients	O
on	O
oral	O
antidiabetic	B-drug
agents	I-drug
receiving	O
VELCADE	B-drug
treatment	O
may	O
require	O
close	O
monitoring	O
of	O
their	O
blood	O
glucose	O
levels	O
and	O
adjustment	O
of	O
the	O
dose	O
of	O
their	O
antidiabetic	B-drug
medication	O
.	O

Drug	O
Laboratory	O
Test	O
Interactions	O
None	O
known	O
.	O

In	O
clinical	O
studies	O
,	O
Tilade	B-drug
has	O
been	O
co	O
-	O
administered	O
with	O
other	O
anti	B-drug
-	I-drug
asthma	I-drug
medications	I-drug
,	O
including	O
inhaled	O
and	O
oral	O
bronchodilators	B-drug
,	O
and	O
inhaled	O
corticosteroids	B-drug
,	O
with	O
no	O
evidence	O
of	O
increased	O
frequency	O
of	O
adverse	O
events	O
or	O
laboratory	O
abnormalities	O
.	O

No	O
formal	O
drug	O
-	O
drug	O
interaction	O
studies	O
,	O
however	O
,	O
have	O
been	O
conducted	O
.	O

Probenecid	B-drug
decreases	O
the	O
renal	O
tubular	O
secretion	O
of	O
amoxicillin	B-drug
.	O

Concurrent	O
use	O
of	O
amoxicillin	B-drug
and	O
probenecid	B-drug
may	O
result	O
in	O
increased	O
and	O
prolonged	O
blood	O
levels	O
of	O
amoxicillin	B-drug
.	O

Chloramphenicol	B-drug
,	O
macrolides	B-drug
,	O
sulfonamides	B-drug
,	O
and	O
tetracy	O
-	O
clines	O
may	O
interfere	O
with	O
the	O
bactericidal	O
effects	O
of	O
penicillin	B-drug
.	O

This	O
has	O
been	O
demonstrated	O
in	O
vitro	O
;	O

however	O
,	O
the	O
clinical	O
significance	O
of	O
this	O
interaction	O
is	O
not	O
well	O
documented	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
:	O
High	O
urine	O
concentrations	O
of	O
ampicillin	B-drug
may	O
result	O
in	O
false	O
-	O
positive	O
reactions	O
when	O
testing	O
for	O
the	O
presence	O
of	O
glucose	B-drug
in	O
urine	O
using	O
CLINITEST	O
?	O
,	O
Benedict?s	O
Solution	O
,	O
or	O
Fehling?s	O
Solution	O
.	O

Since	O
this	O
effect	O
may	O
also	O
occur	O
with	O
amoxicillin	B-drug
,	O
it	O
is	O
recommended	O
that	O
glucose	O
tests	O
based	O
on	O
enzymatic	B-drug
glucose	I-drug
oxi	I-drug
-	I-drug
dase	I-drug
reactions	O
(	O
such	O
as	O
CLINISTIX	O
?	O
)	O
be	O
used	O
.	O

Following	O
administration	O
of	O
ampicillin	B-drug
to	O
pregnant	O
women	O
,	O
a	O
transient	O
decrease	O
in	O
plasma	O
concentration	O
of	O
total	O
conjugated	O
estriol	B-drug
,	O
estriol	O
-	O
glucuronide	O
,	O
conjugated	O
estrone	B-drug
,	O
and	O
estradiol	B-drug
has	O
been	O
noted	O
.	O

This	O
effect	O
may	O
also	O
occur	O
with	O
amoxicillin	B-drug
.	O

Carcinogenesis	O
,	O
Mutagenesis	O
,	O
Impairment	O
of	O
Fertility	O
:	O
Long	O
-	O
term	O
studies	O
in	O
animals	O
have	O
not	O
been	O
performed	O
to	O
evaluate	O
carcinogenic	O
potential	O
.	O

Studies	O
to	O
detect	O
mutagenic	O
potential	O
of	O
amoxicillin	B-drug
alone	O
have	O
not	O
been	O
conducted	O
;	O

however	O
,	O
the	O
following	O
information	O
is	O
available	O
from	O
tests	O
on	O
a	O
4:1	O
mixture	O
of	O
amoxicillin	B-drug
and	O
potassium	B-drug
clavulanate	I-drug
(	O
AUGMENTIN	B-drug
)	O
.	O

AUGMENTIN	B-drug
was	O
non	O
-	O
mutagenic	O
in	O
the	O
Ames	O
bacterial	O
mutation	O
assay	O
,	O
and	O
the	O
yeast	O
gene	O
conversion	O
assay	O
.	O

AUGMENTIN	B-drug
was	O
weakly	O
positive	O
in	O
the	O
mouse	O
lymphoma	O
assay	O
,	O
but	O
the	O
trend	O
toward	O
increased	O
mutation	O
frequencies	O
in	O
this	O
assay	O
occurred	O
at	O
doses	O
that	O
were	O
also	O
associated	O
with	O
decreased	O
cell	O
survival	O
.	O

AUGMENTIN	B-drug
was	O
negative	O
in	O
the	O
mouse	O
micronucleus	O
test	O
,	O
and	O
in	O
the	O
dominant	O
lethal	O
assay	O
in	O
mice	O
.	O

Potassium	B-drug
clavulanate	I-drug
alone	O
was	O
tested	O
in	O
the	O
Ames	O
bacterial	O
mutation	O
assay	O
and	O
in	O
the	O
mouse	O
micronucleus	O
test	O
,	O
and	O
was	O
negative	O
in	O
each	O
of	O
these	O
assays	O
.	O

In	O
a	O
multi	O
-	O
generation	O
reproduction	O
study	O
in	O
rats	O
,	O
no	O
impairment	O
of	O
fertility	O
or	O
other	O
adverse	O
reproductive	O
effects	O
were	O
seen	O
at	O
doses	O
up	O
to	O
500	O
mg	O
/	O
kg	O
(	O
approximately	O
3	O
times	O
the	O
human	O
dose	O
in	O
mg	O
/	O
m2	O
)	O
.	O

Pregnancy	O
:	O
Teratogenic	O
Effects	O
:	O
Pregnancy	O
Category	O
B.	O

Reproduction	O
studies	O
have	O
been	O
performed	O
in	O
mice	O
and	O
rats	O
at	O
doses	O
up	O
to	O
10	O
times	O
the	O
human	O
dose	O
and	O
have	O
revealed	O
no	O
evidence	O
of	O
impaired	O
fertility	O
or	O
harm	O
to	O
the	O
fetus	O
due	O
to	O
amoxicillin	B-drug
.	O

There	O
are	O
,	O
however	O
,	O
no	O
adequate	O
and	O
well	O
-	O
controlled	O
studies	O
in	O
pregnant	O
women	O
.	O

Because	O
animal	O
reproduction	O
studies	O
are	O
not	O
always	O
predictive	O
of	O
human	O
response	O
,	O
this	O
drug	B-drug
should	O
be	O
used	O
during	O
pregnancy	O
only	O
if	O
clearly	O
needed	O
.	O

Labor	O
and	O
Delivery	O
:	O
Oral	B-drug
ampicillin	I-drug
-	O
class	O
antibiotics	O
are	O
poorly	O
absorbed	O
during	O
labor	O
.	O

Studies	O
in	O
guinea	O
pigs	O
showed	O
that	O
intravenous	O
administration	O
of	O
ampicillin	B-drug
slightly	O
decreased	O
the	O
uterine	O
tone	O
and	O
frequency	O
of	O
contractions	O
but	O
moderately	O
increased	O
the	O
height	O
and	O
duration	O
of	O
contractions	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
use	O
of	O
amoxicillin	B-drug
in	O
humans	O
during	O
labor	O
or	O
delivery	O
has	O
immediate	O
or	O
delayed	O
adverse	O
effects	O
on	O
the	O
fetus	O
,	O
prolongs	O
the	O
duration	O
of	O
labor	O
,	O
or	O
increases	O
the	O
likelihood	O
that	O
forceps	O
delivery	O
or	O
other	O
obstetrical	O
intervention	O
or	O
resuscitation	O
of	O
the	O
newborn	O
will	O
be	O
necessary	O
.	O

Nursing	O
Mothers	O
:	O
Penicillins	B-drug
have	O
been	O
shown	O
to	O
be	O
excreted	O
in	O
human	O
milk	O
.	O

Amoxicillin	B-drug
use	O
by	O
nursing	O
mothers	O
may	O
lead	O
to	O
sensitization	O
of	O
infants	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
amoxicillin	B-drug
is	O
administered	O
to	O
a	O
nursing	O
woman	O
.	O

Pediatric	B-drug
Use	O
:	O
Because	O
of	O
incompletely	O
developed	O
renal	O
function	O
in	O
neonates	O
and	O
young	O
infants	O
,	O
the	O
elimination	O
of	O
amoxicillin	B-drug
may	O
be	O
delayed	O
.	O

Dosing	O
of	O
AMOXIL	B-drug
should	O
be	O
modified	O
in	O
pediatric	B-drug
patients	O
12	O
weeks	O
or	O
younger	O
(	O
?	O
3	O
months	O
)	O
.	O

(	O
See	O
DOSAGE	O
AND	O
ADMINISTRATION?Neonates	O
and	O
infants	O
.	O
)	O

Antacids	B-drug
:	O
Administration	O
of	O
flurbiprofen	B-drug
to	O
volunteers	O
under	O
fasting	O
conditions	O
,	O
or	O
with	O
antacid	B-drug
suspension	I-drug
yielded	O
similar	O
serum	O
flurbiprofen	B-drug
time	O
profiles	O
in	O
young	O
subjects	O
(	O
n=12	O
)	O
.	O

In	O
geriatric	O
subjects	O
(	O
n=7	B-drug
)	I-drug
there	O
was	O
a	O
reduction	O
in	O
the	O
rate	O
but	O
not	O
the	O
extent	O
of	O
flurbiprofen	B-drug
absorption	O
.	O

Anticoagulants	B-drug
:	O
Flurbiprofen	B-drug
like	O
other	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
,	O
has	O
been	O
shown	O
to	O
affect	O
bleeding	O
parameters	O
in	O
patients	O
receiving	O
anti	B-drug
-	I-drug
coagulants	I-drug
,	I-drug
and	O
serious	O
clinical	O
bleeding	O
has	O
been	O
reported	O
.	O

The	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
flurbiprofen	B-drug
to	O
patients	O
taking	O
anticoagulants	B-drug
.	O

Aspirin	B-drug
:	O
Concurrent	O
administration	O
of	O
aspirin	B-drug
and	O
flurbiprofen	B-drug
resulted	O
in	O
50	O
%	O
lower	O
serum	O
flurbiprofen	B-drug
concentrations	O
.	O

This	O
effect	O
of	O
aspirin	B-drug
(	O
which	O
also	O
lowers	O
serum	O
concentrations	O
of	O
other	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
given	O
with	O
it	O
)	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
n=	O
15	O
)	O
as	O
well	O
as	O
normal	O
volunteers	O
(	O
n=	O
16	O
)	O
.	O

Concurrent	O
use	O
of	O
flurbiprofen	B-drug
and	O
aspirin	B-drug
is	O
therefore	O
not	O
recommended	O
.	O

Beta	B-drug
-	I-drug
adrenergic	I-drug
Blocking	I-drug
Agents	I-drug
:	O
The	O
effect	O
of	O
flurbiprofen	B-drug
on	O
blood	O
pressure	O
response	O
to	O
propranolol	B-drug
and	O
atenolol	B-drug
was	O
evaluated	O
in	O
men	O
with	O
mild	O
uncomplicated	O
hypertension	O
(	O
n	O
=	O
10	O
)	O
.	O

Flurbiprofen	B-drug
pretreatment	O
attenuated	O
the	O
hypotensive	O
effect	O
of	O
a	O
single	O
dose	O
of	O
propranolol	B-drug
but	O
not	O
atenolol	B-drug
.	O

Flurbiprofen	B-drug
did	O
not	O
appear	O
to	O
affect	O
the	O
beta	B-drug
-	I-drug
blocker	I-drug
-	O
mediated	O
reduction	O
in	O
heart	O
rate	O
.	O

Flurbiprofen	B-drug
did	O
not	O
affect	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	B-drug
,	O
and	O
the	O
mechanism	O
under	O
lying	O
the	O
interference	O
with	O
propranolols	O
hypotensive	O
effect	O
is	O
unknown	O
.	O

Patients	O
taking	O
both	O
flurbiprofen	B-drug
and	O
a	O
beta	B-drug
-	I-drug
blocker	I-drug
should	O
be	O
monitored	O
to	O
ensure	O
that	O
a	O
satisfactory	O
hypotensive	O
effect	O
is	O
achieved	O
.	O

Cimetidine	B-drug
,	O
Ranitidine	B-drug
:	O
In	O
normal	O
volunteers	O
(	O
n=9	B-drug
)	I-drug
,	O
pretreatment	O
with	O
cimetidine	B-drug
or	O
ranitidine	B-drug
did	O
not	O
affect	O
flurbiprofen	B-drug
pharmacokinetics	O
except	O
that	O
a	O
small	O
(	O
13	O
%	O
)	O
but	O
statistically	O
significant	O
increase	O
in	O
the	O
area	O
under	O
the	O
serum	O
concentration	O
curve	O
of	O
flurbiprofen	B-drug
resulted	O
with	O
cimetidine	B-drug
.	O

Digoxin	B-drug
:	O
Studies	O
of	O
concomitant	O
administration	O
of	O
flurbiprofen	B-drug
and	O
digoxin	B-drug
to	O
healthy	O
men	O
(	O
n=	O
14	O
)	O
did	O
not	O
show	O
a	O
change	O
in	O
the	O
steady	O
state	O
serum	O
levels	O
of	O
either	O
drug	B-drug
.	O

Diuretics	B-drug
:	O
Studies	O
in	O
normal	O
volunteers	O
have	O
shown	O
that	O
flurbiprofen	B-drug
like	O
other	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
,	O
can	O
interfere	O
with	O
the	O
effects	O
of	O
furosemide	B-drug
.	I-drug

Although	O
results	O
have	O
varied	O
from	O
study	O
to	O
study	O
,	O
effects	O
have	O
been	O
shown	O
on	O
furosemide	B-drug
-	I-drug
stimulated	I-drug
diuresis	I-drug
,	I-drug
natriuresis	O
,	O
and	O
kaliuresis	O
.	O

Other	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
that	O
inhibit	O
prostaglandin	B-drug
synthesis	O
have	O
been	O
shown	O
to	O
interfere	O
with	O
thiazide	B-drug
diuretics	I-drug
in	O
some	O
studies	O
and	O
with	O
potassium	B-drug
-	I-drug
sparing	I-drug
diuretics	I-drug
.	O

Patients	O
receiving	O
flurbiprofen	B-drug
and	O
furosemide	B-drug
or	O
other	O
diuretics	B-drug
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
is	O
obtained	O
.	O

Oral	O
Hypoglycemic	B-drug
Agents	I-drug
:	O
In	O
one	O
study	O
,	O
flurbiprofen	B-drug
was	O
given	O
to	O
adult	O
diabetics	O
who	O
were	O
already	O
receiving	O
glyburide	B-drug
(	O
n=4	O
)	O
,	O
metformin	B-drug
(	O
n=2	O
)	O
chlorpropamide	B-drug
with	O
phenformin	B-drug
(	O
n=	B-drug
3	I-drug
)	I-drug
or	O
glyburide	B-drug
with	O
phenformin	B-drug
(	O
n=6	O
)	O
.	O

Although	O
there	O
was	O
a	O
slight	O
reduction	O
in	O
blood	O
sugar	O
concentrations	O
during	O
concomitant	O
administration	O
of	O
flurbiprofen	B-drug
and	O
hypoglycemic	B-drug
agents	I-drug
,	O
there	O
were	O
no	O
signs	O
or	O
symptoms	O
of	O
hypoglycemia	O
.	O

Azlocillin	B-drug
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
amikacin	B-drug
,	O
ciprofloxacin	B-drug
,	O
gentamicin	B-drug
,	O
netilmicin	B-drug
,	O
or	O
tobramycin	B-drug
.	O

Because	O
the	O
tetracyclines	B-drug
have	O
been	O
shown	O
to	O
depress	O
plasma	O
prothrombin	O
activity	O
,	O
patients	O
who	O
are	O
on	O
anticoagulant	O
therapy	O
may	O
require	O
downward	O
adjustment	O
of	O
their	O
anticoagulant	B-drug
dosage	O
.	O

Since	O
bacteriostatic	O
drugs	O
,	O
such	O
as	O
the	O
tetracycline	B-drug
class	O
of	O
antibiotics	B-drug
,	O
may	O
interfere	O
with	O
the	O
bactericidal	O
action	O
of	O
penicillins	B-drug
,	O
it	O
is	O
not	O
advisable	O
to	O
administer	O
these	O
drugs	B-drug
concomitantly	O
.	O

Concurrent	O
use	O
of	O
tetracyclines	B-drug
with	O
oral	B-drug
contraceptives	I-drug
may	O
render	O
oral	B-drug
contraceptives	I-drug
less	I-drug
effective	O
.	O

Breakthrough	O
bleeding	O
has	O
been	O
reported	O

Clinical	O
trials	O
have	O
indicated	O
that	O
Pulmozyme	B-drug
can	O
be	O
effectively	O
and	O
safely	O
used	O
in	O
conjunction	O
with	O
standard	O
cystic	O
fibrosis	O
therapies	O
including	O
oral	O
,	O
inhaled	O
and/or	O
parenteral	O
antibiotics	B-drug
,	O
bronchodilators	B-drug
,	O
enzyme	O
supplements	O
,	O
vitamins	B-drug
,	O
oral	O
or	O
inhaled	O
corticosteroids	B-drug
,	O
and	O
analgesics	B-drug
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Immunosuppressive	B-drug
Drugs	O
,	O
Fibric	O
Acid	O
Derivatives	B-drug
,	O
Niacin	B-drug
(	O
Nicotinic	B-drug
Acid	I-drug
,	O
Erythromycin	B-drug
,	O
Azole	B-drug
Antifungals	I-drug
:	O
Skeletal	O
Muscle	O
.	O

ANTACID	B-drug
(	O
Magnesium	B-drug
-	I-drug
Aluminum	I-drug
Hydroxide	I-drug
)	I-drug
:	O
Cerivastatin	B-drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
antacid	B-drug
.	O

CIMETlDINE	O
:	O
Cerivastatin	B-drug
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
cimetidine	B-drug
.	O

CHOLESTYRAMINE	B-drug
:	O
The	O
influence	O
of	O
the	O
bile	B-drug
-	I-drug
acidsequestering	I-drug
agent	I-drug
cholestyramine	O
on	O
the	O
pharmacokinetits	O
of	O
cerivastatin	B-drug
sodium	I-drug
was	O
evaluated	O
in	O
12	O
healthy	O
males	O
in	O
2	O
separate	O
randomized	O
crossover	O
studies	O
.	O

In	O
the	O
first	O
study	O
,	O
concomitant	O
administration	O
of	O
0.2	O
mg	O
cerivastatin	B-drug
sodium	I-drug
and	O
12	O
g	O
cholestyramine	B-drug
resulted	O
in	O
decreases	O
of	O
more	O
than	O
22	O
%	O
for	O
AUC	O
and	O
40	O
%	O
for	O
Cmax	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-drug
sodium	I-drug
alone	O
.	O

However	O
,	O
in	O
the	O
second	O
study	O
,	O
administration	O
of	O
12	O
g	O
cholestyramine	B-drug
1	O
hour	O
before	O
the	O
evening	O
meal	O
and	O
0.3	O
mg	O
cerivastatin	B-drug
sodium	I-drug
approximately	O
4	O
hours	O
after	O
the	O
same	O
evening	O
meal	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
cerivastatin	B-drug
AUC	O
of	O
less	O
than	O
8	O
%	O
,	O
and	O
a	O
decrease	O
in	O
Cmax	O
of	O
about	O
30	O
%	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B-drug
sodium	I-drug
alone	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
expected	O
that	O
a	O
dosing	O
schedule	O
of	O
cerivastatin	B-drug
sodium	I-drug
given	O
at	O
bedtime	O
and	O
cholestyramine	B-drug
given	O
before	O
the	O
evening	O
meal	O
would	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
clinical	O
effect	O
of	O
cerivastatin	B-drug
sodium	I-drug
.	O

DIGOXIN	B-drug
:	O
Plasma	O
digoxin	O
levels	O
and	O
digoxin	B-drug
clearance	O
at	O
steady	O
-	O
state	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
0.2	O
mg	O
cerivastatin	B-drug
sodium	I-drug
.	O

Cerivastatin	B-drug
plasma	O
concentrations	O
were	O
also	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
digoxin	B-drug
.	O

WARFARIN	B-drug
:	O
Co-	O
administration	O
of	O
warfarin	B-drug
and	O
cerivastatin	B-drug
to	O
healthy	O
volunteers	O
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
prothrombin	O
time	O
or	O
clotting	O
factor	B-drug
VII	I-drug
when	O
compared	O
to	O
co	O
-	O
administration	O
of	O
warfarin	B-drug
and	O
placebo	O
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
both	O
the	O
(	O
R	O
)	O
and	O
(	O
S	O
)	O
isomers	O
of	O
warfarin	B-drug
were	O
unaffected	O
by	O
concurrent	O
dosing	O
of	O
0.3	O
mg	O
cerivastatin	B-drug
sodium	I-drug
.	O

Co	O
-	O
administration	O
of	O
warfarin	B-drug
and	O
cerivastatin	B-drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
cerivastatin	B-drug
sodium	I-drug
.	O

ERYTHROMYCIN	B-drug
:	O
In	O
hypercholesterolemic	O
patients	O
,	O
steady	O
-	O
state	O
cerivastatin	B-drug
AUC	O
and	O
Cmax	O
increased	O
approximately	O
50	O
%	O
and	O
24	O
%	O
respectively	O
after	O
10	O
days	O
with	O
co	O
-	O
administration	O
of	O
erythromycin	B-drug
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	B-drug
P450	I-drug
3A4	I-drug
.	O

OTHER	O
CONCOMITANT	O
THERAPY	O
:	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
in	O
clinical	O
studies	O
,	O
cerivastatin	B-drug
sodium	I-drug
was	O
used	O
concomitantly	O
with	O
angiotensin-	B-drug
converting	I-drug
enzyme	I-drug
(	O
ACE	O
)	O
inhibitors	O
,	O
betablockers	O
,	O
calcium	B-drug
-	I-drug
channel	I-drug
blockers	I-drug
,	O
diuretics	B-drug
,	O
and	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
(	O
NSAIDs	B-drug
)	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Caution	O
should	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
neurotoxic	O
and/	O
or	O
nephrotoxic	O
drugs	B-drug
because	O
of	O
possible	O
enhancement	O
of	O
the	O
nephrotoxicity	O
and/or	O
ototoxicity	O
of	O
neomycin	B-drug
.	O

Caution	O
should	O
also	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
aminoglycosides	B-drug
and	O
polymyxins	B-drug
because	O
they	O
may	O
enhance	O
neomycin?s	O
nephrotoxicity	O
and/or	O
ototoxicity	O
and	O
potentiate	O
neomycin	B-drug
sulfate?s	O
neuromuscular	O
blocking	O
effects	O
.	O

Oral	B-drug
neomycin	I-drug
inhibits	O
the	O
gastrointestinal	O
absorption	O
of	O
penicillin	B-drug
V	I-drug
,	O
oral	B-drug
vitamin	I-drug
B-12	I-drug
,	I-drug
methotrexate	B-drug
and	O
5-fluorouracil	B-drug
.	O

The	O
gastrointestinal	O
absorption	O
of	O
digoxin	B-drug
also	O
appears	O
to	O
be	O
inhibited	O
.	O

Therefore	O
,	O
digoxin	O
serum	O
levels	O
should	O
be	O
monitored	O
.	O

Oral	B-drug
neomycin	I-drug
sulfate	O
may	O
enhance	O
the	O
effect	O
of	O
coumarin	B-drug
in	O
anticoagulants	B-drug
by	O
decreasing	O
vitamin	O
K	O
availability	O
.	O

No	O
information	O
available	O
.	O

Digitalis	O
toxicity	O
may	O
be	O
aggravated	O
by	O
the	O
initial	O
release	O
of	O
norepinephrine	B-drug
caused	O
by	O
Bretylium	B-drug
Tosylate	I-drug
Injection	I-drug
.	O

The	O
pressor	B-drug
effects	I-drug
of	O
catecholamines	O
such	O
as	O
dopamine	B-drug
or	O
norepinephrine	B-drug
are	O
enhanced	O
by	O
Bretylium	B-drug
Tosylate	I-drug
.	O

When	O
catecholamines	O
are	O
administered	O
,	O
dilute	O
solutions	O
should	O
be	O
used	O
and	O
blood	O
pressure	O
should	O
be	O
monitored	O
closely	O
.	O

Although	O
there	O
is	O
little	O
published	O
information	O
on	O
concomitant	O
administration	O
of	O
lidocaine	B-drug
and	O
Bretylium	B-drug
Tosylate	I-drug
,	O
these	O
drugs	B-drug
are	O
often	O
administered	O
concurrently	O
without	O
any	O
evidence	O
of	O
interactions	O
resulting	O
in	O
adverse	O
effects	O
or	O
diminished	O
efficacy	O
.	O

A	O
number	O
of	O
substances	O
affect	O
glucose	O
metabolism	O
and	O
may	O
require	O
insulin	B-drug
dose	O
adjustment	O
and	O
particularly	O
close	O
monitoring	O
.	O

?	O
?	O
?	O
The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetic	B-drug
products	O
,	O
ACE	B-drug
inhibitors	I-drug
,	O
disopyramide	B-drug
,	O
fibrates	B-drug
,	O
fluoxetine	B-drug
,	O
monoamine	B-drug
oxidase	I-drug
(	O
MAO	O
)	O
inhibitors	O
,	O
propoxyphene	B-drug
,	O
salicylates	B-drug
,	O
somatostatin	B-drug
analog	I-drug
(	O
e.g.	O
,	O
octreotide	B-drug
)	O
,	O
sulfonamide	B-drug
antibiotics	O
.	O

?	O
?	O
?	O
The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
:	O
corticosteroids	B-drug
,	O
niacin	B-drug
,	O
danazol	B-drug
,	O
diuretics	B-drug
,	O
sympathomimetic	B-drug
agents	I-drug
(	O
e.g.	O
,	O
epinephrine	B-drug
,	O
salbutamol	B-drug
,	O
terbutaline	B-drug
)	O
,	O
isoniazid	B-drug
,	O
phenothiazine	B-drug
derivatives	I-drug
,	O
somatropin	B-drug
,	O
thyroid	B-drug
hormones	I-drug
,	O
estrogens	B-drug
,	O
progestogens	B-drug
(	O
e.g.	O
,	O
in	O
oral	B-drug
contraceptives	I-drug
)	O
.	O

?	B-drug
?	I-drug
?	I-drug
Beta	I-drug
-	I-drug
blockers	I-drug
,	I-drug
clonidine	B-drug
,	O
lithium	B-drug
salts	O
,	O
and	O
alcohol	B-drug
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B-drug
.	O

Pentamidine	B-drug
may	O
cause	O
hypoglycemia	O
,	O
which	O
may	O
sometimes	O
be	O
followed	O
by	O
hyperglycemia	O
.	O

?	O
?	O
?	O
In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	B-drug
medicinal	O
products	O
such	O
as	O
beta	B-drug
-	I-drug
blockers	I-drug
,	I-drug
clonidine	B-drug
,	O
guanethidine	B-drug
,	O
and	O
reserpine	B-drug
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

Mixing	O
of	O
Insulins	B-drug

?	O
?	O
?	O
A	O
clinical	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n=24	O
)	O
demonstrated	O
that	O
mixing	O
NovoLog	B-drug
with	O
NPH	O
human	B-drug
insulin	I-drug
immediately	O
before	O
injection	O
produced	O
some	O
attenuation	O
in	O
the	O
peak	O
concentration	O
of	O
NovoLog	B-drug
,	O
but	O
that	O
the	O
time	O
to	O
peak	O
and	O
the	O
total	O
bioavailability	O
of	O
NovoLog	B-drug
were	O
not	O
significantly	O
affected	O
.	O

If	O
NovoLog	B-drug
is	O
mixed	O
with	O
NPH	O
human	B-drug
insulin	I-drug
,	O
NovoLog	B-drug
should	O
be	O
drawn	O
into	O
the	O
syringe	O
first	O
.	O

The	O
injection	O
should	O
be	O
made	O
immediately	O
after	O
mixing	O
.	O

Because	O
there	O
are	O
no	O
data	O
on	O
the	O
compatibility	O
of	O
NovoLog	B-drug
and	O
crystalline	B-drug
zinc	I-drug
insulin	I-drug
preparations	O
,	O
NovoLog	B-drug
should	O
not	O
be	O
mixed	O
with	O
these	O
preparations	O
.	O

?	O
?	O
?	O
The	O
effects	O
of	O
mixing	O
NovoLog	B-drug
with	O
insulins	B-drug
of	O
animal	O
source	O
or	O
insulin	B-drug
preparations	I-drug
produced	O
by	O
other	O
manufacturers	O
have	O
not	O
been	O
studied	O
.	O

?	O
?	O
?	O
Mixtures	O
should	O
not	O
be	O
administered	O
intravenously	O
.	O

?	O
?	O
?	O
When	O
used	O
in	O
external	O
subcutaneous	O
infusion	O
pumps	O
for	O
insulin	B-drug
,	O
NovoLog	B-drug
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
insulins	B-drug
or	O
diluent	O
.	O

Ethinyl	B-drug
estradiol	I-drug
:	O
Substrate	O
of	O
CYP3A4	B-drug
(	O
major	O
)	O
,	O
3A5	O
-	O
7	O
(	O
minor	O
)	O
;	O

Inhibits	O
CYP1A2	B-drug
(	O
weak	O
)	O
,	O
2B6	O
(	O
weak	O
)	O
,	O
2C19	O
(	O
weak	O
)	O
,	O
3A4	O
(	O
weak	O
)	O
.	O

Acetaminophen	B-drug
:	O
May	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B-drug
estrogens	I-drug
,	I-drug
possibly	O
by	O
inhibiting	O
conjugation	O
.	O

Combination	O
hormonal	O
contraceptives	B-drug
may	O
also	O
decrease	O
the	O
plasma	O
concentration	O
of	O
acetaminophen	B-drug
.	O

Acitretin	B-drug
:	O
Interferes	O
with	O
the	O
contraceptive	B-drug
effect	O
of	O
microdosed	O
progestin	B-drug
-	O
containing	O
minipill	O
preparations	O
.	O

The	O
effect	O
on	O
other	O
progestational	O
contraceptives	B-drug
(	O
eg	O
,	O
implants	O
,	O
injectables	O
)	O
is	O
unknown	O
.	O

Aminoglutethimide	B-drug
:	O
May	O
increase	O
CYP	B-drug
metabolism	O
of	O
progestins	B-drug
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	B-drug
effectiveness	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	B-drug
product	O
is	O
recommended	O
.	O

Antibiotics	B-drug
(	O
ampicillin	B-drug
,	O
tetracycline	B-drug
)	O
:	O
Pregnancy	O
has	O
been	O
reported	O
following	O
concomitant	O
use	O
,	O
however	O
,	O
pharmacokinetic	O
studies	O
have	O
not	O
shown	O
consistent	O
effects	O
with	O
these	O
antibiotics	B-drug
on	O
plasma	O
concentrations	O
of	O
synthetic	O
steroids	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	B-drug
product	O
is	O
recommended	O
.	O

Anticoagulants	B-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
coumarin	B-drug
derivatives	O
.	O

Combination	O
hormonal	O
contraceptives	B-drug
may	O
also	O
increase	O
risk	O
of	O
thromboembolic	O
disorders	O
.	O

Anticonvulsants	B-drug
(	O
carbamazepine	B-drug
,	O
felbamate	B-drug
,	O
phenobarbital	B-drug
,	O
phenytoin	B-drug
,	O
topiramate	B-drug
)	O
:	O
Increase	O
the	O
metabolism	O
of	O
ethinyl	B-drug
estradiol	I-drug
and/or	O
some	O
progestins	B-drug
,	O
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	B-drug
effectiveness	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	B-drug
product	O
is	O
recommended	O
.	O

Ascorbic	B-drug
acid	I-drug
:	O
Doses	O
of	O
ascorbic	B-drug
acid	I-drug
(	O
vitamin	B-drug
C	I-drug
)	O
1	O
g	O
/	O
day	O
have	O
been	O
reported	O
to	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B-drug
estrogens	I-drug
by	O
~47	O
%	O
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
;	O

clinical	O
implications	O
are	O
unclear	O
.	O

Atorvastatin	B-drug
:	O
Atorvastatin	B-drug
increases	O
the	O
AUC	O
for	O
norethindrone	B-drug
and	O
ethinyl	B-drug
estradiol	I-drug
.	O

Benzodiazepines	B-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
decrease	O
the	O
clearance	O
of	O
some	O
benzodiazepines	B-drug
(	O
alprazolam	B-drug
,	O
chlordiazepoxide	B-drug
,	O
diazepam	B-drug
)	O
and	O
increase	O
the	O
clearance	O
of	O
others	O
(	O
lorazepam	B-drug
,	O
oxazepam	B-drug
,	O
temazepam	B-drug
)	O
.	O

Clofibric	B-drug
acid	I-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
increase	O
the	O
clearance	O
of	O
clofibric	B-drug
acid	I-drug
.	O

Cyclosporine	B-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
inhibit	O
the	O
metabolism	O
of	O
cyclosporine	B-drug
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
;	O

monitor	O
cyclosporine	B-drug
levels	O
.	O

CYP3A4	B-drug
inducers	O
:	O
CYP3A4	B-drug
inducers	O
may	O
decrease	O
the	O
levels	O
/	O
effects	O
of	O
ethinyl	B-drug
estradiol	I-drug
.	O

Example	O
inducers	O
include	O
aminoglutethimide	B-drug
,	O
carbamazepine	B-drug
,	O
nafcillin	B-drug
,	O
nevirapine	B-drug
,	O
phenobarbital	B-drug
,	O
phenytoin	B-drug
,	O
and	O
rifamycins	B-drug
.	O

Griseofulvin	B-drug
:	O
Griseofulvin	B-drug
may	O
induce	O
the	O
metabolism	O
of	O
combination	O
hormonal	O
contraceptives	B-drug
causing	O
menstrual	O
changes	O
;	O

pregnancies	O
have	O
been	O
reported	O
.	O

Use	O
of	O
barrier	O
form	O
of	O
contraception	O
is	O
suggested	O
while	O
on	O
griseofulvin	B-drug
therapy	O
.	O

Morphine	B-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
increase	O
the	O
clearance	O
of	O
morphine	B-drug
.	O

Non	B-drug
-	I-drug
nucleoside	I-drug
reverse	I-drug
transcriptase	I-drug
inhibitors	I-drug
(	O
NNRTIs	O
)	O
:	O
Nevirapine	B-drug
may	O
decrease	O
plasma	O
levels	O
of	O
combination	O
hormonal	O
contraceptives	B-drug
;	O

use	O
of	O
a	O
nonhormonal	O
contraceptive	B-drug
product	O
is	O
recommended	O
.	O

No	O
data	O
for	O
delavirdine	B-drug
;	O

incomplete	O
data	O
for	O
efavirenz	B-drug
.	O

Prednisolone	B-drug
:	O
Ethinyl	B-drug
estradiol	I-drug
may	O
inhibit	O
the	O
metabolism	O
of	O
prednisolone	B-drug
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Protease	B-drug
inhibitors	I-drug
:	O
Amprenavir	B-drug
,	O
lopinavir	B-drug
,	O
nelfinavir	B-drug
,	O
and	O
ritonavir	B-drug
have	O
been	O
shown	O
to	O
decrease	O
plasma	O
levels	O
of	O
combination	O
hormonal	O
contraceptives	B-drug
;	O

use	O
of	O
a	O
nonhormonal	O
contraceptive	B-drug
product	O
is	O
recommended	O
.	O

Indinavir	B-drug
has	O
been	O
shown	O
to	O
increase	O
plasma	O
levels	O
of	O
combination	O
hormonal	O
contraceptives	B-drug
.	O

No	O
data	O
for	O
saquinavir	B-drug
.	O

Rifampin	B-drug
:	O
Rifampin	B-drug
increases	O
the	O
metabolism	O
of	O
ethinyl	B-drug
estradiol	I-drug
and	O
some	O
progestins	B-drug
(	O
norethindrone	B-drug
)	O
resulting	O
in	O
decreased	O
contraceptive	B-drug
effectiveness	O
and	O
increased	O
menstrual	O
irregularities	O
.	O

Use	O
of	O
a	O
nonhormonal	O
contraceptive	B-drug
product	O
is	O
recommended	O
.	O

Salicylic	B-drug
acid	I-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
increase	O
the	O
clearance	O
of	O
salicylic	B-drug
acid	I-drug
.	O

Selegiline	B-drug
:	O
Combination	O
hormonal	O
contraceptives	B-drug
may	O
increase	O
the	O
serum	O
concentration	O
of	O
selegiline	B-drug
.	O

Theophylline	B-drug
:	O
Ethinyl	B-drug
estradiol	I-drug
may	O
inhibit	O
the	O
metabolism	O
of	O
theophylline	B-drug
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Tricyclic	B-drug
antidepressants	I-drug
(	O
amitriptyline	B-drug
,	O
imipramine	B-drug
,	O
nortriptyline	B-drug
)	O
:	O
Metabolism	O
may	O
be	O
inhibited	O
by	O
combination	O
hormonal	O
contraceptives	B-drug
,	O
increasing	O
plasma	O
levels	O
of	O
antidepressant	B-drug
;	O

use	O
caution	O
.	O

ETHANOL	B-drug
/	O
NUTRITION	O
/	O
HERB	O
INTERACTIONS	O
:	O
Food	O
:	O
CNS	O
effects	O
of	O
caffeine	B-drug
may	O
be	O
enhanced	O
if	O
combination	O
hormonal	O
contraceptives	B-drug
are	O
used	O
concurrently	O
with	O
caffeine	B-drug
.	O

Grapefruit	O
juice	O
increases	O
ethinyl	B-drug
estradiol	I-drug
concentrations	O
and	O
would	O
be	O
expected	O
to	O
increase	O
progesterone	O
serum	O
levels	O
as	O
well	O
;	O

clinical	O
implications	O
are	O
unclear	O
.	O

Herb	O
/	O
Nutraceutical	O
:	O
St	O
Johns	O
wort	O
may	O
decrease	O
the	O
effectiveness	O
of	O
combination	O
hormonal	O
contraceptives	B-drug
by	O
inducing	O
hepatic	O
enzymes	O
.	O

Avoid	O
dong	B-drug
quai	I-drug
and	O
black	B-drug
cohosh	I-drug
(	O
have	O
estrogen	B-drug
activity	O
)	O
.	O

Avoid	O
saw	B-drug
palmetto	I-drug
,	O
red	B-drug
clover	I-drug
,	O
ginseng	B-drug
.	O

Prior	O
administration	O
of	O
succinylcholine	B-drug
has	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
NUROMAX	B-drug
.	O

The	O
use	O
of	O
NUROMAX	B-drug
before	O
succinylcholine	B-drug
to	O
attenuate	O
some	O
of	O
the	O
side	O
effects	O
of	O
succinylcholine	B-drug
has	O
not	O
been	O
studied	O
.	O

There	O
are	O
no	O
clinical	O
data	O
on	O
concomitant	O
use	O
of	O
NUROMAX	B-drug
and	O
other	O
nondepolarizing	O
neuromuscular	B-drug
blocking	I-drug
agents	I-drug
.	O

Isoflurane	B-drug
,	O
enflurane	B-drug
,	O
and	O
halothane	B-drug
decrease	O
the	O
ED50	O
of	O
NUROMAX	B-drug
by	O
30	O
%	O
to	O
45	O
%	O
.	O

These	O
agents	O
may	O
also	O
prolong	O
the	O
clinically	O
effective	O
duration	O
of	O
action	O
by	O
up	O
to	O
25	O
%	O
.	O

Other	O
drugs	B-drug
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
nondepolarizing	B-drug
agents	O
such	O
as	O
NUROMAX	B-drug
include	O
certain	O
antibiotics	B-drug
(	O
e.	O
g.	O
,	O
aminoglycosides	B-drug
,	O
tetracyclines	B-drug
,	O
bacitracin	B-drug
,	O
polymyxins	B-drug
,	O
lincomycin	B-drug
,	O
clindamycin	B-drug
,	O
colistin	B-drug
,	O
and	O
sodium	B-drug
colistimethate	O
)	O
,	O
magnesium	B-drug
salts	O
,	O
lithium	B-drug
,	O
local	B-drug
anesthetics	I-drug
,	O
procainamide	B-drug
,	O
and	O
quinidine	B-drug
.	O

As	O
with	O
some	O
other	O
nondepolarizing	O
neuromuscular	B-drug
blocking	I-drug
agents	I-drug
,	O
the	O
time	O
of	O
onset	O
of	O
neuromuscular	O
block	O
induced	O
by	O
NUROMAX	B-drug
is	O
lengthened	O
and	O
the	O
duration	O
of	O
block	O
is	O
shortened	O
in	O
patients	O
receiving	O
phenytoin	B-drug
or	O
carbamazepine	B-drug
.	O

Medroxyprogesterone	B-drug
Acetate	I-drug
-	O
L	O
-	O
histidine	O
was	O
observed	O
to	O
enhance	O
(	O
in	O
tissue	O
culture	O
)	O
the	O
effect	O
of	O
medroxyprogesterone	B-drug
acetate	I-drug
in	O
reducing	O
the	O
number	O
of	O
human	O
breast	O
cancer	O
cells	O
that	O
were	O
in	O
the	O
S	O
phase	O
.	O

H1	O
and	O
H2	B-drug
Blockers	I-drug
-	O
Although	O
not	O
reported	O
,	O
L	B-drug
-	I-drug
histidine	I-drug
,	O
via	O
its	O
metabolism	O
to	O
histamine	O
,	O
might	O
decrease	O
the	O
efficacy	O
of	O
H1	O
and	O
H2	B-drug
blockers	I-drug
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	B-drug
may	O
interact	O
with	O
beta	B-drug
-	I-drug
adrenergic	I-drug
receptor	I-drug
blocking	I-drug
agents	I-drug
:	O
Anesthetics	B-drug
,	O
general	O
:	O
exaggeration	O
of	O
the	O
hypotension	O
induced	O
by	O
general	B-drug
anesthetics	I-drug
.	O

Antidiabetic	B-drug
drugs	I-drug
(	O
oral	O
agents	O
and	O
insulin	B-drug
)	O
:	O
hypoglycemia	O
or	O
hyperglycemia	O
;	O

adjust	O
dosage	O
of	O
antidiabetic	B-drug
drug	I-drug
accordingly	O
.	O

Catecholamine	O
-	O
depleting	O
drugs	B-drug
(	O
e.g.	O
,	O
reserpine	B-drug
)	O
:	O
additive	O
effect	O
;	O

monitor	O
closely	O
for	O
evidence	O
of	O
hypotension	O
and/or	O
excessive	O
bradycardia	O
(	O
e.g.	O
,	O
vertigo	O
,	O
syncope	O
,	O
postural	O
hypotension	O
)	O
.	O

Response	O
to	O
Treatment	O
for	O
Anaphylactic	O
Reaction	O
:	O
While	O
taking	O
beta	B-drug
-	I-drug
blockers	I-drug
,	I-drug
patients	O
with	O
a	O
history	O
of	O
severe	O
anaphylactic	O
reaction	O
to	O
a	O
variety	O
of	O
allergens	O
may	O
be	O
more	O
reactive	O
to	O
repeated	O
challenge	O
,	O
either	O
accidental	O
,	O
diagnostic	O
,	O
or	O
therapeutic	O
.	O

Such	O
patients	O
may	O
be	O
unresponsive	O
to	O
the	O
usual	O
doses	O
of	O
epinephrine	B-drug
used	O
to	O
treat	O
allergic	O
reaction	O
.	O

Although	O
no	O
clinical	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
to	O
date	O
,	O
on	O
the	O
basis	O
of	O
the	O
in	O
vitro	O
studies	O
,	O
cytochrome	B-drug
p450	I-drug
inhibitors	O
and	O
inducers	O
are	O
unlikely	O
to	O
affect	O
the	O
metabolism	O
of	O
clofarabine	B-drug
.	O

The	O
effect	O
of	O
clofarabine	B-drug
on	O
the	O
metabolism	O
of	O
cytochrome	B-drug
p450	I-drug
substrates	O
has	O
not	O
been	O
studied	O
.	O

Drug	B-drug
/	O
Laboratory	O
Tests	O
Interactions	O
There	O
are	O
no	O
known	O
clinically	O
significant	O
interactions	O
of	O
CLOLAR	O
?	O
with	O
other	O
medications	B-drug
or	O
laboratory	O
tests	O
.	O

No	O
formal	O
drug	B-drug
/	O
laboratory	O
test	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
CLOLAR	O
?	O
.	O

In	O
vitro	O
drug	O
metabolism	O
studies	O
indicate	O
that	O
Starlix	B-drug
is	O
predominantly	O
metabolized	O
by	O
the	O
cytochrome	B-drug
P450	I-drug
isozyme	O
CYP2C9	O
(	O
70	O
%	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
CYP3A4	B-drug
(	O
30	O
%	O
)	O
.	O

Starlix	B-drug
is	O
a	O
potential	O
inhibitor	O
of	O
the	O
CYP2C9	B-drug
isoenzyme	I-drug
in	O
vivo	O
as	O
indicated	O
by	O
its	O
ability	O
to	O
inhibit	O
the	O
in	O
vitro	O
metabolism	O
of	O
tolbutamide	B-drug
.	O

Inhibition	O
of	O
CYP3A4	B-drug
metabolic	O
reactions	O
was	O
not	O
detected	O
in	O
in	O
vitro	O
experiments	O
.	O

Glyburide	B-drug
:	O
In	O
a	O
randomized	O
,	O
multiple	O
-	O
dose	O
crossover	O
study	O
,	O
patients	O
with	O
Type	O
2	O
diabetes	O
were	O
administered	O
120	O
mg	O
Starlix	B-drug
three	O
times	O
a	O
day	O
before	O
meals	O
for	O
1	O
day	O
in	O
combination	O
with	O
glyburide	B-drug
10	O
mg	O
daily	O
.	O

There	O
were	O
no	O
clinically	O
relevant	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Metformin	B-drug
:	O
When	O
Starlix	B-drug
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
metformin	B-drug
500	I-drug
mg	I-drug
three	O
times	O
daily	O
to	O
patients	O
with	O
Type	O
2	O
diabetes	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Digoxin	B-drug
:	O
When	O
Starlix	B-drug
120	O
mg	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
a	O
single	O
1-mg	O
dose	O
of	O
digoxin	B-drug
to	O
healthy	O
volunteers	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Warfarin	B-drug
:	O
When	O
healthy	O
subjects	O
were	O
administered	O
Starlix	B-drug
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
for	O
four	O
days	O
in	O
combination	O
with	O
a	O
single	O
dose	O
of	O
warfarin	B-drug
30	O
mg	O
on	O
day	O
2	O
,	O
there	O
were	O
no	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Prothrombin	O
time	O
was	O
not	O
affected	O
.	O

Diclofenac	B-drug
:	O
Administration	O
of	O
morning	O
and	O
lunch	O
doses	O
of	O
Starlix	B-drug
120	O
mg	O
in	O
combination	O
with	O
a	O
single	O
75-mg	O
dose	O
of	O
diclofenac	B-drug
in	O
healthy	O
volunteers	O
resulted	O
in	O
no	O
significant	O
changes	O
to	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Nateglinide	B-drug
is	O
highly	O
bound	O
to	O
plasma	B-drug
proteins	I-drug
(	O
98	O
%	O
)	O
,	O
mainly	O
albumin	B-drug
.	O

In	O
vitro	O
displacement	O
studies	O
with	O
highly	O
protein	B-drug
-	O
bound	O
drugs	O
such	O
as	O
furosemide	B-drug
,	I-drug
propranolol	B-drug
,	O
captopril	B-drug
,	O
nicardipine	B-drug
,	O
pravastatin	B-drug
,	O
glyburide	B-drug
,	O
warfarin	B-drug
,	O
phenytoin	B-drug
,	O
acetylsalicylic	B-drug
acid	I-drug
,	O
tolbutamide	B-drug
,	O
and	O
metformin	B-drug
showed	O
no	O
influence	O
on	O
the	O
extent	O
of	O
nateglinide	B-drug
protein	O
binding	O
.	O

Similarly	O
,	O
nateglinide	B-drug
had	O
no	O
influence	O
on	O
the	O
serum	O
protein	B-drug
binding	I-drug
of	O
propranolol	B-drug
,	O
glyburide	B-drug
,	O
nicardipine	B-drug
,	O
warfarin	B-drug
,	O
phenytoin	B-drug
,	O
acetylsalicylic	B-drug
acid	I-drug
,	O
and	O
tolbutamide	B-drug
in	O
vitro	O
.	O

However	O
,	O
prudent	O
evaluation	O
of	O
individual	O
cases	O
is	O
warranted	O
in	O
the	O
clinical	O
setting	O
.	O

Certain	O
drugs	B-drug
,	O
including	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
agents	I-drug
(	O
NSAIDs	B-drug
)	O
,	O
salicylates	B-drug
,	O
monoamine	B-drug
oxidase	I-drug
inhibitors	I-drug
,	O
and	O
non	B-drug
-	I-drug
selective	I-drug
beta	I-drug
-	I-drug
adrenergic	I-drug
-	I-drug
blocking	I-drug
agents	I-drug
may	O
potentiate	O
the	O
hypoglycemic	B-drug
action	I-drug
of	O
Starlix	B-drug
and	O
other	O
oral	O
antidiabetic	B-drug
drugs	I-drug
.	O

Certain	O
drugs	B-drug
including	O
thiazides	B-drug
,	O
corticosteroids	B-drug
,	O
thyroid	B-drug
products	O
,	O
and	O
sympathomimetics	B-drug
may	O
reduce	O
the	O
hypoglycemic	B-drug
action	I-drug
of	O
Starlix	B-drug
and	O
other	O
oral	O
antidiabetic	B-drug
drugs	I-drug
.	O

When	O
these	O
drugs	B-drug
are	O
administered	O
to	O
or	O
withdrawn	O
from	O
patients	O
receiving	O
Starlix	B-drug
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
changes	O
in	O
glycemic	O
control	O
.	O

Drug	O
interaction	O
studies	O
with	O
Xigris	B-drug
have	O
not	O
been	O
performed	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

However	O
,	O
since	O
there	O
is	O
an	O
increased	O
risk	O
of	O
bleeding	O
with	O
Xigris	B-drug
,	O
caution	O
should	O
be	O
employed	O
when	O
Xigris	B-drug
is	O
used	O
with	O
other	O
drugs	B-drug
that	O
affect	O
hemostasis	O
.	O

Approximately	O
2/3	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
3	O
study	O
received	O
either	O
prophylactic	O
low	O
dose	O
heparin	B-drug
(	O
unfractionated	B-drug
heparin	I-drug
up	O
to	O
15,000	O
units	O
/	O
day	O
)	O
or	O
prophylactic	B-drug
doses	O
of	O
low	B-drug
molecular	I-drug
weight	I-drug
heparins	I-drug
as	O
indicated	O
in	O
the	O
prescribing	O
information	O
for	O
the	O
specific	O
products	O
.	O

Concomitant	O
use	O
of	O
prophylactic	O
low	O
dose	O
heparin	B-drug
did	O
not	O
appear	O
to	O
affect	O
safety	O
,	O
however	O
,	O
its	O
effects	O
on	O
the	O
efficacy	O
of	O
Xigris	B-drug
have	O
not	O
been	O
evaluated	O
in	O
an	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interaction	O
Because	O
Xigris	B-drug
may	O
affect	O
the	O
APTT	O
assay	O
,	O
Xigris	B-drug
present	O
in	O
plasma	O
samples	O
may	O
interfere	O
with	O
one	O
-	O
stage	O
coagulation	O
assays	O
based	O
on	O
the	O
APTT	O
(	O
such	O
as	O
factor	B-drug
VIII	I-drug
,	O
IX	O
,	O
and	O
XI	O
assays	O
)	O
.	O

This	O
interference	O
may	O
result	O
in	O
an	O
apparent	O
factor	O
concentration	O
that	O
is	O
lower	O
than	O
the	O
true	O
concentration	O
.	O

Xigris	B-drug
present	O
in	O
plasma	O
samples	O
does	O
not	O
interfere	O
with	O
one	O
-	O
stage	O
factor	O
assays	O
based	O
on	O
the	O
PT	O
(	O
such	O
as	O
factor	B-drug
II	I-drug
,	O
V	O
,	O
VII	O
,	O
and	O
X	O
assays	O
)	O
.	O

Certain	O
drugs	B-drug
tend	O
to	O
produce	O
hyperglycemia	O
and	O
may	O
lead	O
to	O
loss	O
of	O
blood	O
glucose	O
control	O
.	O

These	O
drugs	B-drug
include	O
the	O
thiazides	B-drug
and	O
other	O
diuretics	B-drug
,	O
corticosteroids	B-drug
,	O
phenothiazines	B-drug
,	O
thyroid	B-drug
products	O
,	O
estrogens	B-drug
,	O
oral	B-drug
contraceptives	I-drug
,	O
phenytoin	B-drug
,	O
nicotinic	B-drug
acid	I-drug
,	O
sympathomimetics	B-drug
,	O
calcium	B-drug
channel	I-drug
-	I-drug
blocking	I-drug
drugs	I-drug
,	O
and	O
isoniazid	B-drug
.	O

When	O
such	O
drugs	B-drug
are	O
administered	O
to	O
a	O
patient	O
receiving	O
Acarbose	B-drug
,	O
the	O
patient	O
should	O
be	O
closely	O
observed	O
for	O
loss	O
of	O
blood	O
glucose	O
control	O
.	O

When	O
such	O
drugs	B-drug
are	O
withdrawn	O
from	O
patients	O
receiving	O
Acarbose	B-drug
in	O
combination	O
with	O
sulfonylureas	B-drug
or	O
insulin	B-drug
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
any	O
evidence	O
of	O
hypoglycemia	O
.	O

Intestinal	O
adsorbents	B-drug
(	O
e.	O
g.	O
,	O
charcoal	B-drug
)	O
and	O
digestive	B-drug
enzyme	I-drug
preparations	I-drug
containing	O
carbohydrate	O
-	O
splitting	O
enzymes	O
(	O
e.	O
g.	O
,	O
amylase	B-drug
,	O
pancreatin	B-drug
)	O
may	O
reduce	O
the	O
effect	O
of	O
Acarbose	B-drug
and	O
should	O
not	O
be	O
taken	O
concomitantly	O
.	O

Acarbose	B-drug
has	O
been	O
shown	O
to	O
change	O
the	O
bioavailabillty	O
digoxin	B-drug
when	O
they	O
are	O
co	O
-	O
administered	O
,	O
which	O
may	O
require	O
digoxin	O
dose	O
adjustment	O
.	O

Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
Acarbose	B-drug
has	O
no	O
effect	O
on	O
either	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
digoxin	B-drug
,	O
nifedipine	B-drug
,	O
propranolol	B-drug
,	O
or	O
ranitidine	B-drug
.	O

Acarbose	B-drug
did	O
not	O
interfere	O
with	O
the	O
absorption	O
or	O
disposition	O
of	O
the	O
sulfonylurea	B-drug
glyburide	O
in	O
diabetic	O
patients	O
.	O

Acarbose	B-drug
may	O
affect	O
digoxin	B-drug
bioavailabillty	O
and	O
may	O
require	O
dose	O
adjustment	O
of	O
digoxin	B-drug
by	O
16	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
8	O
-	O
23	O
%	O
)	O
,	O
decrease	O
mean	O
C	O
max	B-drug
digoxin	O
by	O
26	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
16	O
-	O
34	O
%	O
)	O
and	O
decrease	O
mean	O
trough	O
concentrations	O
of	O
digoxin	B-drug
by	O
9	O
%	O
(	O
90	O
%	O
confidence	O
limit	O
:	O
19	O
%	O
decrease	O
to	O
2	O
%	O
increase	O
)	O
.	O

The	O
amount	O
of	O
metformin	B-drug
absorbed	O
while	O
taking	O
Acarbose	B-drug
was	O
bioequivalent	O
to	O
the	O
amount	O
absorbed	O
when	O
taking	O
placebo	O
,	O
as	O
indicated	O
by	O
the	O
plasma	O
AUC	O
values	O
.	O

However	O
,	O
the	O
peak	O
plasma	O
level	O
of	O
metformin	B-drug
was	O
reduced	O
by	O
approximately	O
20	O
%	O
when	O
taking	O
Acarbose	B-drug
due	O
to	O
a	O
slight	O
delay	O
in	O
the	O
absorption	O
of	O
metformin	B-drug
.	O

There	O
is	O
little	O
if	O
any	O
clinically	O
significant	O
interaction	O
between	O
Acarbose	B-drug
and	O
metformin	B-drug
.	O

Effects	O
of	O
Lapatinib	B-drug
on	O
Drug	B-drug
Metabolizing	O
Enzymes	O
and	O
Drug	O
Transport	O
Systems	O
Lapatinib	B-drug
inhibits	O
CYP3A4	B-drug
and	O
CYP2C8	B-drug
in	O
vitro	O
at	O
clinically	O
relevant	O
concentrations	O
.	O

Caution	O
should	O
be	O
exercised	O
and	O
dose	O
reduction	O
of	O
the	O
concomitant	O
substrate	O
drug	B-drug
should	O
be	O
considered	O
when	O
dosing	O
lapatinib	B-drug
concurrently	O
with	O
medications	B-drug
with	O
narrow	O
therapeutic	O
windows	O
that	O
are	O
substrates	O
of	O
CYP3A4	B-drug
or	O
CYP2C8	B-drug
.	O

Lapatinib	B-drug
did	O
not	O
significantly	O
inhibit	O
the	O
following	O
enzymes	O
in	O
human	O
liver	O
microsomes	O
:	O
CYP1A2	B-drug
,	O
CYP2C9	B-drug
,	O
CYP2C19	B-drug
,	O
and	O
CYP2D6	B-drug
or	O
UGT	O
enzymes	O
in	O
vitro	O
,	O
however	O
,	O
the	O
clinical	O
significance	O
is	O
unknown	O
.	O

Lapatinib	B-drug
inhibits	O
human	O
P	O
-	O
glycoprotein	B-drug
.	O

If	O
TYKERB	O
is	O
administered	O
with	O
drugs	B-drug
that	O
are	O
substrates	O
of	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
the	O
substrate	O
drug	B-drug
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Drugs	B-drug
that	O
Inhibit	O
or	O
Induce	O
Cytochrome	B-drug
P450	I-drug
3A4	I-drug
Enzymes	O
Lapatinib	O
undergoes	O
extensive	O
metabolism	O
by	O
CYP3A4	B-drug
,	O
and	O
concomitant	O
administration	O
of	O
strong	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	B-drug
alter	O
lapatinib	B-drug
concentrations	O
significantly	O
.	O

Dose	O
adjustment	O
of	O
lapatinib	B-drug
should	O
be	O
considered	O
for	O
patients	O
who	O
must	O
receive	O
concomitant	O
strong	O
inhibitors	O
or	O
concomitant	O
strong	O
inducers	O
of	O
CYP3A4	B-drug
enzymes	O
.	O

Ketoconazole	B-drug
:	O
In	O
healthy	O
subjects	O
receiving	O
ketoconazole	B-drug
,	O
a	O
CYP3A4	B-drug
inhibitor	O
,	O
at	O
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B-drug
was	O
increased	O
to	O
approximately	O
3.6-fold	O
of	O
control	O
and	O
half	O
-	O
life	O
increased	O
to	O
1.7-fold	O
of	O
control	O
.	O

Carbamazepine	B-drug
:	O
In	O
healthy	O
subjects	O
receiving	O
the	O
CYP3A4	B-drug
inducer	O
,	O
carbamazepine	B-drug
,	O
at	O
100	O
mg	O
twice	O
daily	O
for	O
3	O
days	O
and	O
200	O
mg	O
twice	O
daily	O
for	O
17	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B-drug
was	O
decreased	O
approximately	O
72	O
%	O
.	O

Drugs	B-drug
that	O
Inhibit	O
Drug	O
Transport	O
Systems	O
Lapatinib	B-drug
is	O
a	O
substrate	O
of	O
the	O
efflux	O
transporter	B-drug
P	O
-	O
glycoprotein	O
(	O
Pgp	O
,	O
ABCB1	B-drug
)	O
.	O

If	O
TYKERB	O
is	O
administered	O
with	O
drugs	B-drug
that	O
inhibit	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
lapatinib	B-drug
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Other	O
Chemotherapy	O
Agents	O
In	O
a	O
separate	O
study	O
,	O
concomitant	O
administration	O
of	O
lapatinib	B-drug
with	O
capecitabine	B-drug
did	O
not	O
meaningfully	O
alter	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
(	O
or	O
the	O
metabolites	B-drug
of	O
capecitabine	B-drug
)	O
.	O

Warfarin	B-drug
Concomitant	O
administration	O
of	O
daptomycin	B-drug
(	O
6	O
mg	O
/	O
kg	O
once	O
every	O
24	O
hours	O
for	O
5	O
days	O
)	O
and	O
warfarin	B-drug
(	O
25	O
mg	O
single	O
oral	O
dose	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
drug	B-drug
,	O
and	O
the	O
INR	O
was	O
not	O
significantly	O
altered	O
.	O

As	O
experience	O
with	O
the	O
concomitant	O
administration	O
of	O
daptomycin	B-drug
and	O
warfarin	B-drug
is	O
limited	O
to	O
volunteer	O
studies	O
,	O
anticoagulant	O
activity	O
in	O
patients	O
receiving	O
daptomycin	B-drug
and	O
warfarin	B-drug
should	O
be	O
monitored	O
for	O
the	O
first	O
several	O
days	O
after	O
initiating	O
therapy	O
with	O
Fentanyl	B-drug
.	O

HMG	B-drug
-	I-drug
CoA	I-drug
Reductase	I-drug
Inhibitors	I-drug
Inhibitors	O
of	O
HMG	B-drug
-	I-drug
CoA	I-drug
reductase	I-drug
may	O
cause	O
myopathy	O
,	O
which	O
is	O
manifested	O
as	O
muscle	O
pain	O
or	O
weakness	O
associated	O
with	O
elevated	O
levels	O
of	O
CPK	O
.	O

There	O
were	O
no	O
reports	O
of	O
skeletal	O
myopathy	O
in	O
a	O
placebo	O
-	O
controlled	O
Phase	O
I	O
trial	O
in	O
which	O
10	O
healthy	O
subjects	O
on	O
stable	O
simvastatin	B-drug
therapy	O
were	O
treated	O
concurrently	O
with	O
daptomycin	B-drug
(	O
4	O
mg	O
/	O
kg	O
once	O
every	O
24	O
hours	O
)	O
for	O
14	O
days	O
.	O

Experience	O
with	O
co	O
-	O
administration	O
of	O
HMG	B-drug
-	I-drug
CoA	I-drug
reduc	O
-	O
tase	O
inhibitors	O
and	O
Fentanyl	B-drug
in	O
patients	O
is	O
limited	O
,	O
therefore	O
,	O
consideration	O
should	O
be	O
given	O
to	O
temporarily	O
suspending	O
use	O
of	O
HMG	B-drug
-	I-drug
CoA	I-drug
reductase	I-drug
inhibitors	I-drug
in	O
patients	O
receiving	O
Fentanyl	B-drug
.	O

Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
:	O
There	O
are	O
no	O
reported	O
drug	O
-	O
laboratory	O
test	O
interactions	O
.	O

Fenfluramine	B-drug
may	O
increase	O
slightly	O
the	O
effect	O
of	O
antihypertensive	B-drug
drugs	I-drug
,	O
e.g.	O
,	O
guanethidine	B-drug
,	O
methyldopa	B-drug
,	O
reserpine	B-drug
.	O

Other	O
CNS	B-drug
depressant	I-drug
drugs	I-drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
fenfluramine	B-drug
,	O
since	O
the	O
effects	O
may	O
be	O
additive	O
.	O

Special	O
consideration	O
should	O
be	O
given	O
to	O
the	O
administration	O
of	O
ETHYOL	O
?	O
in	O
patients	O
receiving	O
antihypertensive	B-drug
medications	O
or	O
other	O
drugs	B-drug
that	O
could	O
cause	O
or	O
potentiate	O
hypotension	O
.	O

Caution	O
should	O
be	O
observed	O
when	O
anileridine	B-drug
is	O
coadministered	O
with	O
other	O
opioids	B-drug
,	O
sedatives	B-drug
,	O
phenothiazines	B-drug
,	O
or	O
anesthetics	B-drug
,	O
as	O
these	O
agents	O
may	O
increase	O
respiratory	O
and	O
circulatory	O
depression	O
.	O

Tizoxanide	B-drug
is	O
highly	O
bound	O
to	O
plasma	B-drug
protein	I-drug
(	O
99.9	O
%	O
)	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
nitazoxanide	B-drug
concurrently	O
with	O
other	O
highly	O
plasma	O
protein	O
-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
(	O
e.g.	O
,	O
warfarin	B-drug
)	O
.	O

In	O
vitro	O
metabolism	O
studies	O
have	O
demonstrated	O
that	O
tizoxanide	B-drug
has	O
no	O
significant	O
inhibitory	O
effect	O
on	O
cytochrome	B-drug
P450	I-drug
enzymes	O
.	O

Although	O
no	O
drug	O
-	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
in	O
vivo	O
,	O
it	O
is	O
expected	O
that	O
no	O
significant	O
interaction	O
would	O
occur	O
when	O
nitazoxanide	B-drug
is	O
co	O
-	O
administered	O
with	O
drugs	B-drug
that	O
either	O
are	O
metabolized	O
by	O
or	O
inhibit	O
cytochrome	B-drug
P450	I-drug
enzymes	O
.	O

In	O
occasional	O
susceptible	O
patients	O
or	O
in	O
those	O
receiving	O
anticholinergic	B-drug
drugs	I-drug
(	O
including	O
antiparkinsonism	O
agents	O
)	O
in	O
addition	O
,	O
the	O
atropine	B-drug
-	O
like	O
effects	O
may	O
become	O
more	O
pronounced	O
(	O
e.g.	O
,	O
paralytic	O
ileus	O
)	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
is	O
required	O
when	O
this	O
drug	B-drug
is	O
administered	O
concomitantly	O
with	O
anticholinergic	B-drug
drugs	I-drug
.	O

Avoid	O
the	O
use	O
of	O
preparations	O
such	O
as	O
decongestants	B-drug
and	O
local	B-drug
anesthetics	I-drug
which	O
contain	O
any	O
sympathomimetic	B-drug
amine	I-drug
(	O
e.g.	O
,	O
epinephrine	B-drug
,	O
norepinephrine	B-drug
)	O
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
tricyclic	B-drug
antidepressants	I-drug
can	O
potentiate	O
the	O
effects	O
of	O
catecholamines	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
imipramine	B-drug
hydrochloride	I-drug
is	O
used	O
with	O
agents	O
that	O
lower	O
blood	O
pressure	O
.	O

Imipramine	B-drug
hydrochloride	I-drug
may	O
potentiate	O
the	O
effects	O
of	O
CNS	B-drug
depressant	I-drug
drugs	I-drug
.	O

The	O
plasma	O
concentration	O
of	O
imipramine	B-drug
may	O
increase	O
when	O
the	O
drug	B-drug
is	O
given	O
concomitantly	O
with	O
hepatic	O
enzyme	B-drug
inhibitors	I-drug
(	O
e.g.	O
,	O
cimetidine	B-drug
,	O
fluoxetine	B-drug
)	O
and	O
decrease	O
by	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
barbiturates	B-drug
,	O
phenytoin	B-drug
)	O
,	O
and	O
adjustment	O
of	O
the	O
dosage	O
of	O
imipramine	B-drug
may	O
therefore	O
be	O
necessary	O
.	O

Drugs	B-drug
Metabolized	O
by	O
P450	B-drug
2D6	I-drug
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-drug
hydroxylase	I-drug
)	I-drug
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
to	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	B-drug
2D6	I-drug
isozyme	I-drug
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-drug
antidepressants	I-drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
fraction	O
of	O
drug	B-drug
metabolized	O
by	O
P450	B-drug
2D6	I-drug
,	I-drug
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8-fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	B-drug
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O

metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-drug
that	O
inhibit	O
cytochrome	B-drug
P450	I-drug
2D6	I-drug
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-drug
;	O

cimetidine	B-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	B-drug
2D6	I-drug
(	O
many	O
other	O
antidepressants	B-drug
,	O
phenothiazines	B-drug
,	O
and	O
the	O
Type	O
1C	O
antiarrhythmics	O
propafenone	B-drug
and	O
flecainide	B-drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	B-drug
reuptake	I-drug
inhibitors	I-drug
(	O
SSRIs	O
)	O
,	O
e.	O
g.	O
,	O
fluoxetine	B-drug
,	O
sertraline	B-drug
,	O
and	O
paroxetine	B-drug
,	O
inhibit	O
P450	B-drug
2D6	I-drug
,	I-drug
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	O
-	O
TCA	O
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
,	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
TCA5	O
with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-drug
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	B-drug
metabolite	I-drug
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-drug
antidepressants	I-drug
with	O
drugs	B-drug
that	O
can	O
inhibit	O
cytochrome	B-drug
P450	I-drug
2D6	I-drug
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-drug
antidepressant	I-drug
or	O
the	O
other	O
drug	B-drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	B-drug
is	O
withdrawn	O
from	O
cotherapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-drug
antidepressant	I-drug
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	O
plasma	O
levels	O
whenever	O
a	O
TCA	O
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	B-drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	B-drug
2D6	I-drug
.	I-drug

Certain	O
endocrine	O
and	O
liver	O
function	O
tests	O
may	O
be	O
affected	O
by	O
estrogen	B-drug
-	O
containing	O
oral	B-drug
contraceptives	I-drug
.	O

The	O
following	O
similar	O
changes	O
may	O
be	O
expected	O
with	O
larger	O
doses	O
of	O
estrogen	B-drug
:	O
Increased	O
sulfobromophthalein	O
retention	O
;	O

increased	O
prothrombin	B-drug
and	O
factors	B-drug
VII	I-drug
,	I-drug
VIII	O
,	O
IX	O
,	O
and	O
X	O
;	O

decreased	O
antithrombin	B-drug
3	O
;	O

increased	O
norepinephrine	B-drug
-	O
induced	O
platel	O
et	O
aggregation	O
;	O

increased	O
thyroid	O
binding	O
globulin	O
(	O
TBG	O
)	O
leading	O
to	O
increased	O
circulating	O
total	O
thyroid	B-drug
hormone	I-drug
,	O
as	O
measured	O
by	O
PBI	O
,	O
T4	B-drug
by	O
column	O
,	O
or	O
T4	B-drug
by	O
radioimmunoassay	O
.	O

Free	O
T3	O
resin	O
uptake	O
is	O
decreased	O
,	O
reflecting	O
the	O
elevated	O
TBG	O
;	O

free	O
T4	O
concentration	O
is	O
unaltered	O
:	O
impaired	O
glucose	O
tolerance	O
;	O

decreased	O
pregnanediol	O
excretion	O
;	O

reduced	O
response	O
to	O
metyrapone	O
test	O
;	O

reduced	O
serum	O
folate	O
concentration	O
;	O

increased	O
serum	O
triglyceride	O
and	O
phospholipid	B-drug
concentration	O
.	O

Plasma	O
levels	O
of	O
anticonvulsant	B-drug
agents	O
may	O
become	O
subtherapeutic	O
during	O
cisplatin	B-drug
therapy	O
.	O

In	O
a	O
randomized	O
trial	O
in	O
advanced	O
ovarian	O
cancer	O
,	O
response	O
duration	O
was	O
adversely	O
affected	O
when	O
pyridoxine	B-drug
was	O
used	O
in	O
combination	O
with	O
altretamine	B-drug
(	O
hexamethylmelamine	B-drug
)	O
and	O
cisplatin.1	O

In	O
vitro	O
data	O
indicate	O
that	O
NORVASC	B-drug
has	O
no	O
effect	O
on	O
the	O
human	B-drug
plasma	I-drug
protein	O
binding	O
of	O
digoxin	B-drug
,	O
phenytoin	B-drug
,	O
warfarin	B-drug
,	O
and	O
indomethacin	B-drug
.	O

Effect	O
of	O
other	O
agents	O
on	O
NORVASC	B-drug
.	O

CIMETIDINE	B-drug
:	O
Co	O
-	O
administration	O
of	O
NORVASC	B-drug
with	O
cimetidine	B-drug
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
NORVASC	B-drug
.	O

GRAPEFRUIT	O
JUICE	O
:	O
Co	O
-	O
administration	O
of	O
240	O
mL	O
of	O
grapefruit	O
juice	O
with	O
a	O
single	O
oral	O
dose	O
of	O
amlodipine	B-drug
10	I-drug
mg	I-drug
in	O
20	O
healthy	O
volunteers	O
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
amlodipine	B-drug
.	O

MAALOX	B-drug
(	O
antacid	B-drug
)	O
:	O
Co	O
-	O
administration	O
of	O
the	O
antacid	O
Maalox	B-drug
with	O
a	O
single	O
dose	O
of	O
NORVASC	B-drug
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
NORVASC	B-drug
.	O

SILDENAFIL	B-drug
:	O
A	O
single	O
100	O
mg	O
dose	O
of	O
sildenafil	B-drug
(	O
Viagra	O
?	O
)	O
in	O
subjects	O
with	O
essential	O
hypertension	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
parameters	O
of	O
NORVASC	B-drug
.	O

When	O
NORVASC	B-drug
and	O
sildenafil	B-drug
were	O
used	O
in	O
combination	O
,	O
each	O
agent	O
independently	O
exerted	O
its	O
own	O
blood	O
pressure	O
lowering	O
effect	O
.	O

Effect	O
of	O
NORVASC	B-drug
on	O
other	O
agents	O
.	O

ATORVASTATIN	B-drug
:	O
Co	O
-	O
administration	O
of	O
multiple	O
10	O
mg	O
doses	O
of	O
NORVASC	B-drug
with	O
80	O
mg	O
of	O
atorvastatin	B-drug
resulted	O
in	O
no	O
significant	O
change	O
in	O
the	O
steady	O
state	O
pharmacokinetic	O
parameters	O
of	O
atorvastatin	B-drug
.	O

DIGOXIN	B-drug
:	O
Co	O
-	O
administration	O
of	O
NORVASC	B-drug
with	O
digoxin	B-drug
did	O
not	O
change	O
serum	O
digoxin	O
levels	O
or	O
digoxin	B-drug
renal	O
clearance	O
in	O
normal	O
volunteers	O
.	O

ETHANOL	B-drug
(	O
alcohol	B-drug
)	O
:	O
Single	O
and	O
multiple	O
10	O
mg	O
doses	O
of	O
NORVASC	B-drug
had	O
no	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethanol	B-drug
.	O

WARFARIN	B-drug
:	O
Co	O
-	O
administration	O
of	O
NORVASC	B-drug
with	O
warfarin	B-drug
did	O
not	O
change	O
the	O
warfarin	O
prothrombin	B-drug
response	O
time	O
.	O

In	O
clinical	O
trials	O
,	O
NORVASC	B-drug
has	O
been	O
safely	O
administered	O
with	O
thiazide	B-drug
diuretics	I-drug
,	O
beta	B-drug
-	I-drug
blockers	I-drug
,	I-drug
angiotensin	B-drug
-	I-drug
converting	I-drug
enzyme	I-drug
inhibitors	I-drug
,	O
long	O
-	O
acting	O
nitrates	B-drug
,	O
sublingual	O
nitroglycerin	B-drug
,	O
digoxin	B-drug
,	O
warfarin	B-drug
,	O
non	B-drug
-	I-drug
steroidal	I-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
,	O
antibiotics	B-drug
,	O
and	O
oral	B-drug
hypoglycemic	I-drug
drugs	I-drug
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
:	O
None	O
known	O
.	O

Oral	B-drug
Anticoagulants	I-drug
CAUTION	O
SHOULD	O
BE	O
EXERCISED	O
WHEN	O
COUMARIN	B-drug
ANTICOAGULANTS	O
ARE	O
GIVEN	O
IN	O
CONJUNCTION	O
WITH	O
TRICOR	B-drug
.	O

THE	O
DOSAGE	O
OF	O
THE	O
ANTICOAGULANTS	B-drug
SHOULD	O
BE	O
REDUCED	O
TO	O
MAINTAIN	O
THE	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
AT	O
THE	O
DESIRED	O
LEVEL	O
TO	O
PREVENT	B-drug
BLEEDING	O
COMPLICATIONS	O
.	O

FREQUENT	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
DETERMINATIONS	O
ARE	O
ADVISABLE	O
UNTIL	O
IT	O
HAS	O
BEEN	O
DEFINITELY	O
DETERMINED	O
THAT	O
THE	O
PROTHROMBIN	O
TIME	O
/	O
INR	O
HAS	O
STABILIZED	O
.	O

HMG	B-drug
-	I-drug
CoA	I-drug
reductase	I-drug
inhibitors	I-drug
The	O
combined	O
use	O
of	O
TRICOR	B-drug
and	O
HMG	B-drug
-	I-drug
CoA	I-drug
reductase	I-drug
inhibitors	I-drug
should	O
be	O
avoided	O
unless	O
the	O
benefit	O
of	O
further	O
alterations	O
in	O
lipid	O
levels	O
is	O
likely	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
this	O
drug	B-drug
combination	O
.	O

Resins	B-drug
Since	O
bile	B-drug
acid	I-drug
sequestrants	I-drug
may	O
bind	O
other	O
drugs	B-drug
given	O
concurrently	O
,	O
patients	O
should	O
take	O
TRICOR	B-drug
at	O
least	O
1	O
hour	O
before	O
or	O
4	O
-	O
6	O
hours	O
after	O
a	O
bile	B-drug
acid	I-drug
binding	O
resin	O
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Cyclosporine	B-drug
Because	O
cyclosporine	B-drug
can	O
produce	O
nephrotoxicity	O
with	O
decreases	O
in	O
creatinine	O
clearance	O
and	O
rises	B-drug
in	O
serum	O
creatinine	O
,	O
and	O
because	O
renal	O
excretion	O
is	O
the	O
primary	O
elimination	O
route	O
of	O
fibrate	B-drug
drugs	I-drug
including	O
TRICOR	B-drug
,	O
there	O
is	O
a	O
risk	O
that	O
an	O
interaction	O
will	O
lead	O
to	O
deterioration	O
.	O

The	O
benefits	O
and	O
risks	O
of	O
using	O
TRICOR	B-drug
with	O
immunosuppressants	B-drug
and	O
other	O
potentially	O
nephrotoxic	O
agents	O
should	O
be	O
carefully	O
considered	O
,	O
and	O
the	O
lowest	O
effective	O
dose	O
employed	O

.	O

?	O
Drug	O
-	O
drug	O
interactions	O
In	O
vitro	O
studies	O
using	O
human	O
liver	O
microsomes	O
indicate	O
that	O
fenofibrate	B-drug
and	O
fenofibric	B-drug
acid	I-drug
are	O
not	O
inhibitors	O
of	O
cytochrome	B-drug
(	O
CYP	B-drug
)	O
P450	B-drug
isoforms	O
CYP3A4	O
,	O
CYP2D6	B-drug
,	O
CYP2E1	B-drug
,	O
or	O
CYP1A2	B-drug
.	O

They	O
are	O
weak	O
inhibitors	O
of	O
CYP2C19	B-drug
and	O
CYP2A6	B-drug
,	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
inhibitors	O
of	O
CYP2C9	B-drug
at	O
therapeutic	O
concentrations	O
.	O

Potentiation	O
of	O
coumarin	B-drug
-	I-drug
type	I-drug
anticoagulants	I-drug
has	O
been	O
observed	O
with	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
/	O
INR	O
.	O

Bile	B-drug
acid	I-drug
sequestrants	I-drug
have	O
been	O
shown	O
to	O
bind	O
other	O
drugs	B-drug
given	O
concurrently	O
.	O

Therefore	O
,	O
fenofibrate	B-drug
should	O
be	O
taken	O
at	O
least	O
1	O
hour	O
before	O
or	O
4	O
-	O
6	O
hours	O
after	O
a	O
bile	B-drug
acid	I-drug
binding	O
resin	O
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Concomitant	O
administration	O
of	O
fenofibrate	B-drug
(	O
equivalent	O
to	O
145	O
mg	O
TRICOR	B-drug
)	O
with	O
pravastatin	B-drug
(	O
40	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
Cmax	O
and	O
AUC	O
values	O
for	O
pravastatin	B-drug
by	O
36	O
%	O
(	O
range	O
from	O
69	O
%	O
decrease	O
to	O
321	O
%	O
increase	O
)	O
and	O
28	O
%	O
(	O
range	O
from	O
54	O
%	O
decrease	O
to	O
128	O
%	O
increase	O
)	O
,	O
respectively	O
,	O
and	O
for	O
3?-hydroxy	O
-	O
iso	O
-	O
pravastatin	B-drug
by	O
55	O
%	O
(	O
range	O
from	O
32	O
%	O
decrease	O
to	O
314	O
%	O
increase	O
)	O
and	O
39	O
%	O
(	O
range	O
from	O
24	O
%	O
decrease	O
to	O
261	O
%	O
increase	O
)	O
,	O
respectively	O
in	O
23	O
healthy	O
adults	O
.	O

A	O
single	O
dose	O
of	O
pravastatin	B-drug
had	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
fenofibric	B-drug
acid	I-drug
.	O

Concomitant	O
administration	O
of	O
fenofibrate	B-drug
(	O
equivalent	O
to	O
145	O
mg	O
TRICOR	B-drug
)	O
with	O
atorvastatin	B-drug
(	O
20	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
resulted	O
in	O
approximately	O
17	O
%	O
decrease	O
(	O
range	O
from	O
67	O
%	O
decrease	O
to	O
44	O
%	O
increase	O
)	O
in	O
atorvastatin	B-drug
AUC	O
values	O
in	O
22	O
healthy	O
males	O
.	O

The	O
atorvastatin	B-drug
Cmax	O
values	O
were	O
not	O
significantly	O
affected	O
by	O
fenofibrate	B-drug
.	O

The	O
pharmacokinetics	O
of	O
fenofibric	B-drug
acid	I-drug
were	O
not	O
significantly	O
affected	O
by	O
atorvastatin	B-drug

.	O

?	O

Substances	O
that	O
are	O
inducers	O
of	O
CYP3A4	B-drug
activity	O
increase	O
the	O
metabolism	O
of	O
gefitinib	B-drug
and	O
decrease	O
its	O
plasma	O
concentrations	O
.	O

In	O
patients	O
receiving	O
a	O
potent	O
CYP3A4	B-drug
inducer	O
such	O
as	O
rifampicin	B-drug
or	O
phenytoin	B-drug
,	O
a	O
dose	O
increase	O
to	O
500	O
mg	O
daily	O
should	O
be	O
considered	O
in	O
the	O
absence	O
of	O
severe	O
adverse	O
drug	O
reaction	O
,	O
and	O
clinical	O
response	O
and	O
adverse	O
events	O
should	O
be	O
carefully	O
monitored	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
-	O
Drug	O
-	O
Drug	O
Interactions	O
and	O
DOSAGE	O
AND	O
ADMINISTRATION	O
-	O
Dosage	O
Adjustment	O
sections	O
)	O
.	O

International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and/or	O
bleeding	O
events	O
have	O
been	O
reported	O
in	O
some	O
patients	O
taking	O
warfarin	B-drug
while	O
on	O
IRESSA	B-drug
therapy	O
.	O

Patients	O
taking	O
warfarin	B-drug
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O
.	O

Substances	O
that	O
are	O
potent	O
inhibitors	O
of	O
CYP3A4	B-drug
activity	O
(	O
eg	O
,	O
ketoconazole	B-drug
and	O
itraconazole	B-drug
)	O
decrease	O
gefitinib	B-drug
metabolism	O
and	O
increase	O
gefitinib	B-drug
plasma	O
concentrations	O
.	O

This	O
increase	O
may	O
be	O
clinically	O
relevant	O
as	O
adverse	O
experiences	O
are	O
related	O
to	O
dose	O
and	O
exposure	O
;	O

therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CYP3A4	B-drug
inhibitors	O
with	O
IRESSA	B-drug
.	O

Drugs	B-drug
that	O
cause	O
significant	O
sustained	O
elevation	O
in	O
gastric	O
pH	O
(	O
histamine	B-drug
H2-receptor	I-drug
antagonists	I-drug
such	O
as	O
ranitidine	B-drug
or	O
cimetidine	B-drug
)	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
IRESSA	B-drug
and	O
therefore	O
potentially	O
may	O
reduce	O
efficacy	O
.	O

Phase	O
II	O
clinical	O
trial	O
data	O
,	O
where	O
IRESSA	B-drug
and	O
vinorelbine	B-drug
have	O
been	O
used	O
concomitantly	O
,	O
indicate	O
that	O
IRESSA	B-drug
may	O
exacerbate	O
the	O
neutropenic	O
effect	O
of	O
vinorelbine	B-drug
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
with	O
anti	B-drug
-	I-drug
neoplastic	I-drug
agents	I-drug
have	O
been	O
conducted	O
.	O

In	O
Study	O
1	O
,	O
patients	O
with	O
colorectal	O
cancer	O
were	O
given	O
irinotecan/5-FU	O
/	O
leucovorin	O
(	O
bolus	O
-	O
IFL	O
)	O
with	O
or	O
without	O
AVASTIN	B-drug
.	O

Irinotecan	B-drug
concentrations	O
were	O
similar	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
alone	O
and	O
in	O
combination	O
with	O
AVASTIN	B-drug
.	O

The	O
concentrations	O
of	O
SN38	O
,	O
the	O
active	B-drug
metabolite	I-drug
of	O
irinotecan	B-drug
,	O
were	O
on	O
average	O
33	O
%	O
higher	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
in	O
combination	O
with	O
AVASTIN	B-drug
when	O
compared	O
with	O
bolus	O
-	O
IFL	O
alone	O
.	O

In	O
Study	O
1	O
,	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
plus	O
AVASTIN	B-drug
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
3	O
-	O
4	O
diarrhea	O
and	O
neutropenia	O
.	O

Due	O
to	O
high	O
inter	O
-	O
patient	O
variability	O
and	O
limited	O
sampling	O
,	O
the	O
extent	O
of	O
the	O
increase	O
in	O
SN38	O
levels	O
in	O
patients	O
receiving	O
concurrent	O
irinotecan	B-drug
and	O
AVASTIN	B-drug
is	O
uncertain	O
.	O

Dicumarol	B-drug
and	O
warfarin	B-drug
may	O
decrease	O
hypoprothrombinemic	O
effect	O
.	O

Other	O
depressasnts	O
such	O
as	O
alcohol	B-drug
,	O
barbiturates	B-drug
,	O
and	O
MAOIs	O
may	O
enhance	O
CNS	O
depression	O
when	O
administered	O
with	O
ethchlorvynol	B-drug
.	I-drug

Effect	O
of	O
other	O
drugs	B-drug
on	O
Vardenafil	B-drug

In	O
vitro	O
studies	O
:	O
Studies	O
in	O
human	O
liver	O
microsomes	O
showed	O
that	O
vardenafil	B-drug
is	O
metabolized	O
primarily	O
by	O
cytochrome	B-drug
P450	I-drug
(	O
CYP	B-drug
)	O
isoforms	B-drug
3A4/5	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
by	O
CYP2C9	B-drug
.	O

Therefore	O
,	O
inhibitors	O
of	O
these	O
enzymes	O
are	O
expected	O
to	O
reduce	O
vardenafil	B-drug
clearance	O
.	O

In	O
vivo	O
studies	O
:	O
Cytochrome	B-drug
P450	I-drug
Inhibitors	O

Cimetidine	B-drug
(	O
400	O
mg	O
b.i.d	O
.	O
)	O
had	O
no	O
effect	O
on	O
vardenafil	B-drug
bioavailability	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
vardenafil	B-drug
when	O
co	O
-	O
administered	O
with	O
20	O
mg	O
Vardenafil	B-drug
in	O
healthy	O
volunteers	O
.	O

Erythromycin	B-drug
(	O
500	B-drug
mg	O
t.i.d	O
)	O
produced	O
a	O
4-fold	O
increase	O
in	O
vardenafil	B-drug
AUC	O
and	O
a	O
3-fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	B-drug
5	I-drug
mg	I-drug
in	O
healthy	O
volunteers	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
5	O
mg	O
dose	O
of	O
Vardenafil	B-drug
in	O
a	O
24-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
erythromycin	B-drug
.	O

Ketoconazole	B-drug
(	O
200	O
mg	O
once	O
daily	O
)	O
produced	O
a	O
10-fold	O
increase	O
in	O
vardenafil	B-drug
AUC	O
and	O
a	O
4-fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	B-drug
(	O
5	O
mg	O
)	O
in	O
healthy	O
volunteers	O
.	O

A	O
5-mg	O
Vardenafil	B-drug
dose	O
should	O
not	O
be	O
exceeded	O
when	O
used	O
in	O
combination	O
with	O
200	O
mg	O
once	O
daily	O
ketoconazole	B-drug
.	O

Since	O
higher	O
doses	O
of	O
ketoconazole	B-drug
(	O
400	O
mg	O
daily	O
)	O
may	O
result	O
in	O
higher	O
increases	O
in	O
Cmax	O
and	O
AUC	O
,	O
a	O
single	O
2.5	O
mg	O
dose	O
of	O
Vardenafil	B-drug
should	O
not	O
be	O
exceeded	O
in	O
a	O
24-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ketoconazole	B-drug
400	I-drug
mg	I-drug
daily	O
.	O

HIV	B-drug
Protease	I-drug
Inhibitors	I-drug
:	O
Indinavir	B-drug
(	O
800	B-drug
mg	O
t.i.d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	B-drug
10	I-drug
mg	I-drug
resulted	O
in	O
a	O
16-fold	O
increase	O
in	O
vardenafil	B-drug
AUC	O
,	O
a	O
7-fold	O
increase	O
in	O
vardenafil	B-drug
Cmax	O
and	O
a	O
2-fold	O
increase	O
in	O
vardenafil	B-drug
half	O
-	O
life	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2.5	O
mg	O
Vardenafil	O
dose	O
in	O
a	O
24-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
indinavir	B-drug
.	O

Ritonavir	B-drug
(	O
600	O
mg	O
b.i.d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	B-drug
5	I-drug
mg	I-drug
resulted	O
in	O
a	O
49-fold	O
increase	O
in	O
vardenafil	B-drug
AUC	O
and	O
a	O
13-fold	O
increase	O
in	O
vardenafil	B-drug
Cmax	O
.	O

The	O
interaction	O
is	O
a	O
consequence	O
of	O
blocking	O
hepatic	O
metabolism	O
of	O
vardenafil	B-drug
by	O
ritonavir	B-drug
,	O
a	O
highly	O
potent	O
CYP3A4	B-drug
inhibitor	O
,	O
which	O
also	O
inhibits	O
CYP2C9	B-drug
.	O

Ritonavir	B-drug
significantly	O
prolonged	O
the	O
half	O
-	O
life	O
of	O
vardenafil	B-drug
to	O
26	O
hours	O
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2.5	O
mg	O
Vardenafil	O
dose	O
in	O
a	O
72-hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ritonavir	B-drug
.	O

Other	O
Drug	O
Interactions	O
:	O
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
between	O
vardenafil	B-drug
and	O
the	O
following	O
drugs	B-drug
:	O
glyburide	B-drug
,	O
warfarin	B-drug
,	O
digoxin	B-drug
,	O
Maalox	B-drug
,	O
and	O
ranitidine	B-drug
.	O

In	O
the	O
warfarin	B-drug
study	O
,	O
vardenafil	B-drug
had	O
no	O
effect	O
on	O
the	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
.	O

Effects	O
of	O
Vardenafil	B-drug
on	O
other	O
drugs	B-drug

In	O
vitro	O
studies	O
:	O
Vardenafil	B-drug
and	O
its	O
metabolites	B-drug
had	O
no	O
effect	O
on	O
CYP1A2	B-drug
,	O
2A6	O
,	O
and	O
2E1	O
(	O
Ki	B-drug
  	I-drug
100uM	I-drug
)	I-drug
.	O

Weak	O
inhibitory	O
effects	O
toward	O
other	O
isoforms	B-drug
(	O
CYP2C8	B-drug
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
3A4	O
)	O
were	O
found	O
,	O
but	O
Ki	O
values	O
were	O
in	O
excess	O
of	O
plasma	O
concentrations	O
achieved	O
following	O
dosing	O
.	O

The	O
most	O
potent	O
inhibitory	O
activity	O
was	O
observed	O
for	O
vardenafil	B-drug
metabolite	O
M1	O
,	O
which	O
had	O
a	O
Ki	O
of	O
1.4	O
uM	O
toward	O
CYP3A4	B-drug
,	O
which	O
is	O
about	O
20	O
times	O
higher	O
than	O
the	O
M1	O
Cmax	O
values	O
after	O
an	O
80	O
mg	O
Vardenafil	B-drug
dose	O
.	O

In	O
vivo	O
studies	O
:	O
Nitrates	B-drug
:	O
The	O
blood	O
pressure	O
lowering	O
effects	O
of	O
sublingual	O
nitrates	B-drug
(	O
0.4	O
mg	O
)	O
taken	O
1	O
and	O
4	O
hours	O
after	O
vardenafil	B-drug
and	O
increases	O
in	O
heart	O
rate	O
when	O
taken	O
at	O
1	O
,	O
4	O
and	O
8	O
hours	O
were	O
potentiated	O
by	O
a	O
20	O
mg	O
dose	O
of	O
Vardenafil	B-drug
in	O
healthy	O
middle	O
-	O
aged	O
subjects	O
.	O

These	O
effects	O
were	O
not	O
observed	O
when	O
Vardenafil	B-drug
20	I-drug
mg	I-drug
was	O
taken	O
24	O
hours	O
before	O
the	O
NTG	O
.	O

Potentiation	O
of	O
the	O
hypotensive	O
effects	O
of	O
nitrates	B-drug
for	O
patients	O
with	O
ischemic	O
heart	O
disease	O
has	O
not	O
been	O
evaluated	O
,	O
and	O
concomitant	O
use	O
of	O
Vardenafil	B-drug
and	O
nitrates	B-drug
is	O
contraindicated	O
.	O

Nifedipine	B-drug
:	O
Vardenafil	B-drug
20	I-drug
mg	I-drug
,	O
when	O
co	O
-	O
administered	O
with	O
slow	O
-	O
release	O
nifedipine	B-drug
30	I-drug
mg	I-drug
or	O
60	O
mg	O
once	O
daily	O
,	O
did	O
not	O
affect	O
the	O
relative	O
bioavailability	O
(	O
AUC	O
)	O
or	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
nifedipine	B-drug
,	O
a	O
drug	B-drug
that	O
is	O
metabolized	O
via	O
CYP3A4	B-drug
.	O

Nifedipine	B-drug
did	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
Vardenafil	B-drug
when	O
taken	O
in	O
combination	O
.	O

In	O
these	O
patients	O
whose	O
hypertension	O
was	O
controlled	O
with	O
nifedipine	B-drug
,	O
Vardenafil	B-drug
20	I-drug
mg	I-drug
produced	O
mean	O
additional	O
supine	O
systolic	O
/	O
diastolic	O
blood	O
pressure	O
reductions	O
of	O
6/5	O
mm	O
Hg	O
compared	O
to	O
placebo	O
.	O

Alpha	O
-	O
blockers	O
:	O
When	O
Vardenafil	B-drug
10	O
or	O
20	O
mg	O
was	O
given	O
to	O
healthy	O
volunteers	O
either	O
simultaneously	O
or	O
6	O
hours	O
after	O
a	O
10	O
mg	O
dose	O
of	O
terazosin	B-drug
,	O
significant	O
hypotension	O
developed	O
in	O
a	O
substantial	O
number	O
of	O
subjects	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B-drug
10	I-drug
mg	I-drug
and	O
terazosin	B-drug
10	I-drug
mg	O
,	O
6	O
of	O
8	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B-drug
20	I-drug
mg	I-drug
and	O
terazosin	B-drug
10	I-drug
mg	O
,	O
2	O
of	O
9	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

When	O
Vardenafil	B-drug
dosing	O
was	O
separated	O
from	O
terazosin	B-drug
10	I-drug
mg	O
by	O
6	O
hours	O
,	O
7	O
of	O
28	O
subjects	O
who	O
received	O
20	O
mg	O
of	O
Vardenafil	B-drug
experienced	O
a	O
decrease	O
in	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

In	O
a	O
similar	O
study	O
with	O
tamsulosin	B-drug
in	O
healthy	O
volunteers	O
,	O
1	O
of	O
24	O
subjects	O
dosed	O
with	O
Vardenafil	B-drug
20	I-drug
mg	I-drug
and	O
tamsulosin	B-drug
0.4	I-drug
mg	I-drug
separated	O
by	O
6	O
hours	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

Two	O
of	O
16	O
subjects	O
dosed	O
simultaneously	O
with	O
Vardenafil	B-drug
10	I-drug
mg	I-drug
and	O
tamsulosin	B-drug
0.4	I-drug
mg	I-drug
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

The	O
administration	O
of	O
lower	O
doses	O
of	O
Vardenafil	B-drug
with	O
alpha	O
-	O
blockers	O
has	O
not	O
been	O
completely	O
evaluated	O
to	O
determine	O
if	O
they	O
can	O
be	O
safely	O
administered	O
together	O
.	O

Based	O
on	O
these	O
data	O
,	O
Vardenafil	B-drug
should	O
not	O
be	O
used	O
in	O
patients	O
on	O
alpha	B-drug
-	I-drug
blocker	I-drug
therapy	O
.	O

Ritonavir	B-drug
and	O
indinavir	B-drug
:	O
Upon	O
concomitant	O
administration	O
of	O
5	O
mg	O
of	O
Vardenafil	B-drug
with	O
600	O
mg	O
BID	O
ritonavir	B-drug
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
ritonavir	B-drug
were	O
reduced	O
by	O
approximately	O
20	O
%	O
.	O

Upon	O
administration	O
of	O
10	O
mg	O
of	O
Vardenafil	B-drug
with	O
800	O
mg	O
TID	O
indinavir	B-drug
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
indinavir	B-drug
were	O
reduced	O
by	O
40	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

Alcohol	B-drug
:	O
Alcohol	B-drug
(	O
0.5	O
g	O
/	O
kg	O
body	O
weight	O
:	O
approximately	O
40	O
mL	O
of	O
absolute	O
alcohol	O
in	O
a	O
70	O
kg	O
person	O
)	O
and	O
vardenafil	B-drug
plasma	O
levels	O
were	O
not	O
altered	O
when	O
dosed	O
simultaneously	O
.	O

Vardenafil	B-drug
(	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
alcohol	B-drug
during	O
the	O
4-hour	O
observation	O
period	O
in	O
healthy	O
volunteers	O
when	O
administered	O
with	O
alcohol	B-drug
(	O
0.5	O
g	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Aspirin	B-drug
:	O
Vardenafil	B-drug
(	O
10	O
mg	O
and	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
increase	O
in	O
bleeding	O
time	O
caused	O
by	O
aspirin	B-drug
(	O
two	O
81	O
mg	O
tablets	O
)	O
.	O

Other	O
interactions	O
:	O
Vardenafil	B-drug
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
glyburide	B-drug
(	O
glucose	B-drug
and	O
insulin	B-drug
concentrations	O
)	O
and	O
warfarin	B-drug
(	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
)	O
.	O

CYP3A4	B-drug
Inhibitors?Felodipine	O
is	O
metabolized	O
by	O
CYP3A4	B-drug
.	O

Co	O
-	O
administration	O
of	O
CYP3A4	B-drug
inhibitors	O
(	O
eg	O
,	O
ketoconazole	B-drug
,	O
itraconazole	B-drug
,	O
erythromycin	B-drug
,	O
grapefruit	O
juice	O
,	O
cimetidine	B-drug
)	O
with	O
felodipine	B-drug
may	O
lead	O
to	O
several-	O
fold	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
felodipine	B-drug
,	O
either	O
due	O
to	O
an	O
increase	O
in	O
bioavailability	O
or	O
due	O
to	O
a	O
decrease	O
in	O
metabolism	O
.	O

These	O
increases	O
in	O
concentration	O
may	O
lead	O
to	O
increased	O
effects	O
,	O
(	O
lower	O
blood	O
pressure	O
and	O
increased	O
heart	O
rate	O
)	O
.	O

These	O
effects	O
have	O
been	O
observed	O
with	O
co	O
-	O
administration	O
of	O
itraconazole	B-drug
(	O
a	O
potent	O
CYP3A4	B-drug
inhibitor	O
)	O
.	O

Caution	O
should	O
be	O
used	O
when	O
CYP3A4	B-drug
inhibitors	O
are	O
co	O
-	O
administered	O
with	O
felodipine	B-drug
.	O

A	O
conservative	O
approach	O
to	O
dosing	O
felodipine	B-drug
should	O
be	O
taken	O
.	O

The	O
following	O
specific	O
interactions	O
have	O
been	O
reported	O
:	O
Itraconazole?Co	O
-	O
administration	O
of	O
another	O
extended	O
release	O
formulation	O
of	O
felodipine	B-drug
with	O
itraconazole	B-drug
resulted	O
in	O
approximately	O
8-fold	O
increase	O
in	O
the	O
AUC	O
,	O
more	O
than	O
6-	O
fold	O
increase	O
in	O
the	O
Cmax	O
,	O
and	O
2-fold	O
prolongation	O
in	O
the	O
half-	O
life	O
of	O
felodipine	B-drug
.	O

Erythromycin?Co	O
-	O
administration	O
of	O
felodipine	B-drug
(	O
PLENDIL	B-drug
)	O
with	O
erythromycin	B-drug
resulted	O
in	O
approximately	O
2.5-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
and	O
about	O
2-	O
fold	O
prolongation	O
in	O
the	O
half-	O
life	O
of	O
felodipine	B-drug
.	O

Grapefruit	B-drug
juice?Co	O
-	O
administration	O
of	O
felodipine	B-drug
with	O
grapefruit	O
juice	O
resulted	O
in	O
more	O
than	O
2-fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
but	O
no	O
prolongation	O
in	O
the	O
half-	O
life	O
of	O
felodipine	B-drug
.	O

Cimetidine?Co	O
-	O
administration	O
of	O
felodipine	B-drug
with	O
cimetidine	B-drug
(	O
a	O
non	O
-	O
specific	O
CYP-450	O
inhibitor	O
)	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
50	O
%	O
in	O
the	O
AUC	O
and	O
the	O
Cmax	O
,	O
of	O
felodipine	B-drug
.	O

Beta	O
-	O
Blocking	O
Agents	O
?	O
A	O
pharmacokinetic	O
study	O
of	O
felodipine	B-drug
in	O
conjunction	O
with	O
metoprolol	B-drug
demonstrated	O
no	O
significant	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
felodipine	B-drug
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
metoprolol	B-drug
,	O
however	O
,	O
were	O
increased	O
approximately	O
31	O
and	O
38	O
%	O
,	O
respectively	O
.	O

In	O
controlled	O
clinical	O
trials	O
,	O
however	O
,	O
beta	B-drug
blockers	I-drug
including	O
metoprolol	B-drug
were	O
concurrently	O
administered	O
with	O
felodipine	B-drug
and	O
were	O
well	O
tolerated	O
.	O

Digoxin	O
?	O
When	O
given	O
concomitantly	O
with	O
PLENDIL	B-drug
the	O
pharmacokinetics	O
of	O
digoxin	B-drug
in	O
patients	O
with	O
heart	O
failure	O
were	O
not	O
significantly	O
altered	O
.	O

Anticonvulsants	O
?	O
In	O
a	O
pharmacokinetic	O
study	O
,	O
maximum	O
plasma	O
concentrations	O
of	O
felodipine	B-drug
were	O
considerably	O
lower	O
in	O
epileptic	O
patients	O
on	O
long	O
-	O
term	O
anticonvulsant	O
therapy	O
(	O
eg	O
,	O
phenytoin	B-drug
,	O
carbamazepine	B-drug
,	O
or	O
phenobarbital	B-drug
)	O
than	O
in	O
healthy	O
volunteers	O
.	O

In	O
such	O
patients	O
,	O
the	O
mean	O
area	O
under	O
the	O
felodipine	B-drug
plasma	O
concentration	O
-	O
time	O
curve	O
was	O
also	O
reduced	O
to	O
approximately	O
6	O
%	O
of	O
that	O
observed	O
in	O
healthy	O
volunteers	O
.	O

Since	O
a	O
clinically	O
significant	O
interaction	O
may	O
be	O
anticipated	O
,	O
alternative	O
antihypertensive	B-drug
therapy	O
should	O
be	O
considered	O
in	O
these	O
patients	O
.	O

Tacrolimus	O
?	O
Felodipine	B-drug
may	O
increase	O
the	O
blood	O
concentration	O
of	O
tacrolimus	B-drug
.	O

When	O
given	O
concomitantly	O
with	O
felodipine	B-drug
,	O
the	O
tacrolimus	B-drug
blood	O
concentration	O
should	O
be	O
followed	O
and	O
the	O
tacrolimus	O
dose	O
may	O
need	O
to	O
be	O
adjusted	O
.	O

Other	O
Concomitant	O
Therapy	O
?	O
In	O
healthy	O
subjects	O
there	O
were	O
no	O
clinically	O
significant	O
interactions	O
when	O
felodipine	B-drug
was	O
given	O
concomitantly	O
with	O
indomethacin	B-drug
or	O
spironolactone	B-drug
.	O

Interaction	O
with	O
Food	O
?	O
See	O
CLINICAL	O
PHARMACOLOGY	O
,	O
Pharmacokinetics	O
and	O
Metabolism	O
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B-drug
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
some	O
quinolones	B-drug
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	B-drug
-	O
related	O
side	O
-	O
effects	O
in	O
patients	O
on	O
concomitant	O
theophylline	B-drug
-	O
quinolone	O
therapy	O
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B-drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	O
adjusted	O
as	O
required	O
.	O

Quinolones	B-drug
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-drug
.	O

This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	B-drug
and	O
a	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O

Although	O
this	O
interaction	O
has	O
not	O
been	O
reported	O
with	O
cinoxacin	B-drug
,	O
caution	O
should	O
be	O
exercised	O
when	O
cinoxacin	B-drug
is	O
given	O
concomitantly	O
with	O
caffeine	B-drug
-	I-drug
containing	I-drug
products	O
.	O

Antacids	B-drug
or	O
sucralfate	B-drug
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
some	O
quinolones	B-drug
,	O
resulting	O
in	O
low	O
urine	O
levels	O
.	O

Also	O
,	O
concomitant	O
administration	O
of	O
quinolones	B-drug
with	O
products	O
containing	O
iron	B-drug
,	O
multivitamins	B-drug
containing	O
zinc	B-drug
,	O
or	O
Videx	B-drug
(	O
didanosine	B-drug
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	B-drug
powder	O
for	O
oral	O
solution	O
may	O
result	O
in	O
low	O
urine	O
levels	O
.	O

Quinolones	B-drug
,	O
including	O
cinoxacin	B-drug
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	B-drug
anticoagulants	I-drug
,	O
such	O
as	O
warfarin	B-drug
or	O
its	O
derivatives	B-drug
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
tests	O
should	O
be	O
closely	O
monitored	O
.	O

Seizures	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
another	O
quinolone	B-drug
class	I-drug
antimicrobial	I-drug
and	O
the	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drug	I-drug
fenbufen	O
concurrently	O
.	O

Animal	O
studies	O
also	O
suggest	O
an	O
increased	O
potential	O
for	O
seizures	O
when	O
these	O
2	O
drugs	B-drug
are	O
given	O
concomitantly	O
.	O

Fenbufen	B-drug
is	O
not	O
approved	O
in	O
the	O
United	O
States	O
at	O
this	O
time	O
.	O

Physicians	O
are	O
provided	O
this	O
information	O
to	O
increase	O
awareness	O
of	O
the	O
potential	O
for	O
serious	O
interactions	O
when	O
cinoxacin	B-drug
and	O
certain	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
agents	I-drug
are	O
administered	O
concomitantly	O
.	O

Elevated	O
cyclosporine	B-drug
serum	O
levels	O
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
quinolones	B-drug
and	O
cyclosporine	B-drug
.	O

Clinical	O
interaction	O
studies	O
with	O
cimetidine	B-drug
and	O
warfarin	B-drug
indicated	O
that	O
the	O
coadministration	O
of	O
Femara	B-drug
with	O
these	O
drugs	B-drug
does	O
not	O
result	O
in	O
clinically-	O
significant	O
drug	O
interactions	O
.	O

(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
)	O
Coadministration	O
of	O
Femara	B-drug
and	O
tamoxifen	B-drug
20	I-drug
mg	I-drug
daily	O
resulted	O
in	O
a	O
reduction	O
of	O
letrozole	B-drug
plasma	O
levels	O
by	O
38	O
%	O
on	O
average	O
.	O

There	O
is	O
no	O
clinical	O
experience	O
to	O
date	O
on	O
the	O
use	O
of	O
Femara	B-drug
in	O
combination	O
with	O
other	O
anticancer	O
agents	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
-	O
Interactions	O
None	O
observed	O
.	O

Renal	O
clearance	O
measurements	O
of	O
PAH	O
can	O
not	O
be	O
made	O
with	O
any	O
significant	O
accuracy	O
in	O
patients	O
receiving	O
sulfonamides	B-drug
,	O
procaine	B-drug
,	O
or	O
thiazolesulfone	O
.	O

These	O
compounds	O
interfere	O
with	O
chemical	O
color	O
development	O
essential	O
to	O
the	O
analytical	O
procedures	O
.	O

Probenecid	B-drug
depresses	O
tubular	O
secretion	O
of	O
certain	O
weak	O
acids	O
such	O
as	O
PAH	O
.	O

Therefore	O
,	O
patients	O
receiving	O
probenecid	B-drug
will	O
have	O
erroneously	O
low	O
ERPF	O
and	O
Tm	O
PAH	O
values	O
.	O

Concomitant	O
oral	O
administration	O
of	O
ketoconazole	B-drug
(	O
a	O
known	O
inhibitor	O
of	O
CYP3A4	B-drug
activity	O
in	O
the	O
liver	B-drug
and	O
in	O
the	O
intestinal	O
mucosa	O
)	O
caused	O
an	O
eight	O
-	O
fold	O
increase	O
of	O
the	O
systemic	O
exposure	O
to	O
oral	B-drug
budesonide	I-drug
.	O

If	O
treatment	O
with	O
inhibitors	O
of	O
CYP3A4	B-drug
activity	O
(	O
such	O
as	O
ketoconazole	B-drug
,	O
intraconazole	O
,	O
ritonavir	B-drug
,	O
indinavir	B-drug
,	O
saquinavir	B-drug
,	O
erythromycin	B-drug
,	O
etc	O
.	O
)	O
is	O
indicated	O
,	O
reduction	O
of	O
the	O
budesonide	B-drug
dose	O
should	O
be	O
considered	O
.	O

After	O
extensive	O
intake	O
of	O
grapefruit	O
juice	O
(	O
which	O
inhibits	O
CYP3A4	B-drug
activity	O
predominantly	O
in	O
the	O
intestinal	O
mucosa	O
)	O
,	O
the	O
systemic	O
exposure	O
for	O
oral	B-drug
budesonide	I-drug
increased	O
about	O
two	O
times	O
.	O

As	O
with	O
other	O
drugs	B-drug
primarily	O
being	O
metabolized	O
through	O
CYP3A4	B-drug
,	O
ingestion	O
of	O
grapefruit	B-drug
or	O
grapefruit	O
juice	O
should	O
be	O
avoided	O
in	O
connection	O
with	O
budesonide	B-drug
administration	O
.	O

The	O
following	O
drug	O
interactions	O
were	O
studied	O
with	O
ketoprofen	B-drug
doses	O
of	O
200	O
mg	O
/	O
day	O
.	O

The	O
possibility	O
of	O
increased	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Orudis	B-drug
doses	O
greater	O
than	O
50	O
mg	O
as	O
a	O
single	O
dose	O
or	O
200	O
mg	O
of	O
ketoprofen	B-drug
per	O
day	O
are	O
used	O
concomitantly	O
with	O
highly	O
bound	O
drugs	O
.	O

1	O
.	O

Antacids	B-drug
:	O
Concomitant	O
administration	O
of	O
magnesium	B-drug
hydroxide	I-drug
and	O
aluminum	B-drug
hydroxide	I-drug
does	O
not	O
interfere	O
with	O
the	O
rate	O
or	O
extent	O
of	O
the	O
absorption	O
of	O
ketoprofen	B-drug
administered	O
as	O
Orudis	B-drug
.	O

2	O
.	O

Aspirin	B-drug
:	O
Ketoprofen	B-drug
does	O
not	O
alter	O
aspirin	B-drug
absorption	O
;	O

however	O
,	O
in	O
a	O
study	O
of	O
12	O
normal	O
subjects	O
,	O
concurrent	O
administration	O
of	O
aspirin	B-drug
decreased	O
ketoprofen	B-drug
protein	O
binding	O
and	O
increased	O
ketoprofen	B-drug
plasma	O
clearance	O
from	O
0.07	O
L	O
/	O
kg	O
/	O
h	O
without	O
aspirin	B-drug
to	O
0.11	O
L	O
/	O
kg	O
/	O
h	O
with	O
aspirin	B-drug
.	O

The	O
clinical	O
significance	O
of	O
these	O
changes	O
has	O
not	O
been	O
adequately	O
studied	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
aspirin	B-drug
and	O
ketoprofen	B-drug
is	O
not	O
recommended	O
.	O

3	O
.	O

Diuretic	B-drug
:	O
Hydrochlorothiazide	B-drug
,	O
given	O
concomitantly	O
with	O
ketoprofen	B-drug
,	O
produces	O
a	O
reduction	O
in	O
urinary	O
potassium	O
and	O
chloride	O
excretion	O
compared	O
to	O
hydrochlorothiazide	B-drug
alone	O
.	O

Patients	O
taking	O
diuretics	B-drug
are	O
at	O
a	O
greater	O
risk	O
of	O
developing	O
renal	O
failure	O
secondary	O
to	O
a	O
decrease	O
in	O
renal	O
blood	O
flow	O
caused	O
by	O
prostaglandin	O
inhibition	O
.	O

4	O
.	O

Digoxin	B-drug
:	O
In	O
a	O
study	O
in	O
12	O
patients	O
with	O
congestive	O
heart	O
failure	O
where	O
ketoprofen	B-drug
and	O
digoxin	B-drug
were	O
concomitantly	O
administered	O
,	O
ketoprofen	B-drug
did	O
not	O
alter	O
the	O
serum	O
levels	O
of	O
digoxin	B-drug
.	O

5	O
.	O

Warfarin	B-drug
:	O
In	O
a	O
short	O
-	O
term	O
controlled	O
study	O
in	O
14	O
normal	O
volunteers	O
,	O
ketoprofen	B-drug
did	O
not	O
significantly	O
interfere	O
with	O
the	O
effect	O
of	O
warfarin	B-drug
on	O
prothrombin	O
time	O
.	O

Bleeding	O
from	O
a	O
number	O
of	O
sites	O
may	O
be	O
a	O
complication	O
of	O
warfarin	O
treatment	O
and	O
GI	O
bleeding	O
a	O
complication	O
of	O
ketoprofen	B-drug
treatment	O
.	O

Because	O
prostaglandina	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
ketoprofen	B-drug
has	O
an	O
effect	O
on	O
platelet	O
function	O
as	O
well	O
,	O
concurent	O
therapy	O
with	O
ketoprofen	B-drug
and	O
warfarin	B-drug
requires	O
close	O
monitoring	O
of	O
patients	O
on	O
both	O
drugs	B-drug
.	O

6	O
.	O

Probenecid	B-drug
:	O
Probenecid	B-drug
increases	O
both	O
free	O
and	O
bound	O
ketoprofen	B-drug
by	O
reducing	O
the	O
plasma	O
clearance	O
of	O
ketoprofen	B-drug
to	O
about	O
one	O
-	O
third	O
,	O
as	O
well	O
as	O
decreasing	O
its	O
protein	O
binding	O
.	O

Therefore	O
,	O
the	O
combination	O
of	O
ketoprofen	B-drug
and	O
probenecid	B-drug
is	O
not	O
recommended	O
.	O

7	O
.	O

Methotrexate	B-drug
:	O
Ketoprofen	B-drug
,	O
like	O
other	O
NSAIDs	B-drug
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
methotrexate	B-drug
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
the	O
drug	B-drug
and	O
increased	O
toxicity	O
.	O

8	O
.	O

Lithium	B-drug
:	O
Nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
agents	I-drug
have	O
been	O
reported	O
to	O
increase	O
steadystate	O
plasma	O
lithium	O
levels	O
.	O

It	O
is	O
recommended	O
that	O
plasma	O
lithium	O
levels	O
be	O
monitored	O
when	O
ketoprofen	B-drug
is	O
coadministered	O
with	O
lithium	B-drug
.	O

DRUG	B-drug
/	O
LABORATORY	O
TEST	O
INTERACTIONS	O
:	O
EFFECT	O
ON	O
BLOOD	O
COAGULATION	O
Ketoprofen	B-drug
decreases	O
platelet	O
adhesion	O
and	O
aggregation	O
.	O

Therefore	O
,	O
it	O
can	O
prolong	O
bleeding	O
time	O
by	O
approximately	O
3	O
to	O
4	O
minutes	O
from	O
baseline	O
values	O
.	O

There	O
is	O
no	O
significant	O
change	O
in	O
platelet	O
count	O
,	O
prothrombin	O
time	O
,	O
partial	O
thromboplastin	O
time	O
,	O
or	O
thrombin	O
time	O
.	O

The	O
administration	O
of	O
local	B-drug
anesthetic	I-drug
solutions	O
containing	O
epinephrine	B-drug
or	O
norepinephrine	B-drug
to	O
patients	O
receiving	O
monoamine	B-drug
oxidase	I-drug
inhibitors	I-drug
,	O
tricyclic	B-drug
antidepressants	I-drug
or	O
phenothiazines	B-drug
may	O
produce	O
severe	O
,	O
prolonged	O
hypotension	O
or	O
hypertension	O
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
when	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B-drug
drugs	I-drug
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	O
-	O
type	O
oxytocic	B-drug
drugs	I-drug
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

The	O
para	B-drug
-	I-drug
aminobenzoic	I-drug
acid	I-drug
metabolite	O
of	O
chloroprocaine	B-drug
inhibits	O
the	O
action	O
of	O
sulfonamides	B-drug
.	O

Therefore	O
,	O
chloroprocaine	B-drug
should	O
not	O
be	O
used	O
in	O
any	O
condition	O
in	O
which	O
a	O
sulfonamide	B-drug
drug	O
is	O
being	O
employed	O
.	O

In	O
normal	O
volunteers	O
receiving	O
indomethacin	B-drug
,	O
the	O
administration	O
of	O
diflunisal	B-drug
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-drug
.	O

In	O
some	O
patients	O
,	O
combined	O
use	O
of	O
INDOCIN	B-drug
and	O
diflunisal	B-drug
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
diflunisal	B-drug
and	O
INDOCIN	B-drug
should	O
not	O
be	O
used	O
concomitantly	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
it	O
was	O
found	O
that	O
chronic	O
concurrent	O
administration	O
of	O
3.6	O
g	O
of	O
aspirin	B-drug
per	O
day	O
decreases	O
indomethacin	B-drug
blood	O
levels	O
approximately	O
20	O
%	O
.	O

The	O
concomitant	O
use	O
of	O
INDOCIN	B-drug
with	O
other	O
NSAIDs	B-drug
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
INDOCIN	B-drug
does	O
not	O
influence	O
the	O
hypoprothrombinemia	O
produced	O
by	O
anticoagulants	B-drug
.	O

However	O
,	O
when	O
any	O
additional	O
drug	B-drug
,	O
including	O
INDOCIN	B-drug
,	O
is	O
added	O
to	O
the	O
treatment	O
of	O
patients	O
on	O
anticoagulant	O
therapy	O
,	O
the	O
patients	O
should	O
be	O
observed	O
for	O
alterations	O
of	O
the	O
prothrombin	O
time	O
.	O

In	O
post	O
-	O
marketing	O
experience	O
,	O
bleeding	O
has	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
treatment	O
with	O
anticoagulants	B-drug
and	O
INDOCIN	B-drug
.	O

Caution	O
should	O
be	O
exercised	O
when	O
INDOCIN	B-drug
and	O
anticoagulants	B-drug
are	O
administered	O
concomitantly	O
.	O

When	O
INDOCIN	B-drug
is	O
given	O
to	O
patients	O
receiving	O
probenecid	B-drug
,	O
the	O
plasma	O
levels	O
of	O
indomethacin	B-drug
are	O
likely	O
to	O
be	O
increased	O
.	O

Therefore	O
,	O
a	O
lower	O
total	O
daily	O
dosage	O
of	O
INDOCIN	B-drug
may	O
produce	O
a	O
satisfactory	O
therapeutic	O
effect	O
.	O

When	O
increases	O
in	O
the	O
dose	O
of	O
INDOCIN	B-drug
are	O
made	O
,	O
they	O
should	O
be	O
made	O
carefully	O
and	O
in	O
small	O
increments	O
.	O

Caution	O
should	O
be	O
used	O
if	O
INDOCIN	B-drug
is	O
administered	O
simultaneously	O
with	O
methotrexate	B-drug
.	O

INDOCIN	B-drug
has	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B-drug
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Administration	O
of	O
non	B-drug
-	I-drug
steroidal	I-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
concomitantly	O
with	O
cyclosporine	B-drug
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	O
-	O
induced	O
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	B-drug
.	O

NSAIDs	B-drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B-drug
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Capsules	O
INDOCIN	O
50	O
mg	O
t.i.d	O
.	O
produced	O
a	O
clinically	O
relevant	O
elevation	O
of	O
plasma	O
lithium	B-drug
and	O
reduction	O
in	O
renal	O
lithium	B-drug
clearance	O
in	O
psychiatric	O
patients	O
and	O
normal	O
subjects	O
with	O
steady	O
state	O
plasma	O
lithium	B-drug
concentrations	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
inhibition	O
of	O
prostaglandin	B-drug
synthesis	O
.	O

As	O
a	O
consequence	O
,	O
when	O
INDOCIN	B-drug
and	O
lithium	B-drug
are	O
given	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
carefully	O
observed	O
for	O
signs	O
of	O
lithium	O
toxicity	O
.	O

(	O
Read	O
circulars	O
for	O
lithium	B-drug
preparations	O
before	O
use	O
of	O
such	O
concomitant	O
therapy	O
.	O
)	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
monitoring	O
serum	O
lithium	B-drug
concentration	O
should	O
be	O
increased	O
at	O
the	O
outset	O
of	O
such	O
combination	O
drug	B-drug
treatment	O
.	O

INDOCIN	B-drug
given	O
concomitantly	O
with	O
digoxin	B-drug
has	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
concentration	O
and	O
prolong	O
the	O
half	O
-	O
life	O
of	O
digoxin	B-drug
.	O

Therefore	O
,	O
when	O
INDOCIN	B-drug
and	O
digoxin	B-drug
are	O
used	O
concomitantly	O
,	O
serum	O
digoxin	O
levels	O
should	O
be	O
closely	O
monitored	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
INDOCIN	B-drug
can	O
reduce	O
the	O
diuretic	B-drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-drug
effects	O
of	O
loop	O
,	O
potassium	B-drug
-	O
sparing	O
,	O
and	O
thiazide	B-drug
diuretics	I-drug
.	O

Therefore	O
,	O
when	O
INDOCIN	B-drug
and	O
INDOCIN	B-drug
.	O

(	O
Indomethacin	B-drug
)	O
diuretics	B-drug
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-drug
is	O
obtained	O
.	O

INDOCIN	B-drug
reduces	O
basal	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
,	O
as	O
well	O
as	O
those	O
elevations	O
of	O
PRA	O
induced	O
by	O
furosemide	B-drug
administration	O
,	O
or	O
salt	B-drug
or	O
volume	O
depletion	O
.	O

These	O
facts	O
should	O
be	O
considered	O
when	O
evaluating	O
plasma	O
renin	O
activity	O
in	O
hypertensive	O
patients	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
triamterene	B-drug
to	O
a	O
maintenance	O
schedule	O
of	O
INDOCIN	B-drug
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers	O
.	O

INDOCIN	B-drug
and	O
triamterene	B-drug
should	O
not	O
be	O
administered	O
together	O
.	O

INDOCIN	B-drug
and	O
potassium	B-drug
-	I-drug
sparing	I-drug
diuretics	I-drug
each	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
.	O

The	O
potential	O
effects	O
of	O
INDOCIN	B-drug
and	O
potassium	B-drug
-	I-drug
sparing	I-drug
diuretics	I-drug
on	O
potassium	B-drug
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Most	O
of	O
the	O
above	O
effects	O
concerning	O
diuretics	B-drug
have	O
been	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
mechanisms	O
involving	O
inhibition	O
of	O
prostaglandin	B-drug
synthesis	O
by	O
INDOCIN	B-drug
.	O

Blunting	O
of	O
the	O
antihypertensive	B-drug
effect	O
of	O
beta	B-drug
-	I-drug
adrenoceptor	I-drug
blocking	I-drug
agents	O
by	O
non	B-drug
-	I-drug
steroidal	I-drug
antiinflammatory	I-drug
drugs	I-drug
including	O
INDOCIN	B-drug
has	O
been	O
reported	O
.	O

Therefore	O
,	O
when	O
using	O
these	O
blocking	O
agents	O
to	O
treat	O
hypertension	O
,	O
patients	O
should	O
be	O
observed	O
carefully	O
in	O
order	O
to	O
confirm	O
that	O
the	O
desired	O
therapeutic	O
effect	O
has	O
been	O
obtained	O
.	O

INDOCIN	B-drug
can	O
reduce	O
the	O
antihypertensive	B-drug
effects	O
of	O
captopril	B-drug
and	O
losartan	B-drug
.	O

False	O
-	O
negative	O
results	O
in	O
the	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
in	O
patients	O
being	O
treated	O
with	O
INDOCIN	B-drug
have	O
been	O
reported	O
.	O

Thus	O
,	O
results	O
of	O
the	O
DST	O
should	O
be	O
interpreted	O
with	O
caution	O
in	O
these	O
patients	O
.	O

There	O
is	O
no	O
known	O
drug	O
interference	O
with	O
standard	O
clinical	O
laboratory	O
tests	O
.	O

Steroids	O
enhance	O
the	O
renal	O
toxicity	O
of	O
edetate	B-drug
calcium	I-drug
disodium	I-drug
in	O
animals	O
.	O
7	O
Edetate	B-drug
calcium	I-drug
disodium	I-drug
interferes	O
with	O
the	O
action	O
of	O
zinc	B-drug
insulin	O
preparations	O
by	O
chelating	O
the	O
zinc	B-drug
.	I-drug
7	O

Ketorolac	B-drug
is	O
highly	O
bound	O
to	O
human	O
plasma	B-drug
protein	I-drug
(	O
mean	O
99.2	O
%	O
)	O
.	O

Warfarin	B-drug
,	O
Digoxin	B-drug
,	O
Salicylate	B-drug
,	O
and	O
Heparin	O
The	O
in	O
vitro	O
binding	O
of	O
warfarin	B-drug
to	O
plasma	B-drug
proteins	I-drug
is	O
only	O
slightly	O
reduced	O
by	O
ketorolac	B-drug
tromethamine	I-drug
(	O
99.5	O
%	O
control	O
vs	O
99.3	O
%	O
)	O
when	O
ketorolac	B-drug
plasma	O
concentrations	O
reach	O
5	B-drug
to10	I-drug
m	O
g	O
/	O
mL.	O

Ketorolac	B-drug
does	O
not	O
alter	O
digoxin	B-drug
protein	O
binding	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
,	O
at	O
therapeutic	O
concentrations	O
of	O
salicylate	B-drug
(	O
300	O
m	O
g	O
/	O
mL	O
)	O
,	O
the	O
binding	O
of	O
ketorolac	B-drug
was	O
reduced	O
from	O
approximately	O
99.2	O
%	O
to	O
97.5	O
%	O
,	O
representing	O
a	O
potential	O
twofold	O
increase	O
in	O
unbound	O
ketorolac	B-drug
plasma	O
levels	O
.	O

Therapeutic	O
concentrations	O
of	O
digoxin	B-drug
,	O
warfarin	B-drug
,	O
ibuprofen	B-drug
,	O
naproxen	B-drug
,	O
piroxicam	B-drug
,	O
acetaminophen	B-drug
,	O
phenytoin	B-drug
andtolbutamide	O
did	O
not	O
alter	O
ketorolac	B-drug
tromethamine	I-drug
protein	O
binding	O
.	O

In	O
a	O
study	O
involving	O
12	O
adult	O
volunteers	O
,	O
TORADOLORAL	O
was	O
coadministered	O
with	O
a	O
single	O
dose	O
of	O
25	O
mg	O
warfarin	B-drug
,	O
causing	O
no	O
significant	O
changes	O
in	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B-drug
.	O

In	O
another	O
study	O
,	O
TORADOLIV	O
/	O
IM	O
was	O
given	O
with	O
two	O
doses	O
of	O
5000	O
U	O
of	O
heparin	B-drug
to	O
11	O
healthy	O
volunteers	O
,	O
resulting	O
in	O
a	O
mean	O
template	O
bleeding	O
time	O
of	O
6.4	O
minutes	O
(	O
3.2	O
to	O
11.4	O
min	O
)	O
compared	O
to	O
a	O
mean	O
of	O
6.0	O
minutes	O
(	O
3.4	O
to	O
7.5	O
min	O
)	O
for	O
heparin	B-drug
alone	O
and	O
5.1	O
minutes	O
(	O
3.5	O
to	O
8.5	O
min	O
)	O
for	O
placebo	O
.	O

Although	O
these	O
results	O
do	O
not	O
indicate	O
a	O
significant	O
interaction	O
between	O
TORADOL	B-drug
and	O
warfarin	B-drug
or	O
heparin	B-drug
,	O
the	O
administration	O
of	O
TORADOL	B-drug
to	O
patients	O
taking	O
anticoagulants	B-drug
should	O
be	O
done	O
extremely	O
cautiously	O
,	O
and	O
patients	O
should	O
be	O
closely	O
monitored	O
.	O

Furosemide	B-drug
TORADOLIV	I-drug
/	I-drug
IM	O
reduced	O
the	O
diuretic	B-drug
response	O
to	O
furosemide	B-drug
in	O
normovolemic	O
healthy	O
subjects	O
by	O
approximately	O
20	O
%	O
(	O
mean	O
sodium	B-drug
and	O
urinary	O
output	O
decreased	O
17	O
%	O
)	O
.	O

Probenecid	B-drug
Concomitant	O
administration	O
of	O
TORADOLORAL	O
and	O
probenecid	B-drug
resulted	O
in	O
decreased	O
clearance	O
of	O
ketorolac	B-drug
and	O
significant	O
increases	O
in	O
ketorolac	B-drug
plasma	O
levels	O
(	O
total	O
AUC	O
increased	O
approximately	O
threefold	O
from	O
5.4	O
to	O
17.8	O
m	O
g	O
/	O
h	O
/	O
mL	O
)	O
and	O
terminal	O
half	O
-	O
life	O
increased	O
approximately	O
twofold	O
from	O
6.6	O
to	O
15.1	O
hours	O
.	O

Therefore	O
,	O
concomitant	O
use	O
of	O
TORADOL	B-drug
and	O
probenecid	B-drug
is	O
contraindicated	O
.	O

Lithium	B-drug
Inhibition	O
of	O
renal	O
lithium	B-drug
clearance	O
,	O
leading	O
to	O
an	O
increase	O
in	O
plasma	O
lithium	B-drug
concentration	O
,	O
has	O
been	O
reported	O
with	O
some	O
prostaglandin	B-drug
synthesis	O
-	O
inhibiting	O
drugs	B-drug
.	O

The	O
effect	O
of	O
TORADOL	B-drug
on	O
plasma	O
lithium	B-drug
has	O
not	O
been	O
studied	O
,	O
but	O
cases	O
of	O
increased	O
lithium	O
plasma	O
levels	O
during	O
TORADOL	B-drug
therapy	O
have	O
been	O
reported	O
.	O

Methotrexate	B-drug
Concomitant	O
administration	O
of	O
methotrexate	B-drug
and	O
some	O
NSAIDs	B-drug
has	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
methotrexate	B-drug
,	O
enhancing	O
the	O
toxicity	O
of	O
methotrexate	B-drug
.	O

The	O
effect	O
of	O
TORADOL	B-drug
on	O
methotrexate	B-drug
clearance	O
has	O
not	O
been	O
studied	O
.	O

Nondepolarizing	O
Muscle	B-drug
Relaxants	I-drug
In	O
postmarketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
a	O
possible	O
interaction	O
between	O
TORADOLIV	O
/	O
IM	O
and	O
nondepolarizing	O
muscle	B-drug
relaxants	I-drug
that	O
resulted	O
in	O
apnea	O
.	O

The	O
concurrent	O
use	O
of	O
TORADOL	B-drug
with	O
muscle	B-drug
relaxants	I-drug
has	O
not	O
been	O
formally	O
studied	O
.	O

ACE	B-drug
Inhibitors	I-drug
Concomitant	O
use	O
of	O
ACE	B-drug
inhibitors	I-drug
may	O
increase	O
the	O
risk	O
of	O
renal	O
impairment	O
,	O
particularly	O
in	O
volume	O
-	O
depleted	O
patients	O
.	O

Antiepileptic	B-drug
Drugs	I-drug
Sporadic	O
cases	O
of	O
seizures	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
TORADOL	B-drug
and	O
antiepileptic	B-drug
drugs	I-drug
(	O
phenytoin	B-drug
,	O
carbamazepine	B-drug
)	O
.	O

Psychoactive	B-drug
Drugs	I-drug
Hallucinations	O
have	O
been	O
reported	O
when	O
TORADOL	B-drug
was	O
used	O
in	O
patients	O
taking	O
psychoactive	B-drug
drugs	I-drug
(	O
fluoxetine	B-drug
,	O
thiothixene	B-drug
,	O
alprazolam	B-drug
)	O
.	O

Morphine	B-drug
TORADOLIV	O
/	O
IM	O
has	O
been	O
administered	O
concurrently	O
with	O
morphine	B-drug
in	O
several	O
clinical	O
trials	O
of	O
postoperative	O
pain	O
without	O
evidence	O
of	O
adverse	O
interactions	O
.	O

Do	O
not	O
mix	O
TORADOL	B-drug
and	O
morphine	B-drug
in	O
the	O
same	O
syringe	O
.	O

There	O
is	O
no	O
evidence	O
in	O
animal	O
or	O
human	O
studies	O
that	O
TORADOL	B-drug
induces	O
or	O
inhibits	O
hepatic	O
enzymes	O
capable	O
of	O
metabolizing	O
itself	O
or	O
other	O
drugs	B-drug

.	O

?	O

Probenecid	B-drug
may	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
cephalosporins	B-drug
when	O
used	O
concurrently	O
,	O
resulting	O
in	O
increased	O
and	O
more	O
prolonged	O
cephalosporin	B-drug
blood	O
levels	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
positive	O
reaction	O
for	O
glucose	B-drug
in	O
the	O
urine	O
may	O
occur	O
with	O
Benedicts	O
solution	O
,	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
?	O
tablets	O
,	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
such	O
as	O
CLINISTIX	O
?	O
.	O

Positive	O
direct	O
and	O
indirect	O
antiglobulin	B-drug
(	O
Coombs	O
)	O
tests	O
have	O
occurred	O
;	O

these	O
may	O
also	O
occur	O
in	O
neonates	O
whose	O
mothers	O
received	O
cephalosporins	B-drug
before	O
delivery	O
.	O

As	O
DIFFERIN	B-drug
Gel	O
has	O
the	O
potential	O
to	O
produce	O
local	O
irritation	O
in	O
some	O
patients	O
,	O
concomitant	O
use	O
of	O
other	O
potentially	O
irritating	O
topical	O
products	O
(	O
medicated	O
or	O
abrasive	O
soaps	O
and	O
cleansers	O
,	O
soaps	O
and	O
cosmetics	O
that	O
have	O
a	O
strong	O
drying	O
effect	O
,	O
and	O
products	O
with	O
high	O
concentrations	O
of	O
alcohol	B-drug
,	O
astringents	B-drug
,	O
spices	O
or	O
lime	B-drug
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Particular	O
caution	O
should	O
be	O
exercised	O
in	O
using	O
preparations	O
containing	O
sulfur	B-drug
,	O
resorcinol	B-drug
,	O
or	O
salicylic	B-drug
acid	I-drug
in	O
combination	O
with	O
DIFFERIN	B-drug
Gel	O
.	O

If	O
these	O
preparations	O
have	O
been	O
used	O
it	O
is	O
advisable	O
not	O
to	O
start	O
therapy	O
with	O
DIFFERIN	B-drug
Gel	O
until	O
the	O
effects	O
of	O
such	O
preparations	O
in	O
the	O
skin	O
have	O
subsided	O
.	O

Amiodarone	B-drug
is	O
metabolized	O
to	O
desethylamiodarone	B-drug
by	O
the	O
cytochrome	B-drug
P450	I-drug
(	O
CYP450	O
)	O
enzyme	O
group	O
,	O
specifically	O
cytochromes	B-drug
P450	I-drug
3A4	I-drug
(	O
CYP3A4	B-drug
)	O
and	O
CYP2C8	B-drug
.	O

The	O
CYP3A4	B-drug
isoenzyme	I-drug
is	O
present	O
in	O
both	O
the	O
liver	B-drug
and	O
intestines	O
.	O

Amiodarone	B-drug
is	O
also	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
CYP3A4	B-drug
.	O

Therefore	O
,	O
amiodarone	B-drug
has	O
the	O
potential	O
for	O
interactions	O
with	O
drugs	B-drug
or	O
substances	O
that	O
may	O
be	O
substrates	O
,	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	B-drug
.	O

While	O
only	O
a	O
limited	O
number	O
of	O
in	O
vivo	O
drug	O
-	O
drug	O
interactions	O
with	O
amiodarone	B-drug
have	O
been	O
reported	O
,	O
chiefly	O
with	O
the	O
oral	O
formulation	O
,	O
the	O
potential	O
for	O
other	O
interactions	O
should	O
be	O
anticipated	O
.	O

This	O
is	O
especially	O
important	O
for	O
drugs	B-drug
associated	O
with	O
serious	O
toxicity	O
,	O
such	O
as	O
other	O
antiarrhythmics	B-drug
.	O

If	O
such	O
drugs	B-drug
are	O
needed	O
,	O
their	O
dose	O
should	O
be	O
reassessed	O
and	O
,	O
where	O
appropriate	O
,	O
plasma	O
concentration	O
measured	O
.	O

In	O
view	O
of	O
the	O
long	O
and	O
variable	O
half	O
-	O
life	O
of	O
amiodarone	B-drug
,	O
potential	O
for	O
drug	O
interactions	O
exists	O
not	O
only	O
with	O
concomitant	O
medication	B-drug
but	O
also	O
with	O
drugs	B-drug
administered	O
after	O
discontinuation	O
of	O
amiodarone	B-drug
.	O

Since	O
amiodarone	B-drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-drug
and	O
CYP2C8	B-drug
,	O
drugs	B-drug
/	O
substances	O
that	O
inhibit	O
these	O
isoenzymes	B-drug
may	O
decrease	O
the	O
metabolism	O
and	O
increase	O
serum	O
concentration	O
of	O
amiodarone	B-drug
.	O

Reported	O
examples	O
include	O
the	O
following	O
:	O
Protease	B-drug
Inhibitors	I-drug
:	O
Protease	B-drug
inhibitors	I-drug
are	O
known	O
to	O
inhibit	O
CYP3A4	B-drug
to	O
varying	O
degrees	O
.	O

A	O
case	O
report	O
of	O
one	O
patient	O
taking	O
amiodarone	B-drug
200	I-drug
mg	I-drug
and	O
indinavir	B-drug
800	O
mg	O
three	O
times	O
a	O
day	O
resulted	O
in	O
increases	O
in	O
amiodarone	B-drug
concentrations	O
from	O
0.9	O
mg	O
/	O
L	O
to	O
1.3	O
mg	O
/	O
L.	O

DEA	O
concentrations	O
were	O
not	O
affected	O
.	O

There	O
was	O
no	O
evidence	O
of	O
toxicity	O
.	O

Monitoring	O
for	O
amiodarone	B-drug
toxicity	O
and	O
serial	O
measurement	O
of	O
amiodarone	B-drug
serum	O
concentration	O
during	O
concomitant	O
protease	B-drug
inhibitor	I-drug
therapy	O
should	O
be	O
considered	O
.	O

Histamine	B-drug
H2	I-drug
antagonists	I-drug
:	O
Cimetidine	B-drug
inhibits	O
CYP3A4	B-drug
and	O
can	O
increase	O
serum	O
amiodarone	O
levels	O
.	O

Other	O
substances	O
:	O
Grapefruit	O
juice	O
given	O
to	O
healthy	O
volunteers	O
increased	O
amiodarone	B-drug
AUC	O
by	O
50	O
%	O
and	O
Cmax	O
by	O
84	O
%	O
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
amiodarone	B-drug
.	O

Grapefruit	O
juice	O
should	O
not	O
be	O
taken	O
during	O
treatment	O
with	O
oral	O
amiodarone	B-drug
.	O

This	O
information	O
should	O
be	O
considered	O
when	O
changing	O
from	O
intravenous	O
amiodarone	B-drug
to	O
oral	O
amiodarone	B-drug
.	O

Amiodarone	B-drug
may	O
suppress	O
certain	O
CYP450	O
enzymes	O
,	O
including	O
CYP1A2	B-drug
,	O
CYP2C9	B-drug
,	O
CYP2D6	B-drug
,	O
and	O
CYP3A4	B-drug
.	O

This	O
inhibition	O
can	O
result	O
in	O
unexpectedly	O
high	O
plasma	O
levels	O
of	O
other	O
drugs	B-drug
which	O
are	O
metabolized	O
by	O
those	O
CYP450	O
enzymes	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Immunosuppressives	O
:	O
Cyclosporine	B-drug
(	O
CYP3A4	B-drug
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	B-drug
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	B-drug
resulting	O
in	O
elevated	O
creatinine	O
,	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	B-drug
.	O

HMG	B-drug
-	I-drug
CoA	I-drug
Reductase	I-drug
Inhibitors	I-drug
:	O
Simvastatin	B-drug
(	O
CYP3A4	B-drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-drug
has	O
been	O
associated	O
with	O
reports	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
.	O

Cardiovasculars	O
:	O
Cardiac	B-drug
glycosides	I-drug
:	O
In	O
patients	O
receiving	O
digoxin	B-drug
therapy	O
,	O
administration	O
of	O
oral	O
amiodarone	B-drug
regularly	O
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	B-drug
concentration	O
that	O
may	O
reach	O
toxic	O
levels	O
with	O
resultant	O
clinical	O
toxicity	O
.	O

Amiodarone	B-drug
taken	O
concomitantly	O
with	O
digoxin	B-drug
increases	O
the	O
serum	O
digoxin	B-drug
concentration	O
by	O
70	O
%	O
after	O
one	O
day	O
.	O

On	O
administration	O
of	O
oral	O
amiodarone	B-drug
,	O
the	O
need	O
for	O
digitalis	O
therapy	O
should	O
be	O
reviewed	O
and	O
the	O
dose	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
discontinued	O
.	O

If	O
digitalis	B-drug
treatment	O
is	O
continued	O
,	O
serum	O
levels	O
should	O
be	O
closely	O
monitored	O
and	O
patients	O
observed	O
for	O
clinical	O
evidence	O
of	O
toxicity	O
.	O

These	O
precautions	O
probably	O
should	O
apply	O
to	O
digitoxin	B-drug
administration	O
as	O
well	O
.	O

Antiarrhythmics	B-drug
:	O
Other	O
antiarrhythmic	B-drug
drugs	I-drug
,	O
such	O
as	O
quinidine	B-drug
,	O
procainamide	B-drug
,	O
disopyramide	B-drug
,	O
and	O
phenytoin	B-drug
,	O
have	O
been	O
used	O
concurrently	O
with	O
amiodarone	B-drug
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
quinidine	B-drug
,	O
procainamide	B-drug
,	O
and	O
phenytoin	B-drug
during	O
concomitant	O
therapy	O
with	O
amiodarone	B-drug
.	O

Phenytoin	B-drug
decreases	O
serum	O
amiodarone	O
levels	O
.	O

Amiodarone	B-drug
taken	O
concomitantly	O
with	O
quinidine	B-drug
increases	O
quinidine	B-drug
serum	O
concentration	O
by	O
33	O
%	O
after	O
two	O
days	O
.	O

Amiodarone	B-drug
taken	O
concomitantly	O
with	O
procainamide	B-drug
for	O
less	O
than	O
seven	O
days	O
increases	O
plasma	O
concentrations	O
of	O
procainamide	B-drug
and	O
n	O
-	O
acetyl	O
procainamide	B-drug
by	O
55	O
%	O
and	O
33	O
%	O
,	O
respectively	O
.	O

Quinidine	B-drug
and	O
procainamide	O
doses	O
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
when	O
either	O
is	O
administered	O
with	O
amiodarone	B-drug
.	O

Plasma	O
levels	O
of	O
flecainide	B-drug
have	O
been	O
reported	O
to	O
increase	O
in	O
the	O
presence	O
of	O
oral	O
amiodarone	B-drug
;	O

because	O
of	O
this	O
,	O
the	O
dosage	O
of	O
flecainide	B-drug
should	O
be	O
adjusted	O
when	O
these	O
drugs	B-drug
are	O
administered	O
concomitantly	O
.	O

In	O
general	O
,	O
any	O
added	O
antiarrhythmic	B-drug
drug	I-drug
should	O
be	O
initiated	O
at	O
a	O
lower	O
than	O
usual	O
dose	O
with	O
careful	O
monitoring	O
.	O

Combination	O
of	O
amiodarone	B-drug
with	O
other	O
antiarrhythmic	B-drug
therapy	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
life	O
-	O
threatening	O
ventricular	O
arrhythmias	O
who	O
are	O
incompletely	O
responsive	O
to	O
a	O
single	O
agent	O
or	O
incompletely	O
responsive	O
to	O
amiodarone	B-drug
.	O

During	O
transfer	O
to	O
oral	O
amiodarone	B-drug
,	O
the	O
dose	O
levels	O
of	O
previously	O
administered	O
agents	O
should	O
be	O
reduced	O
by	O
30	O
to	O
50	O
%	O
several	O
days	O
after	O
the	O
addition	O
of	O
oral	O
amiodarone	B-drug
.	O

The	O
continued	O
need	O
for	O
the	O
other	O
antiarrhythmic	B-drug
agent	I-drug
should	O
be	O
reviewed	O
after	O
the	O
effects	O
of	O
amiodarone	B-drug
have	O
been	O
established	O
,	O
and	O
discontinuation	O
ordinarily	O
should	O
be	O
attempted	O
.	O

If	O
the	O
treatment	O
is	O
continued	O
,	O
these	O
patients	O
should	O
be	O
particularly	O
carefully	O
monitored	O
for	O
adverse	O
effects	O
,	O
especially	O
conduction	O
disturbances	O
and	O
exacerbation	O
of	O
tachyarrhythmias	O
,	O
as	O
amiodarone	B-drug
is	O
continued	O
.	O

In	O
amiodarone	B-drug
-	O
treated	O
patients	O
who	O
require	O
additional	O
antiarrhythmic	B-drug
therapy	O
,	O
the	O
initial	O
dose	O
of	O
such	O
agents	O
should	O
be	O
approximately	O
half	O
of	O
the	O
usual	O
recommended	O
dose	O
.	O

Antihypertensives	B-drug
:	O
Amiodarone	B-drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
?	O
-receptor	O
blocking	O
agents	O
(	O
e.g.	O
,	O
propranolol	B-drug
,	O
a	O
CYP3A4	B-drug
inhibitor	O
)	O
or	O
calcium	B-drug
channel	I-drug
antagonists	O
(	O
e.g.	O
,	O
verapamil	B-drug
,	O
a	O
CYP3A4	B-drug
substrate	O
,	O
and	O
diltiazem	B-drug
,	O
a	O
CYP3A4	B-drug
inhibitor	O
)	O
because	O
of	O
the	O
possible	O
potentiation	O
of	O
bradycardia	O
,	O
sinus	O
arrest	O
,	O
and	O
AV	O
block	O
;	O

if	O
necessary	O
,	O
amiodarone	B-drug
can	O
continue	O
to	O
be	O
used	O
after	O
insertion	O
of	O
a	O
pacemaker	O
in	O
patients	O
with	O
severe	O
bradycardia	O
or	O
sinus	O
arrest	O
.	O

Anticoagulants	B-drug
:	O
Potentiation	O
of	O
warfarin	B-drug
-	O
type	O
(	O
CYP2C9	B-drug
and	O
CYP3A4	B-drug
substrate	O
)	O
anticoagulant	B-drug
response	O
is	O
almost	O
always	O
seen	O
in	O
patients	O
receiving	O
amiodarone	B-drug
and	O
can	O
result	O
in	O
serious	O
or	O
fatal	O
bleeding	O
.	O

Since	O
the	O
concomitant	O
administration	O
of	O
warfarin	B-drug
with	O
amiodarone	B-drug
increases	O
the	O
prothrombin	O
time	O
by	O
100	O
%	O
after	O
3	O
to	O
4	O
days	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	B-drug
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
to	O
one	O
-	O
half	O
,	O
and	O
prothrombin	O
times	O
should	O
be	O
monitored	O
closely	O
.	O

Some	O
drugs	B-drug
/	O
substances	O
are	O
known	O
to	O
accelerate	O
the	O
metabolism	O
of	O
amiodarone	B-drug
by	O
stimulating	O
the	O
synthesis	O
of	O
CYP3A4	B-drug
(	O
enzyme	O
induction	O
)	O
.	O

This	O
may	O
lead	O
to	O
low	O
amiodarone	B-drug
serum	O
levels	O
and	O
potential	O
decrease	O
in	O
efficacy	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Antibiotics	B-drug
:	O
Rifampin	B-drug
is	O
a	O
potent	O
inducer	O
of	O
CYP3A4	B-drug
.	O

Administration	O
of	O
rifampin	B-drug
concomitantly	O
with	O
oral	O
amiodarone	B-drug
has	O
been	O
shown	O
to	O
result	O
in	O
decreases	O
in	O
serum	O
concentrations	O
of	O
amiodarone	B-drug
and	O
desethylamiodarone	B-drug
.	O

Other	O
substances	O
,	O
including	O
herbal	B-drug
preparations	I-drug
:	O
St.	O
John?s	O
Wort	O
(	O
Hypericum	B-drug
perforatum	I-drug
)	O
induces	O
CYP3A4	B-drug
.	O

Since	O
amiodarone	B-drug
is	O
a	O
substrate	O
for	O
CYP3A4	B-drug
,	O
there	O
is	O
the	O
potential	O
that	O
the	O
use	O
of	O
St.	O
John?s	O
Wort	O
in	O
patients	O
receiving	O
amiodarone	B-drug
could	O
result	O
in	O
reduced	O
amiodarone	B-drug
levels	O
.	O

Other	O
reported	O
interactions	O
with	O
amiodarone	B-drug
:	O
Fentanyl	B-drug
(	O
CYP3A4	B-drug
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B-drug
may	O
cause	O
hypotension	O
,	O
bradycardia	O
,	O
and	O
decreased	O
cardiac	O
output	O
.	O

Sinus	O
bradycardia	O
has	O
been	O
reported	O
with	O
oral	O
amiodarone	B-drug
in	O
combination	O
with	O
lidocaine	B-drug
(	O
CYP3A4	B-drug
substrate	O
)	O
given	O
for	O
local	B-drug
anesthesia	I-drug
.	O

Seizure	O
,	O
associated	O
with	O
increased	O
lidocaine	B-drug
concentrations	O
,	O
has	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
intravenous	O
amiodarone	B-drug
.	O

Dextromethorphan	B-drug
is	O
a	O
substrate	O
for	O
both	O
CYP2D6	B-drug
and	O
CYP3A4	B-drug
.	O

Amiodarone	B-drug
inhibits	O
CYP2D6	B-drug
.	O

Cholestyramine	B-drug
increases	O
enterohepatic	O
elimination	O
of	O
amiodarone	B-drug
and	O
may	O
reduce	O
its	O
serum	O
levels	O
and	O
t1/2	O
.	O

Disopyramide	B-drug
increases	O
QT	O
prolongation	O
which	O
could	O
cause	O
arrhythmia	O
.	O

Fluoroquinolones	B-drug
,	O
macrolide	B-drug
antibiotics	I-drug
,	O
and	O
azoles	O
are	O
known	O
to	O
cause	O
QTc	O
prolongation	O
.	O

There	O
have	O
been	O
reports	O
of	O
QTc	O
prolongation	O
,	O
with	O
or	O
without	O
TdP	O
,	O
in	O
patients	O
taking	O
amiodarone	B-drug
when	O
fluoroquinolones	B-drug
,	O
macrolide	B-drug
antibiotics	I-drug
,	O
or	O
azoles	O
were	O
administered	O
concomitantly	O
.	O

Hemodynamic	O
and	O
electrophysiologic	O
interactions	O
have	O
also	O
been	O
observed	O
after	O
concomitant	O
administration	O
with	O
propranolol	B-drug
,	O
diltiazem	B-drug
,	O
and	O
verapamil	B-drug
.	O

Volatile	O
Anesthetic	B-drug
Agents	I-drug
:	O
.	O

In	O
addition	O
to	O
the	O
interactions	O
noted	O
above	O
,	O
chronic	O
(	O
 	O
2	O
weeks	O
)	O
oral	O
Cordarone	B-drug
administration	O
impairs	O
metabolism	O
of	O
phenytoin	B-drug
,	O
dextromethorphan	B-drug
,	O
and	O
methotrexate	B-drug
.	O

Electrolyte	O
Disturbances	O
Patients	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
should	O
have	O
the	O
condition	O
corrected	O
whenever	O
possible	O
before	O
being	O
treated	O
with	O
Cordarone	B-drug
I.V.	I-drug
,	O
as	O
these	O
disorders	O
can	O
exaggerate	O
the	O
degree	O
of	O
QTc	O
prolongation	O
and	O
increase	O
the	O
potential	O
for	O
TdP.	O

Special	O
attention	O
should	O
be	O
given	O
to	O
electrolyte	O
and	O
acid	O
-	O
base	O
balance	O
in	O
patients	O
experiencing	O
severe	O
or	O
prolonged	O
diarrhea	O
or	O
in	O
patients	O
receiving	O
concomitant	O
diuretics	B-drug
.	O

Atovaquone	B-drug
is	O
highly	O
bound	O
to	O
plasma	B-drug
protein	I-drug
(	O
99.9	O
%	O
)	O
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
MEPRON	B-drug
concurrently	O
with	O
other	O
highly	O
plasma	O
protein-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
.	O

The	O
extent	O
of	O
plasma	B-drug
protein	I-drug
binding	O
of	O
atovaquone	B-drug
in	O
human	B-drug
plasma	I-drug
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
therapeutic	O
concentrations	O
of	O
phenytoin	B-drug
(	O
15	O
mcg/	O
mL	O
)	O
,	O
nor	O
is	O
the	O
binding	O
of	O
phenytoin	B-drug
affected	O
by	O
the	O
presence	O
of	O
atovaquone	B-drug
.	O

Rifampin	B-drug
:	O
Coadministration	O
of	O
rifampin	B-drug
and	O
MEPRON	B-drug
Suspension	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
average	O
steady-	O
state	O
plasma	O
atovaquone	B-drug
concentrations	O
.	O

Alternatives	O
to	O
rifampin	B-drug
should	O
be	O
considered	O
during	O
the	O
course	O
of	O
PCP	O
treatment	O
with	O
MEPRON	B-drug
.	O

Rifabutin	B-drug
,	O
another	O
rifamycin	B-drug
,	O
is	O
structurally	O
similar	O
to	O
rifampin	B-drug
and	O
may	O
possibly	O
have	O
some	O
of	O
the	O
same	O
drug	O
interactions	O
as	O
rifampin	B-drug
.	O

No	O
interaction	O
trials	O
have	O
been	O
conducted	O
with	O
MEPRON	B-drug
and	O
rifabutin	B-drug
.	O

Drug/	O
Laboratory	O
Test	O
Interactions	O
:	O
It	O
is	O
not	O
known	O
if	O
MEPRON	B-drug
interferes	O
with	O
clinical	O
laboratory	O
test	O
or	O
assay	O
results	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
CASODEX	B-drug
can	O
displace	O
coumarin	B-drug
anticoagulants	O
,	O
such	O
as	O
warfarin	B-drug
,	O
from	O
their	O
protein	B-drug
-	O
binding	O
sites	O
.	O

It	O
is	O
recommended	O
that	O
if	O
CASODEX	B-drug
is	O
started	O
in	O
patients	O
already	O
receiving	O
coumarin	B-drug
anticoagulants	O
,	O
prothrombin	O
times	O
should	O
be	O
closely	O
monitored	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B-drug
dose	O
may	O
be	O
necessary	O
.	O

No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B-drug
,	O
digoxin	B-drug
,	O
warfarin	B-drug
,	O
cimetidine	B-drug
and	O
phenobarbital	B-drug
.	O

Rifampin	B-drug
,	O
an	O
inducer	O
of	O
drug	O
metabolism	O
,	O
decreased	O
the	O
concentrations	O
of	O
losartan	B-drug
and	O
its	O
active	B-drug
metabolite	I-drug
.	O

In	O
humans	O
,	O
two	O
inhibitors	O
of	O
P450	B-drug
3A4	I-drug
have	O
been	O
studied	O
.	O

Ketoconazole	B-drug
did	O
not	O
affect	O
the	O
conversion	O
of	O
losartan	B-drug
to	O
the	O
active	B-drug
metabolite	I-drug
after	O
intravenous	O
administration	O
of	O
losartan	B-drug
,	O
and	O
erythromycin	B-drug
had	O
no	O
clinically	O
significant	O
effect	O
after	O
oral	O
administration	O
.	O

Fluconazole	B-drug
,	O
an	O
inhibitor	O
of	O
P450	B-drug
2C9	O
,	O
decreased	O
active	B-drug
metabolite	I-drug
concentration	O
and	O
increased	O
losartan	B-drug
concentration	O
.	O

The	O
pharmacodynamic	O
consequences	O
of	O
concomitant	O
use	O
of	O
losartan	B-drug
and	O
inhibitors	O
of	O
P450	B-drug
2C9	O
have	O
not	O
been	O
examined	O
.	O

Subjects	O
who	O
do	O
not	O
metabolize	O
losartan	B-drug
to	O
active	B-drug
metabolite	I-drug
have	O
been	O
shown	O
to	O
have	O
a	O
specific	O
,	O
rare	O
defect	O
in	O
cytochrome	B-drug
P450	I-drug
2C9	I-drug
.	O

These	O
data	O
suggest	O
that	O
the	O
conversion	O
of	O
losartan	B-drug
to	O
its	O
active	B-drug
metabolite	I-drug
is	O
mediated	O
primarily	O
by	O
P450	B-drug
2C9	O
and	O
not	O
P450	B-drug
3A4	I-drug
.	O

As	O
with	O
other	O
drugs	B-drug
that	O
block	O
angiotensin	B-drug
II	I-drug
or	O
its	O
effects	O
,	O
concomitant	O
use	O
of	O
potassium	B-drug
-	I-drug
sparing	I-drug
diuretics	I-drug
(	O
e.g.	O
,	O
spironolactone	B-drug
,	O
triamterene	B-drug
,	O
amiloride	B-drug
)	O
,	O
potassium	B-drug
supplements	O
,	O
or	O
salt	B-drug
substitutes	O
containing	O
potassium	B-drug
may	O
lead	O
to	O
increases	O
in	O
serum	O
potassium	O
.	O

As	O
with	O
other	O
antihypertensive	B-drug
agents	I-drug
,	O
the	O
antihypertensive	B-drug
effect	O
of	O
losartan	B-drug
may	O
be	O
blunted	O
by	O
the	O
non	B-drug
-	I-drug
steroidal	I-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drug	I-drug
indomethacin	O

.	O

?	O

Administration	O
of	O
thiazide	B-drug
diuretics	I-drug
to	O
hypoparathyroid	O
patients	O
who	O
are	O
concurrently	O
being	O
treated	O
with	O
dihydrotachysterol	B-drug
may	O
cause	O
hypercalcemia	O
.	O

Injection	O
There	O
is	O
inadequate	O
systematic	O
experience	O
with	O
the	O
use	O
of	O
baclofen	B-drug
injection	O
in	O
combination	O
with	O
other	B-drug
medications	I-drug
to	O
predict	O
specific	O
drug	O
-	O
drug	O
interactions	O
.	O

Interactions	O
attributed	O
to	O
the	O
combined	O
use	O
of	O
baclofen	B-drug
injection	O
and	O
epidural	O
morphine	B-drug
include	O
hypotension	O
and	O
dyspnea	O
.	O

SIDE	O
EFFECTS	O
(	O
KEMSTRO	O
)	O
The	O
most	O
common	O
adverse	O
reaction	O
during	O
treatment	O
with	O
baclofen	B-drug
is	O
transient	O
drowsiness	O
(	O
10	O
-	O
63	O
%	O
)	O
.	O

In	O
one	O
controlled	O
study	O
of	O
175	O
patients	O
,	O
transient	O
drowsiness	O
was	O
observed	O
in	O
63	O
%	O
of	O
those	O
receiving	O
baclofen	B-drug
tablets	I-drug
compared	O
to	O
36	O
%	O
of	O
those	O
in	O
the	O
placebo	O
group	O
.	O

Other	O
common	O
adverse	O
reactions	O
are	O
dizziness	O
(	O
5	O
-	O
15	O
%	O
)	O
,	O
weakness	O
(	O
5	O
-	O
15	O
%	O
)	O
and	O
fatigue	O
(	O
2	O
-	O
4	O
%	O
)	O
.	O

Others	O
reported	O
:	O
Neuropsychiatric	O
:	O
Confusion	O
(	O
1	O
-	O
11	O
%	O
)	O
,	O
headache	O
(	O
4	O
-	O
8	O
%	O
)	O
,	O
insomnia	O
(	O
2	O
-	O
7	O
%	O
)	O
;	O

and	O
,	O
rarely	O
,	O
euphoria	O
,	O
excitement	O
,	O
depression	O
,	O
hallucinations	O
,	O
paresthesia	O
,	O
muscle	O
pain	O
,	O
tinnitus	O
,	O
slurred	O
speech	O
,	O
coordination	O
disorder	O
,	O
tremor	O
,	O
rigidity	O
,	O
dystonia	O
,	O
ataxia	O
,	O
blurred	O
vision	O
,	O
nystagmus	O
,	O
strabismus	O
,	O
miosis	O
,	O
mydriasis	O
,	O
diplopia	O
,	O
dysarthria	O
,	O
epileptic	O
seizure	O
.	O

Cardiovascular	O
:	O
Hypotension	O
(	O
0	O
-	O
9	O
%	O
)	O
.	O

Rare	O
instances	O
of	O
dyspnea	O
,	O
palpitation	O
,	O
chest	O
pain	O
,	O
syncope	O
.	O

Gastrointestinal	O
:	O
Nausea	O
(	O
4	O
-	O
12	O
%	O
)	O
,	O
constipation	O
(	O
2	O
-	O
6	O
%	O
)	O
;	O

and	O
,	O
rarely	O
,	O
dry	O
mouth	O
,	O
anorexia	O
,	O
taste	O
disorder	O
,	O
abdominal	O
pain	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
positive	O
test	O
for	O
occult	O
blood	O
in	O
stool	O
.	O

Genitourinary	O
:	O
Urinary	O
frequency	O
(	O
2	O
-	O
6	O
%	O
)	O
;	O

and	O
,	O
rarely	O
,	O
enuresis	O
,	O
urinary	O
retention	O
,	O
dysuria	O
,	O
impotence	O
,	O
inability	O
to	O
ejaculate	O
,	O
nocturia	O
,	O
hematuria	O
.	O

Other	O
:	O
Instances	O
of	O
rash	O
,	O
pruritus	O
,	O
ankle	O
edema	O
,	O
excessive	O
perspiration	O
,	O
weight	O
gain	O
,	O
nasal	O
congestion	O
.	O

Some	O
of	O
the	O
CNS	O
and	O
genitourinary	O
symptoms	O
may	O
be	O
related	O
to	O
the	O
underlying	O
disease	O
rather	O
than	O
to	O
drug	O
therapy	O
.	O

The	O
following	O
laboratory	O
tests	O
have	O
been	O
found	O
to	O
be	O
abnormal	O
in	O
a	O
few	O
patients	O
receiving	O
baclofen	B-drug
:	O
increased	O
SGOT	O
,	O
elevated	O
alkaline	B-drug
phosphatase	I-drug
,	O
and	O
elevation	O
of	O
blood	O
sugar	O
.	O

The	O
adverse	O
experience	O
profile	O
seen	O
with	O
KEMSTROTM	O
was	O
similar	O
to	O
that	O
seen	O
with	O
baclofen	B-drug
tablets	I-drug
.	O

Preliminary	O
data	O
which	O
suggest	O
that	O
dapsone	B-drug
may	O
inhibit	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
Lamprene	B-drug
have	O
not	O
been	O
confirmed	O
.	O

If	O
leprosy	B-drug
-	O
associated	O
inflammatory	O
reactions	O
develop	O
in	O
patients	O
being	O
treated	O
with	O
dapsone	B-drug
and	O
clofazimine	B-drug
,	O
it	O
is	O
still	O
advisable	O
to	O
continue	O
treatment	O
with	O
both	O
drugs	B-drug
.	O

No	O
significant	O
drug	B-drug
-	O
drug	O
pharmacokinetic	O
(	O
or	O
pharmacodynamic	O
)	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B-drug
,	O
digoxin	B-drug
,	O
warfarin	B-drug
,	O
and	O
nifedipine	B-drug
.	O

In	O
vitro	O
studies	O
show	O
significant	O
inhibition	O
of	O
the	O
formation	O
of	O
oxidized	O
irbesartan	B-drug
metabolites	O
with	O
the	O
known	O
cytochrome	O
CYP	B-drug
2C9	I-drug
substrates	O
/	O
inhibitors	O
sulphenazole	O
,	O
tolbutamide	B-drug
and	O
nifedipine	B-drug
.	O

However	O
,	O
in	O
clinical	O
studies	O
the	O
consequences	O
of	O
concomitant	O
irbesartan	B-drug
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-drug
were	O
negligible	O
.	O

Based	O
on	O
in	O
vitro	O
data	O
,	O
no	O
interaction	O
would	O
be	O
expected	O
with	O
drugs	B-drug
whose	O
metabolism	O
is	O
dependent	O
upon	O
cytochrome	B-drug
P450	I-drug
isozymes	I-drug
1A1	I-drug
,	I-drug
1A2,2A6,2B6,2D6,2E1,or	O
3A4	O
.	O

In	O
separate	O
studies	O
of	O
patients	O
receiving	O
maintenance	O
doses	O
of	O
warfarin	B-drug
,	O
hydrochlorothiazide	B-drug
,	O
or	O
digoxin	B-drug
,	O
irbesartan	B-drug
administration	O
for	O
7	O
days	O
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B-drug
(	O
prothrombin	O
time	O
)	O
or	O
pharmacokinetics	O
of	O
digoxin	B-drug
.	O

The	O
pharmacokinetics	O
of	O
irbesartan	B-drug
were	O
not	O
affected	O
by	O
coadministration	O
of	O
nifedipine	B-drug
or	O
hydrochlorothiazide	B-drug

.	O

?	O

Geocillin	B-drug
(	O
carbenicillin	B-drug
indanyl	I-drug
sodium	I-drug
)	O
blood	O
levels	O
may	O
be	O
increased	O
and	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	B-drug
.	O

When	O
ertapenem	B-drug
is	O
co	O
-	O
administered	O
with	O
probenecid	B-drug
(	O
500	B-drug
mg	O
p.o	O
.	O
every	O
6	O
hours	O
)	O
,	O
probenecid	B-drug
competes	O
for	O
active	O
tubular	O
secretion	O
and	O
reduces	O
the	O
renal	O
clearance	O
of	O
ertapenem	B-drug
.	O

Based	O
on	O
total	O
ertapenem	B-drug
concentrations	O
,	O
probenecid	B-drug
increased	O
the	O
AUC	O
by	O
25	O
%	O
and	O
reduced	O
the	O
plasma	O
and	O
renal	O
clearances	O
by	O
20	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

The	O
half	O
-	O
life	O
increased	O
from	O
4.0	O
to	O
4.8	O
hours	O
.	O

Because	O
of	O
the	O
small	O
effect	O
on	O
half	O
-	O
life	O
,	O
the	O
coadministration	O
with	O
probenecid	B-drug
to	O
extend	O
the	O
half	O
-	O
life	O
of	O
ertapenem	B-drug
is	O
not	O
recommended	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
ertapenem	B-drug
does	O
not	O
inhibit	O
P	O
-	O
glycoprotein	B-drug
-	O
mediated	O
transport	O
of	O
digoxin	B-drug
or	O
vinblastine	B-drug
and	O
that	O
ertapenem	B-drug
is	O
not	O
a	O
substrate	O
for	O
P	O
-	O
glycoprotein	B-drug
-	O
mediated	O
transport	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
indicate	O
that	O
ertapenem	B-drug
does	O
not	O
inhibit	O
metabolism	O
mediated	O
by	O
any	O
of	O
the	O
following	O
six	O
cytochrome	B-drug
p450	I-drug
(	O
CYP	B-drug
)	O
isoforms	B-drug
:	O
1A2	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
and	O
3A4	O
.	O

Drug	O
interactions	O
caused	O
by	O
inhibition	O
of	O
P	O
-	O
glycoprotein	B-drug
-	O
mediated	O
drug	O
clearance	O
or	O
CYP	B-drug
-	O
mediated	O
drug	O
clearance	O
with	O
the	O
listed	O
isoforms	B-drug
are	O
unlikely	O
.	O

Other	O
than	O
with	O
probenecid	B-drug
,	O
no	O
specific	O
clinical	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O

.	O

?	O
?	O

Co	O
-	O
administration	O
of	O
nelfinavir	B-drug
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B-drug
(	O
2	O
 	O
span	O
class=	O
c94	O
?	O
?	O

600	O
mg	O
tablets	O
)	O
results	O
in	O
increased	O
azithromycin	B-drug
serum	O
concentrations	O
.	O

Although	O
a	O
dose	O
adjustment	O
of	O
azithromycin	B-drug
is	O
not	O
recommended	O
when	O
administered	O
in	O
combination	O
with	O
nelfinavir	B-drug
,	O
close	O
monitoring	O
for	O
known	O
side	O
effects	O
of	O
azithromycin	B-drug
,	O
such	O
as	O
liver	O
enzyme	O
abnormalities	O
and	O
hearing	O
impairment	O
,	O
is	O
warranted	O
.	O

Azithromycin	B-drug
did	O
not	O
affect	O
the	O
prothrombin	O
time	O
response	O
to	O
a	O
single	O
dose	O
of	O
warfarin	B-drug
.	O

However	O
,	O
prudent	O
medical	O
practice	O
dictates	O
careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
all	O
patients	O
treated	O
with	O
azithromycin	B-drug
and	O
warfarin	B-drug
concomitantly	O
.	O

Concurrent	O
use	O
of	O
macrolides	B-drug
and	O
warfarin	B-drug
in	O
clinical	O
practice	O
has	O
been	O
associated	O
with	O
increased	O
anticoagulant	O
effects	O
.	O

Drug	O
interaction	O
studies	O
were	O
performed	O
with	O
azithromycin	B-drug
and	O
other	O
drugs	B-drug
likely	O
to	O
be	O
co	O
-	O
administered	O
.	O

When	O
used	O
in	O
therapeutic	O
doses	O
,	O
azithromycin	B-drug
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
atorvastatin	B-drug
,	O
carbamazepine	B-drug
,	O
cetirizine	B-drug
,	O
didanosine	B-drug
,	O
efavirenz	B-drug
,	O
fluconazole	B-drug
,	O
indinavir	B-drug
,	O
midazolam	B-drug
,	O
rifabutin	B-drug
,	O
sildenafil	B-drug
,	O
theophylline	B-drug
(	O
intravenous	O
and	O
oral	O
)	O
,	O
triazolam	B-drug
,	O
trimethoprim	B-drug
/	O
sulfamethoxazole	B-drug
or	O
zidovudine	B-drug
.	O

Co	O
-	O
administration	O
with	O
efavirenz	B-drug
or	O
fluconazole	B-drug
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
azithromycin	B-drug
.	O

No	O
dosage	O
adjustment	O
of	O
either	O
drug	B-drug
is	O
recommended	O
when	O
azithromycin	B-drug
is	O
co	O
administered	O
with	O
any	O
of	O
the	O
above	O
agents	O
.	O

Interactions	O
with	O
the	O
drugs	B-drug
listed	O
below	O
have	O
not	O
been	O
reported	O
in	O
clinical	O
trials	O
with	O
azithromycin	B-drug
;	O

however	O
,	O
no	O
specific	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
to	O
evaluate	O
potential	O
drug	O
-	O
drug	O
interaction	O
.	O

Nonetheless	O
,	O
they	O
have	O
been	O
observed	O
with	O
macrolide	B-drug
products	O
.	O

Until	O
further	O
data	O
are	O
developed	O
regarding	O
drug	O
interactions	O
when	O
azithromycin	B-drug
and	O
these	O
drugs	B-drug
are	O
used	O
concomitantly	O
,	O
careful	O
monitoring	O
of	O
patients	O
is	O
advised	O
:	O
Digoxin?elevated	O
digoxin	O
concentrations	O
.	O

Ergotamine	B-drug
or	O
dihydroergotamine?acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Cyclosporine	B-drug
,	O
hexobarbital	B-drug
and	O
phenytoin	B-drug
concentrations	O
.	O

Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
reported	O
laboratory	O
test	O
interactions	O
.	O

Repeat	O
Treatment	O
Studies	O
evaluating	O
the	O
use	O
of	O
repeated	O
courses	O
of	O
Zmax	B-drug
have	O
not	O
been	O
conducted	O
.	O

Isoflurane	B-drug
potentiates	O
the	O
muscle	B-drug
relaxant	I-drug
effect	O
of	O
all	O
muscle	B-drug
relaxants	I-drug
,	O
most	O
notably	O
nondepolarizing	O
muscle	B-drug
relaxants	I-drug
,	O
and	O
MAC	O
(	O
minimum	O
alveolar	O
concentration	O
)	O
is	O
reduced	O
by	O
concomitant	O
administration	O
of	O
N	O
span	O
class=	O
c13	O
2O.	O

See	O
CLINICAL	O
PHARMACOLOGY	O
.	O

No	O
formal	O
drug	B-drug
/	O
drug	O
interaction	O
studies	O
with	O
Plenaxis	O
?	O
were	O
performed	O
.	O

Cytochrome	B-drug
P-450	I-drug
is	O
not	O
known	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
Plenaxis	O
?	O
.	O

Plenaxis	O
?	O
is	O
highly	O
bound	O
to	O
plasma	B-drug
proteins	I-drug
(	O
96	O
to	O
99	O
%	O
)	O
.	O

Laboratory	O
Tests	O
Response	O
to	O
Plenaxis	O
?	O
should	O
be	O
monitored	O
by	O
measuring	O
serum	O
total	B-drug
testosterone	I-drug
concentrations	O
just	O
prior	O
to	O
administration	O
on	O
Day	O
29	O
and	O
every	O
8	O
weeks	O
thereafter	O
.	O

Serum	O
transaminase	B-drug
levels	O
should	O
be	O
obtained	O
before	O
starting	O
treatment	O
with	O
Plenaxis	O
?	O
and	O
periodically	O
during	O
treatment	O
.	O

Periodic	O
measurement	O
of	O
serum	O
PSA	O
levels	O
may	O
also	O
be	O
considered	O
.	O

Although	O
clinical	O
studies	O
have	O
not	O
established	O
a	O
cause	O
and	O
effect	O
relationship	O
,	O
physicians	O
should	O
be	O
aware	O
that	O
variable	O
effects	O
an	O
blood	O
coagulation	O
have	O
been	O
reported	O
very	O
rarely	O
in	O
patients	O
receiving	O
oral	B-drug
anticoagulants	I-drug
and	O
chlordiazepoxide	B-drug
.	O

The	O
concomitant	O
use	O
of	O
alcohol	B-drug
or	O
other	O
central	B-drug
nervous	I-drug
system	I-drug
depressants	I-drug
may	O
have	O
an	O
additive	O
effect	O
.	O

Drug	O
Interaction	O
with	O
Erythromycin	B-drug
and	O
Ketoconazole	B-drug
Fexofenadine	O
has	O
been	O
shown	O
to	O
exhibit	O
minimal	O
(	O
ca	O
.	O
5	O
%	O
)	O
metabolism	O
.	O

However	O
,	O
co	O
?	O
administration	O
of	O
fexofenadine	B-drug
hydrochloride	I-drug
with	O
either	O
ketoconazole	B-drug
or	O
erythromycin	B-drug
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
fexofenadine	B-drug
.	O

Fexofenadine	B-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
erythromycin	B-drug
or	O
ketoconazole	B-drug
.	O

In	O
2	O
separate	O
studies	O
,	O
fexofenadine	B-drug
hydrochloride	I-drug
120	I-drug
mg	O
twice	O
daily	O
(	O
240	O
mg	O
total	O
daily	O
dose	O
)	O
was	O
co	O
-	O
administered	O
with	O
either	O
erythromycin	B-drug
500	I-drug
mg	I-drug
every	O
8	O
hours	O
or	O
ketoconazole	B-drug
400	I-drug
mg	I-drug
once	O
daily	O
under	O
steady	O
-	O
state	O
conditions	O
to	O
healthy	O
volunteers	O
(	O
n=24	O
,	O
each	O
study	O
)	O
.	O

No	O
differences	O
in	O
adverse	O
events	O
or	O
QTc	O
interval	O
were	O
observed	O
when	O
subjects	O
were	O
administered	O
fexofenadine	B-drug
hydrochloride	I-drug
alone	O
or	O
in	O
combination	O
with	O
either	O
erythromycin	B-drug
or	O
ketoconazole	B-drug
.	O

The	O
findings	O
of	O
these	O
studies	O
are	O
summarized	O
in	O
the	O
following	O
table	O
:	O
Effects	O
on	O
steady	O
-	O
state	O
fexofenadine	B-drug
pharmacokinetics	O
after	O
7	O
days	O
of	O
co	O
-	O
administration	O
with	O
fexofenadine	B-drug
hydrochloride	I-drug
120	I-drug
mg	O
every	O
12	O
hours	O
(	O
two	O
times	O
the	O
recommended	O
twice	O
daily	O
dose	O
)	O
in	O
healthy	O
volunteers	O
(	O
n=24	O
)	O

Concomitant	O
Drug	B-drug

cmaxSS	O
(	O
Peak	O
plasma	O
concentration	O
)	O

AUCss(0	O
-	O
12h	O
)	O
(	O
Extent	O
of	O
systemic	O
exposure	O
)	O

Erythromycin	B-drug
(	O
500	O
mg	O
every	O
8	O
hrs	O
)	O

+82	O
%	O

+109	O
%	O

Ketoconazole	B-drug
(	O
400	O
mg	O
once	O
daily	O
)	O

+135	O
%	O

+164	O
%	O

The	O
changes	O
in	O
plasma	O
levels	O
were	O
within	O
the	O
range	O
of	O
plasma	O
levels	O
achieved	O
in	O
adequate	O
and	O
well	O
-	O
controlled	O
clinical	O
trials	O
.	O

The	O
mechanism	O
of	O
these	O
interactions	O
has	O
been	O
evaluated	O
in	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
and	O
in	O
vivo	O
animal	O
models	O
.	O

These	O
studies	O
indicate	O
that	O
ketoconazole	B-drug
or	O
erythromycin	B-drug
co	O
-	O
administration	O
enhances	O
fexofenadine	B-drug
gastrointestinal	O
absorption	O
.	O

This	O
observed	O
increase	O
in	O
the	O
bioavailability	O
of	O
fexofenadine	B-drug
may	O
be	O
due	O
to	O
transport	O
-	O
related	O
effects	O
,	O
such	O
as	O
p	O
-	O
glycoprotein	B-drug
.	O
in	O
vivo	O
animal	O
studies	O
also	O
suggest	O
that	O
in	O
addition	O
to	O
enhancing	O
absorption	O
,	O
ketoconazole	B-drug
decreases	O
fexofenadine	B-drug
gastrointestinal	O
secretion	O
,	O
while	O
erythromycin	B-drug
may	O
also	O
decrease	O
biliary	O
excretion	O
.	O

Drug	O
Interactions	O
with	O
Antacids	B-drug
Administration	O
of	O
120	O
mg	O
of	O
fexofenadine	B-drug
hydrochloride	I-drug
(	O
2	O
x	O
60	O
mg	O
capsule	O
)	O
within	O
15	O
minutes	O
of	O
an	O
aluminum	O
and	O
magnesium	B-drug
containing	I-drug
antacid	I-drug
(	O
Maalox	O
?	O
)	O
decreased	O
fexofenadine	B-drug
AUC	O
by	O
41	O
%	O
and	O
cmax	O
by	O
43	O
%	O
.	O

ALLEGRA	B-drug
should	O
not	O
be	O
taken	O
closely	O
in	O
time	O
with	O
aluminum	O
and	O
magnesium	B-drug
containing	I-drug
antacids	I-drug
.	O

Interactions	O
with	O
Fruit	O
Juices	O
Fruit	O
juices	O
such	O
as	O
grapefruit	B-drug
,	O
orange	O
and	O
apple	O
may	O
reduce	O
the	O
bioavailability	O
and	O
exposure	O
of	O
fexofenadine	B-drug
.	O

This	O
is	O
based	O
on	O
the	O
results	O
from	O
3	O
clinical	O
studies	O
using	O
histamine	O
induced	O
skin	O
wheals	O
and	O
flares	O
coupled	O
with	O
population	O
pharmacokinetic	O
analysis	O
.	O

The	O
size	O
of	O
wheal	O
and	O
flare	O
were	O
significantly	O
larger	O
when	O
fexofenadine	B-drug
hydrochloride	I-drug
was	O
administered	O
with	O
either	O
grapefruit	B-drug
or	O
orange	O
juices	O
compared	O
to	O
water	B-drug
.	O

Based	O
on	O
the	O
literature	O
reports	O
,	O
the	O
same	O
effects	O
may	O
be	O
extrapolated	O
to	O
other	O
fruit	O
juices	O
such	O
as	O
apple	O
juice	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
observations	O
is	O
unknown	O
.	O

In	O
addition	O
,	O
based	O
on	O
the	O
population	O
pharmacokinetics	O
analysis	O
of	O
the	O
combined	O
data	O
from	O
grapefruit	B-drug
and	O
orange	O
juices	O
studies	O
with	O
the	O
data	O
from	O
a	O
bioequivalence	O
study	O
,	O
the	O
bioavailability	O
of	O
fexofenadine	B-drug
was	O
reduced	O
by	O
36	O
%	O
.	O

Therefore	O
,	O
to	O
maximize	O
the	O
effects	O
of	O
fexofenadine	B-drug
,	O
it	O
is	O
recommended	O
that	O
ALLEGRA	B-drug
should	O
be	O
taken	O
with	O
water	B-drug

.	O

?	O

Amantadine	B-drug
,	O
tricyclic	B-drug
antidepressants	I-drug
,	O
and	O
MAOIs	O
may	O
increase	O
anticholinergic	B-drug
effect	O
of	O
clidinium	B-drug
.	O

Clidinium	B-drug
may	O
decrease	O
the	O
effect	O
of	O
phenothiazines	B-drug
,	O
levodopa	B-drug
,	O
and	O
ketoconazole	B-drug
.	O

Cholestyramine	B-drug
and	O
Charcoal	B-drug
Administration	O
of	O
cholestyramine	B-drug
or	O
activated	B-drug
charcoal	I-drug
in	O
patients	O
(	O
n=13	O
)	O
and	O
volunteers	O
(	O
n=96	O
)	O
resulted	O
in	O
a	O
rapid	O
and	O
significant	O
decrease	O
in	O
plasma	O
M1	O
(	O
the	O
active	B-drug
metabolite	I-drug
of	O
leflunomide	B-drug
)	O
concentration	O
.	O

Hepatotoxic	O
Drugs	B-drug
Increased	O
side	O
effects	O
may	O
occur	O
when	O
leflunomide	B-drug
is	O
given	O
concomitantly	O
with	O
hepatotoxic	O
substances	O
.	O

This	O
is	O
also	O
to	O
be	O
considered	O
when	O
leflunomide	B-drug
treatment	O
is	O
followed	O
by	O
such	O
drugs	B-drug
without	O
a	O
drug	O
elimination	O
procedure	O
.	O

In	O
a	O
small	O
(	O
n=30	O
)	O
combination	O
study	O
of	O
ARAVA	B-drug
with	O
methotrexate	B-drug
,	O
a	O
2-	O
to	O
3-fold	O
elevation	O
in	O
liver	B-drug
enzymes	I-drug
was	O
seen	O
in	O
5	O
of	O
30	O
patients	O
.	O

All	O
elevations	O
resolved	O
,	O
2	O
with	O
continuation	O
of	O
both	O
drugs	B-drug
and	O
3	O
after	O
discontinuation	O
of	O
leflunomide	B-drug
.	O

A	O
 	O
3-fold	O
increase	O
was	O
seen	O
in	O
another	O
5	O
patients	O
.	O

All	O
of	O
these	O
also	O
resolved	O
,	O
2	O
with	O
continuation	O
of	O
both	O
drugs	B-drug
and	O
3	O
after	O
discontinuation	O
of	O
leflunomide	B-drug
.	O

Three	O
patients	O
met	B-drug
ACR	O
criteria	O
for	O
liver	O
biopsy	O
(	O
1	O
:	O
Roegnik	O
Grade	O
I	O
,	O
2	O
:	O
Roegnik	O
Grade	O
IIIa	O
)	O
.	O

No	O
pharmacokinetic	O
interaction	O
was	O
identified	O
.	O

NSAIDs	B-drug
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
diclofenac	B-drug
and	O
ibuprofen	B-drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
;	O

however	O
,	O
there	O
was	O
extensive	O
concomitant	O
use	O
of	O
NSAIDs	B-drug
in	O
clinical	O
studies	O
and	O
no	O
differential	O
effect	O
was	O
observed	O
.	O

Tolbutamide	B-drug
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
tolbutamide	B-drug
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O

Rifampin	B-drug
Following	O
concomitant	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ARAVA	B-drug
to	O
subjects	O
receiving	O
multiple	O
doses	O
of	O
rifampin	B-drug
,	O
M1	O
peak	O
levels	O
were	O
increased	O
(	O
~40	O
%	O
)	O
over	O
those	O
seen	O
when	O
ARAVA	B-drug
was	O
given	O
alone	O
.	O

Because	O
of	O
the	O
potential	O
for	O
ARAVA	B-drug
levels	O
to	O
continue	O
to	O
increase	O
with	O
multiple	O
dosing	O
,	O
caution	O
should	O
be	O
used	O
if	O
patients	O
are	O
to	O
be	O
receiving	O
both	O
ARAVA	B-drug
and	O
rifampin	B-drug
.	O

Warfarin	B-drug
Increased	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
when	O
ARAVA	B-drug
and	O
warfarin	B-drug
were	O
co	O
-	O
administered	O
has	O
been	O
rarely	O
reported	O
.	O

CNS	O
depression?producing	O
medications	O
-	O
concurrent	O
use	O
may	O
potentiate	O
the	O
effects	O
of	O
either	O
these	O
medications	B-drug
or	O
diphenidol	B-drug
;	O

anticholinergics	B-drug
or	O
other	B-drug
medications	I-drug
with	O
anticholinergic	B-drug
activity	O
-	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	B-drug
are	O
used	O
concurrently	O
with	O
diphenidol	B-drug
;	I-drug

apomorphine	B-drug
-	O
prior	O
ingestion	O
of	O
diphenidol	B-drug
may	O
decrease	O
the	O
emetic	B-drug
response	O
to	O
apomorphine	B-drug
in	O
the	O
treatment	O
of	O
poisoning	O
.	O

No	O
specific	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
.	O

For	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
Gemzar	B-drug
and	O
cisplatin	B-drug
in	O
combination	O
,	O
see	O
Drug	O
Interactions	O
under	O
CLINICAL	O
PHARMACOLOGY	O
section	O
.	O

Administration	O
of	O
doxapram	B-drug
to	O
patients	O
who	O
are	O
receiving	O
sympathomimetic	B-drug
or	O
monoamine	B-drug
oxidase	I-drug
inhibiting	O
drugs	O
may	O
result	O
in	O
an	O
additive	B-drug
pressor	I-drug
effect	I-drug
.	O

In	O
patients	O
who	O
have	O
received	O
muscle	B-drug
relaxants	I-drug
,	O
doxapram	B-drug
may	O
temporarily	O
mask	O
the	O
residual	O
effects	O
of	O
muscle	O
relaxant	O
drugs	B-drug
.	O

In	O
patients	O
who	O
have	O
received	O
general	O
anesthesia	O
utilizing	O
a	O
volatile	O
agent	O
known	O
to	O
sensitize	O
the	O
myocardium	O
to	O
catecholamines	O
,	O
administration	O
of	O
doxapram	B-drug
should	O
be	O
delayed	O
until	O
the	O
volatile	O
agent	O
has	O
been	O
excreted	O
in	O
order	O
to	O
lessen	O
the	O
potential	O
for	O
arrhythmias	O
,	O
including	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
.	O

Diuretics	B-drug
:	O
Patients	O
on	O
diuretics	B-drug
,	O
especially	O
those	O
with	O
intravascular	O
volume	O
depletion	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
fosinopril	B-drug
sodium	I-drug
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B-drug
or	O
increasing	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
fosinopril	B-drug
sodium	I-drug
.	O

If	O
this	O
is	O
not	O
possible	O
,	O
the	O
starting	O
dose	O
should	O
be	O
reduced	O
and	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
several	O
hours	O
following	O
an	O
initial	O
dose	O
and	O
until	O
blood	O
pressure	O
has	O
stabilized	O
(	O
see	O
DOSAGE	O
AND	O
ADMINISTRATION	O
.	O
)	O

Potassium	B-drug
Supplements	O
and	O
Potassium	B-drug
-	I-drug
Sparing	I-drug
Diuretics	I-drug
:	O
Fosinopril	B-drug
sodium	I-drug
can	O
attenuate	O
potassium	B-drug
loss	O
caused	O
by	O
thiazide	B-drug
diuretics	I-drug
.	O

Potassium	B-drug
-	I-drug
sparing	I-drug
diuretics	I-drug
(	O
spironolactone	B-drug
,	O
amiloride	B-drug
,	O
triamterene	B-drug
,	O
and	O
others	O
)	O
or	O
potassium	B-drug
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Therefore	O
,	O
if	O
concomitant	O
use	O
of	O
such	O
agents	O
is	O
indicated	O
,	O
they	O
should	O
be	O
given	O
with	O
caution	O
,	O
and	O
the	O
patients	O
serum	O
potassium	O
should	O
be	O
monitored	O
frequently	O
.	O

Lithium	B-drug
:	O
Increased	O
serum	O
lithium	O
levels	O
and	O
symptoms	O
of	O
lithium	O
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B-drug
inhibitors	I-drug
during	O
therapy	O
with	O
lithium	B-drug
.	O

These	O
drugs	B-drug
should	O
be	O
coadministered	O
with	O
caution	O
,	O
and	O
frequent	O
monitoring	O
of	O
serum	O
lithium	O
levels	O
is	O
recommended	O
.	O

If	O
a	O
diuretic	B-drug
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	O
toxicity	O
may	O
be	O
increased	O
.	O

Antacids	B-drug
:	O
In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
coadministration	O
of	O
an	O
antacid	B-drug
(	O
aluminum	B-drug
hydroxide	I-drug
,	I-drug
magnesium	B-drug
hydroxide	I-drug
,	O
and	O
simethicone	B-drug
)	O
with	O
fosinopril	B-drug
reduced	O
serum	O
levels	O
and	O
urinary	O
excretion	O
of	O
fosinoprilat	B-drug
as	O
compared	O
with	O
fosinopril	B-drug
administered	O
alone	O
,	O
suggesting	O
that	O
antacids	B-drug
may	O
impair	O
absorption	O
of	O
fosinopril	B-drug
.	O

Therefore	O
,	O
if	O
concomitant	O
administration	O
of	O
these	O
agents	O
is	O
indicated	O
,	O
dosing	O
should	O
be	O
separated	O
by	O
2	O
hours	O
.	O

Other	O
:	O
Neither	O
fosinopril	B-drug
sodium	I-drug
nor	O
its	O
metabolites	B-drug
have	O
been	O
found	O
to	O
interact	O
with	O
food	O
.	O

In	O
separate	O
single	O
or	O
multiple	O
dose	O
pharmacokinetic	O
interaction	O
studies	O
with	O
chlorthalidone	B-drug
,	I-drug
nifedipine	B-drug
,	O
propanolol	B-drug
,	O
hydrochlorothiazide	B-drug
,	O
cimetidine	B-drug
,	O
metoclopramide	B-drug
,	O
propantheline	B-drug
,	O
digoxin	B-drug
,	O
and	O
warfarin	B-drug
,	O
the	O
bioavailability	O
of	O
fosinoprilat	B-drug
was	O
not	O
altered	O
by	O
coadministration	O
of	O
fosinopril	B-drug
with	O
any	O
one	O
of	O
these	O
drugs	B-drug
.	O

In	O
a	O
study	O
with	O
concomitant	O
administration	O
of	O
aspirin	B-drug
and	O
fosinopril	B-drug
sodium	I-drug
,	O
the	O
bioavailability	O
of	O
unbound	O
fosinoprilat	B-drug
was	O
not	O
altered	O
.	O

In	O
a	O
pharmacokinetic	O
interaction	O
study	O
with	O
warfarin	B-drug
,	O
bioavailability	O
parameters	O
,	O
the	O
degree	O
of	O
protein	O
binding	O
,	O
and	O
the	O
anticoagulant	O
effect	O
(	O
measured	O
by	O
prothrombin	O
time	O
)	O
of	O
warfarin	B-drug
were	O
not	O
significantly	O
changed	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interaction	O
Fosinopril	B-drug
may	O
cause	O
a	O
false	O
low	O
measurement	O
of	O
serum	O
digoxin	O
levels	O
with	O
the	O
Digi-	O
Tab	O
?	O
RIA	O
Kit	O
for	O
Digoxin	B-drug
.	O

Other	O
kits	O
,	O
such	O
as	O
the	O
Coat	O
-	O
A	O
-	O
Count	O
?	O
RIA	O
Kit	O
,	O
may	O
be	O
used	O
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B-drug
and	O
aminoglycoside	B-drug
antibiotics	I-drug
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
cephalothin	B-drug
,	O
high	O
concentrations	O
of	O
cefoxitin	B-drug
(	O
100	O
micrograms	O
/	O
mL	O
)	O
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
the	O
Jaff	O
?	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
of	O
creatinine	B-drug
reported	O
.	O

Serum	O
samples	O
from	O
patients	O
treated	O
with	O
cefoxitin	B-drug
should	O
not	O
be	O
analyzed	O
for	O
creatinine	B-drug
if	O
withdrawn	O
within	O
2	O
hours	O
of	O
drug	O
administration	O
.	O

High	O
concentrations	O
of	O
cefoxitin	B-drug
in	O
the	O
urine	O
may	O
interfere	O
with	O
measurement	O
of	O
urinary	O
17-hydroxy	O
-	O
corticosteroids	B-drug
by	O
the	O
Porter	O
-	O
Silber	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
reported	O
.	O

A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	B-drug
in	O
the	O
urine	O
may	O
occur	O
.	O

This	O
has	O
been	O
observed	O
with	O
CLINITEST	O
?	O
reagent	O
tablets	O

.	O

?	O
Registered	O
trademark	O
of	O
Ames	O
Company	O
,	O
Division	O
of	O
Miles	O
Laboratories	O
,	O
Inc.	O

Before	O
using	O
this	O
medication	B-drug
,	I-drug
tell	O
your	O
doctor	O
or	O
pharmacist	O
of	O
all	O
prescription	O
and	O
nonprescription	O
products	O
you	O
may	O
use	O
,	O
especially	O
of	O
:	O
aminoglycosides	B-drug
(	O
e.g.	O
,	O
gentamicin	B-drug
,	O
amikacin	B-drug
)	O
,	O
amphotericin	B-drug
B	I-drug
,	O
cyclosporine	B-drug
,	O
non	B-drug
-	I-drug
steroidal	I-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
(	O
e.g.	O
,	O
ibuprofen	B-drug
)	O
,	O
tacrolimus	B-drug
,	O
vancomycin	B-drug
.	O

Do	O
not	O
start	O
or	O
stop	O
any	O
medicine	B-drug
without	O
doctor	O
or	O
pharmacist	O
approval	O
.	O

DIAMOX	B-drug
modifies	O
phenytoin	B-drug
metabolism	O
with	O
increased	O
serum	O
levels	O
of	O
phenytoin	B-drug
.	O

This	O
may	O
increase	O
or	O
enhance	O
the	O
occurrence	O
of	O
osteomalacia	O
in	O
some	O
patients	O
receiving	O
chronic	O
phenytoin	B-drug
therapy	O
.	O

Caution	O
is	O
advised	O
in	O
patients	O
receiving	O
chronic	O
concomitant	O
therapy	O
.	O

By	O
decreasing	O
the	O
gastrointestinal	O
absorption	O
of	O
primidone	B-drug
,	O
DIAMOX	B-drug
may	O
decrease	O
serum	O
concentrations	O
of	O
primidone	B-drug
and	O
its	O
metabolites	B-drug
,	O
with	O
a	O
consequent	O
possible	O
decrease	O
in	O
anticonvulsant	B-drug
effect	O
.	O

Caution	O
is	O
advised	O
when	O
beginning	O
,	O
discontinuing	O
,	O
or	O
changing	O
the	O
dose	O
of	O
DIAMOX	B-drug
in	O
patients	O
receiving	O
primidone	B-drug
.	O

Because	O
of	O
possible	O
additive	O
effects	O
with	O
other	O
carbonic	B-drug
anhydrase	I-drug
inhibitors	I-drug
,	O
concomitant	O
use	O
is	O
not	O
advisable	O
.	O

Acetazolamide	B-drug
may	O
increase	O
the	O
effects	O
of	O
other	O
folic	B-drug
acid	I-drug
antagonists	I-drug
.	O

Acetazolamide	B-drug
may	O
increase	O
or	O
decrease	O
blood	O
glucose	O
levels	O
.	O

Consideration	O
should	O
be	O
taken	O
in	O
patients	O
being	O
treated	O
with	O
antidiabetic	B-drug
agents	I-drug
.	O

Acetazolamide	B-drug
decreases	O
urinary	O
excretion	O
of	O
amphetamine	B-drug
and	O
may	O
enhance	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
effect	O
.	O

Acetazolamide	B-drug
reduces	O
urinary	O
excretion	O
of	O
quinidine	B-drug
and	O
may	O
enhance	O
its	O
effect	O
.	O

Acetazolamide	B-drug
may	O
prevent	B-drug
the	O
urinary	O
antiseptic	B-drug
effect	O
of	O
methenamine	B-drug
.	O

Acetazolamide	B-drug
increases	O
lithium	B-drug
excretion	O
and	O
the	O
lithium	B-drug
may	O
be	O
decreased	O
.	O

Acetazolamide	B-drug
and	O
sodium	B-drug
bicarbonate	I-drug
used	O
concurrently	O
increases	O
the	O
risk	O
of	O
renal	O
calculus	O
formation	O
.	O

Acetazolamide	B-drug
may	O
elevate	O
cyclosporine	B-drug
levels	O
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B-drug
dinitrate	I-drug
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B-drug
.	O

Alcohol	B-drug
,	O
in	O
particular	O
,	O
has	O
been	O
found	O
to	O
exhibit	O
additive	O
effects	O
of	O
this	O
variety	O
.	O

Drug	O
interaction	O
studies	O
with	O
decitabine	B-drug
have	O
not	O
been	O
conducted	O
.	O

In	O
vitro	O
studies	O
in	O
human	O
liver	O
microsomes	O
suggest	O
that	O
decitabine	B-drug
is	O
unlikely	O
to	O
inhibit	O
or	O
induce	O
cytochrome	B-drug
P450	I-drug
enzymes	O
.	O

In	O
vitro	O
metabolism	O
studies	O
have	O
suggested	O
that	O
decitabine	B-drug
is	O
not	O
a	O
substrate	O
for	O
the	O
human	O
liver	O
cytochrome	B-drug
P450	I-drug
enzymes	O
.	O

As	O
plasma	B-drug
protein	I-drug
binding	O
of	O
decitabine	B-drug
is	O
negligible	O
(	O
1	O
%	O
)	O
,	O
interactions	O
due	O
to	O
displacement	O
of	O
more	O
highly	O
protein	O
bound	O
drugs	O
from	O
plasma	B-drug
proteins	I-drug
are	O
not	O
expected	O
.	O

Drug	O
Interaction	O
During	O
Pregnancy	O
:	O
Cromolyn	B-drug
sodium	I-drug
and	O
isoproterenol	B-drug
were	O
studied	O
following	O
subcutaneous	O
injections	O
in	O
pregnant	O
mice	O
.	O

Cromolyn	B-drug
sodium	I-drug
alone	O
in	O
doses	O
up	O
to	O
540	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
did	O
not	O
cause	O
significant	O
increases	O
in	O
resorptions	O
or	O
major	O
malformations	O
.	O

Isoproterenol	B-drug
alone	O
at	O
a	O
dose	O
of	O
2.7	O
mg	O
/	O
kg	O
/	O
day	O
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
increased	O
both	O
resorptions	O
and	O
malformations	O
.	O

The	O
addition	O
of	O
540	O
mg	O
/	O
kg	O
/	O
day	O
of	O
cromolyn	B-drug
sodium	I-drug
(	O
approximately	O
340	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
to	O
2.7	O
mg	O
/	O
kg	O
/	O
day	O
of	O
isoproterenol	B-drug
(	O
approximately	O
7	O
times	O
the	O
maximum	O
recommended	O
daily	O
inhalation	O
dose	O
in	O
adults	O
on	O
a	O
mg	O
/	O
m2	O
basis	O
)	O
appears	O
to	O
have	O
increased	O
the	O
incidence	O
of	O
both	O
resorptions	O
and	O
malformations	O
.	O

Iodine	B-drug
or	O
iodine	B-drug
excess	O
may	O
decrease	O
the	O
effect	O
of	O
Carbimazole	B-drug
,	O
and	O
an	O
iodine	O
deficiency	O
can	O
increase	O
the	O
effect	O
of	O
Carbimazole	B-drug
.	O

Serum	O
concentration	O
of	O
digoxin	B-drug
and	O
digitoxin	B-drug
may	O
increase	O
when	O
patients	O
take	O
antithyroid	B-drug
agents	I-drug
.	O

A	O
decrease	O
of	O
the	O
dosage	O
may	O
be	O
necessary	O
when	O
patient	O
becomes	O
euthyroid	O
.	O

Antithyroid	B-drug
agents	I-drug
may	O
decrease	O
thyroidal	O
uptake	O
of	O
sodium	B-drug
iodide	I-drug
I131	I-drug
,	O
a	O
rebound	O
in	O
uptake	O
may	O
occur	O
up	O
to	O
5	O
days	O
after	O
sudden	O
withdrawal	O
of	O
Carbimazole	B-drug
.	O

Patients	O
response	O
to	O
oral	B-drug
anticoagulants	I-drug
may	O
be	O
affected	O
by	O
his	O
/	O
her	O
thyroid	B-drug
and	O
metabolic	O
status	O
.	O

An	O
evaluation	O
of	O
prothrombin	O
time	O
and	O
an	O
adjustment	O
of	O
anticoagulant	B-drug
dosage	O
are	O
recommended	O

No	O
specific	O
information	O
available	O

.	O

?	O

DOSTINEX	B-drug
should	O
not	O
be	O
administered	O
concurrently	O
with	O
D2-antagonists	O
,	O
such	O
as	O
phenothiazines	B-drug
,	O
butyrophenones	B-drug
,	O
thioxanthines	O
,	O
or	O
metoclopramide	B-drug
.	O

Alcohol	B-drug
(	O
increases	O
bioavailability	O
by	O
50	O
%	O
)	O
,	O
cimetidine	B-drug
,	O
and	O
valproates	O
.	O

No	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
.	O

Interactions	O
for	O
vitamin	O
D	O
analogues	O
(	O
Vitamin	B-drug
D2	I-drug
,	O
Vitamin	B-drug
D3	I-drug
,	O
Calcitriol	B-drug
,	O
and	O
Calcidiol	B-drug
)	O
:	O
Cholestyramine	B-drug
:	O
Cholestyramine	B-drug
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	O
soluble	O
vitamins	O
;	O

as	O
such	O
it	O
may	O
impair	O
intestinal	O
absorption	O
of	O
any	O
of	O
vitamin	B-drug
D.	O

Phenytoin	B-drug
/	O
Phenobarbital	B-drug
:	O
The	O
coadministration	O
of	O
phenytoin	B-drug
or	O
phenobarbital	B-drug
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B-drug
D	I-drug
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B-drug
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	B-drug
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B-drug
may	O
be	O
necessary	O
if	O
these	O
drugs	B-drug
are	O
administered	O
simultaneously	O
.	O

Thiazides	B-drug
:	O
Thiazides	B-drug
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	B-drug
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B-drug
with	O
vitamin	B-drug
D	I-drug
causes	O
hypercalcemia	O
.	O

Therefore	O
,	O
precaution	O
should	O
be	O
taken	O
when	O
coadministration	O
is	O
necessary	O
.	O

Digitalis	B-drug
:	O
Vitamin	B-drug
D	I-drug
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B-drug
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B-drug
:	O
Ketoconazole	B-drug
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B-drug
D.	O

Reductions	O
in	O
serum	O
endogenous	O
vitamin	O
D	O
concentrations	O
have	O
been	O
observed	O
following	O
the	O
administration	O
of	O
300	O
mg	O
/	O
day	O
to	O
1200	O
mg	O
/	O
day	O
ketoconazole	B-drug
for	O
a	O
week	O
to	O
healthy	O
men	O
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B-drug
with	O
vitamin	B-drug
D	I-drug
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	B-drug
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	O
D	O
analogues	O
,	O
which	O
promote	O
calcium	B-drug
absorption	O
,	O
and	O
corticosteroids	B-drug
,	O
which	O
inhibit	O
calcium	B-drug
absorption	O
.	O

Phosphate	B-drug
-	I-drug
Binding	I-drug
Agents	I-drug
:	O
Since	O
vitamin	B-drug
D	I-drug
also	O
has	O
an	O
effect	O
on	O
phosphate	O
transport	O
in	O
the	O
intestine	O
,	O
kidneys	O
and	O
bones	O
,	O
the	O
dosage	O
of	O
phosphate	B-drug
-	I-drug
binding	I-drug
agents	I-drug
must	O
be	O
adjusted	O
in	O
accordance	O
with	O
the	O
serum	O
phosphate	O
concentration	O
.	O

Vitamin	B-drug
D	I-drug
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	O
D	O
analogues	O
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B-drug
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B-drug
-	I-drug
containing	I-drug
preparations	I-drug
should	O
be	O
avoided	O
.	O

Magnesium	B-drug
:	O
Magnesium	B-drug
-	I-drug
containing	I-drug
preparations	I-drug
(	O
eg	O
,	O
antacids	B-drug
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B-drug
D	I-drug
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

The	O
administration	O
of	O
local	B-drug
anesthetic	I-drug
solutions	O
containing	O
epinephrine	B-drug
or	O
norepinephrine	B-drug
to	O
patients	O
receiving	O
monoamine	B-drug
oxidase	I-drug
inhibitors	I-drug
or	O
tricyclic	B-drug
antidepressants	I-drug
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Concurrent	O
use	O
of	O
these	O
agents	O
should	O
generally	O
be	O
avoided	O
.	O

In	O
situations	O
in	O
which	O
concurrent	O
therapy	O
is	O
necessary	O
,	O
careful	O
patient	O
monitoring	O
is	O
essential	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B-drug
drugs	I-drug
and	O
of	O
ergot	O
-	O
type	O
oxytocic	B-drug
drugs	I-drug
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Phenothiazines	B-drug
and	O
butyrophenones	B-drug
may	O
reduce	O
or	O
reverse	O
the	O
pressor	B-drug
effect	I-drug
of	O
epinephrine	B-drug
.	O

No	O
clinically	O
relevant	O
drug	O
-	O
drug	O
interactions	O
have	O
been	O
observed	O
with	O
drugs	B-drug
likely	O
to	O
be	O
co	O
-	O
administered	O
with	O
anidulafungin	B-drug
.	O

Calcium	B-drug
Supplements	O
/	O
Antacids	B-drug

Products	O
containing	O
calcium	B-drug
and	O
other	O
multivalent	O
cations	B-drug
(	O
such	O
as	O
aluminum	O
,	O
magnesium	B-drug
,	O
iron	B-drug
)	O
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
Ibandronate	B-drug
.	O

Ibandronate	B-drug
should	O
be	O
taken	O
at	O
least	O
60	O
minutes	O
before	O
any	O
oral	O
medications	O
containing	O
multivalent	O
cations	B-drug
(	O
including	O
antacids	B-drug
,	O
supplements	O
or	O
vitamins	B-drug
)	O
.	O

H2	B-drug
Blockers	I-drug
and	O
Proton	B-drug
Pump	I-drug
Inhibitors	I-drug
(	O
PPIs	O
)	O

Of	O
over	O
3500	O
patients	O
enrolled	O
in	O
the	O
Ibandronate	B-drug
osteoporosis	O
Treatment	O
and	O
Prevention	O
Studies	O
,	O
15	O
%	O
used	O
anti	B-drug
-	I-drug
peptic	I-drug
agents	I-drug
(	O
primarily	O
H2	B-drug
blockers	I-drug
and	O
PPIs	O
)	O
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B-drug
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
.	O

Similarly	O
,	O
of	O
over	O
1600	O
patients	O
enrolled	O
in	O
a	O
study	O
comparing	O
once	O
-	O
monthly	O
with	O
daily	O
dosing	O
regimens	O
of	O
ibandronate	B-drug
,	O
14	O
%	O
of	O
patients	O
used	O
anti	B-drug
-	I-drug
peptic	I-drug
agents	I-drug
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B-drug
150	I-drug
mg	I-drug
once	O
monthly	O
was	O
similar	O
to	O
that	O
in	O
patients	O
treated	O
with	O
Ibandronate	B-drug
2.5	I-drug
mg	I-drug
once	O
daily	O
.	O

Aspirin	B-drug
/	O
Nonsteroidal	B-drug
Antiinflammatory	I-drug
Drugs	O
(	O
NSAIDs	B-drug
)	O

In	O
the	O
large	O
,	O
placebo	O
-	O
controlled	O
osteoporosis	O
Treatment	O
Study	O
,	O
aspirin	B-drug
and	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
were	O
taken	O
by	O
62	O
%	O
of	O
the	O
2946	O
patients	O
.	O

Among	O
aspirin	B-drug
or	O
NSAID	B-drug
users	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
ibandronate	B-drug
2.5	I-drug
mg	I-drug
daily	O
(	O
28.9	O
%	O
)	O
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
(	O
30.7	O
%	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
1-year	O
monthly	O
comparison	O
study	O
,	O
aspirin	B-drug
and	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
were	O
taken	O
by	O
39	O
%	O
of	O
the	O
1602	O
patients	O
.	O

The	O
incidence	O
of	O
upper	O
gastrointestinal	O
events	O
in	O
patients	O
concomitantly	O
taking	O
aspirin	B-drug
or	O
NSAIDs	B-drug
was	O
similar	O
in	O
patients	O
taking	O
ibandronate	B-drug
2.5	I-drug
mg	I-drug
daily	O
(	O
21.7	O
%	O
)	O
and	O
150	O
mg	O
once	O
monthly	O
(	O
22.0	O
%	O
)	O
.	O

However	O
,	O
since	O
aspirin	B-drug
,	O
NSAIDs	B-drug
,	O
and	O
bisphosphonates	B-drug
are	O
all	O
associated	O
with	O
gastrointestinal	O
irritation	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
concomitant	O
use	O
of	O
aspirin	B-drug
or	O
NSAIDs	B-drug
with	O
Ibandronate	B-drug
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O

Bisphosphonates	B-drug
are	O
known	O
to	O
interfere	O
with	O
the	O
use	O
of	O
bone	O
-	O
imaging	O
agents	O
.	O

Specific	O
studies	O
with	O
ibandronate	B-drug
have	O
not	O
been	O
performed	O
.	O

Benzthiazide	B-drug
may	O
interact	O
with	O
alcohol	B-drug
,	O
blood	B-drug
thinners	O
,	O
decongestant	B-drug
drugs	I-drug
(	O
allergy	O
,	O
cold	O
,	O
and	O
sinus	O
medicines	B-drug
)	O
,	O
diabetic	O
drugs	B-drug
,	O
lithium	B-drug
,	O
norepinephrine	B-drug
,	O
NSAIDs	B-drug
like	O
Aleve	B-drug
or	O
Ibuprofen	B-drug
,	O
and	O
high	O
blood	O
pressure	O
medications	B-drug
.	O

Central	B-drug
nervous	I-drug
system	I-drug
depressant	I-drug
(	O
CNS	O
)	O
drugs	B-drug
including	O
alcohol	B-drug
,	O
antidepressants	B-drug
,	O
antihistamines	B-drug
,	O
antipsychotics	B-drug
,	O
blood	O
pressure	O
medications	B-drug
(	O
reserpine	B-drug
,	O
methyldopa	B-drug
,	O
beta	B-drug
-	I-drug
blockers	I-drug
)	I-drug
,	O
motion	O
sickness	O
medications	B-drug
,	O
muscle	B-drug
relaxants	I-drug
,	O
narcotics	B-drug
,	O
sedatives	B-drug
,	O
sleeping	O
pills	O
and	O
tranquilizers	B-drug

Ketoconazole	B-drug
/	O
Itraconazole	B-drug
,	O
Macrolides	B-drug
,	O
Including	O
Erythromycin	B-drug

May	O
interact	O
with	O
wthionamide	O
(	O
Trecator	B-drug
-	I-drug
SC	I-drug
)	O
and	O
isoniazid	B-drug
(	O
Nydrazid	B-drug
)	O
.	O

Co	O
-	O
treatment	O
with	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	B-drug
increases	O
erlotinib	B-drug
AUC	O
by	O
2/3	O
.	O

Caution	O
should	O
be	O
used	O
when	O
administering	O
or	O
taking	O
TARCEVA	B-drug
with	O
ketoconazole	B-drug
and	O
other	O
strong	O
CYP3A4	B-drug
inhibitors	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
atazanavir	B-drug
,	O
clarithromycin	B-drug
,	O
indinavir	B-drug
,	O
itraconazole	B-drug
,	O
nefazodone	B-drug
,	O
nelfinavir	B-drug
,	O
ritonavir	B-drug
,	O
saquinavir	B-drug
,	O
telithromycin	B-drug
,	O
troleandomycin	B-drug
(	O
TAO	B-drug
)	I-drug
,	O
and	O
voriconazole	B-drug
.	O

Pre	O
-	O
treatment	O
with	O
the	O
CYP3A4	O
inducer	O
rifampicin	B-drug
decreased	O
erlotinib	B-drug
AUC	O
by	O
about	O
2/3	O
.	O

Alternate	O
treatments	O
lacking	O
CYP3A4	B-drug
inducing	O
activity	O
should	O
be	O
considered	O
.	O

If	O
an	O
alternative	O
treatment	O
is	O
unavailable	O
,	O
a	O
TARCEVA	B-drug
dose	O
greater	O
than	O
150	O
mg	O
should	O
be	O
considered	O
for	O
NSCLC	O
patients	O
,	O
and	O
greater	O
than	O
100	O
mg	O
considered	O
for	O
pancreatic	O
cancer	O
patients	O
.	O

If	O
the	O
TARCEVA	B-drug
dose	O
is	O
adjusted	O
upward	O
,	O
the	O
dose	O
will	O
need	O
to	O
be	O
reduced	O
upon	O
discontinuation	O
of	O
rifampicin	B-drug
or	O
other	O
inducers	O
.	O

Other	O
CYP3A4	B-drug
inducers	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
rifabutin	B-drug
,	O
rifapentine	B-drug
,	O
phenytoin	B-drug
,	O
carbamazepine	B-drug
,	O
phenobarbital	B-drug
and	O
St.	B-drug
Johns	I-drug
Wort	I-drug
.	O

Hepatotoxicity	O
Asymptomatic	O
increases	O
in	O
liver	O
transaminases	B-drug
have	O
been	O
observed	O
in	O
TARCEVA	B-drug
treated	O
patients	O
;	O

therefore	O
,	O
periodic	O
liver	O
function	O
testing	O
(	O
transaminases	B-drug
,	O
bilirubin	B-drug
,	O
and	O
alkaline	B-drug
phosphatase	I-drug
)	O
should	O
be	O
considered	O
.	O

Dose	O
reduction	O
or	O
interruption	O
of	O
TARCEVA	B-drug
should	O
be	O
considered	O
if	O
changes	O
in	O
liver	O
function	O
are	O
severe	O
.	O

Patients	O
with	O
Hepatic	O
Impairment	O
In	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
erlotinib	B-drug
is	O
cleared	O
primarily	O
by	O
the	O
liver	B-drug
.	O

Therefore	O
,	O
erlotinib	B-drug
exposure	O
may	O
be	O
increased	O
in	O
patients	O
with	O
hepatic	O
dysfunction	O
.	O

Elevated	O
International	O
Normalized	O
Ratio	O
and	O
Potential	O
Bleeding	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
infrequent	O
reports	O
of	O
bleeding	O
events	O
including	O
gastrointestinal	O
and	O
non	O
-	O
gastrointestinal	O
bleedings	O
have	O
been	O
reported	O
in	O
clinical	O
studies	O
,	O
some	O
associated	O
with	O
concomitant	O
warfarin	B-drug
administration	O
.	O

Patients	O
taking	O
warfarin	B-drug
or	O
other	O
coumarin	B-drug
-	I-drug
derivative	I-drug
anticoagulants	I-drug
should	O
be	O
monitored	O
regularly	O
for	O
changes	O
in	O
prothrombin	O
time	O
or	O
INR	O

.	O

?	O
?	O

Although	O
BETAGAN	B-drug
used	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
pupil	O
size	O
,	O
mydriasis	O
resulting	O
from	O
concomitant	O
therapy	O
with	O
BETAGAN	B-drug
and	O
epinephrine	B-drug
may	O
occur	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	B-drug
-	I-drug
blocker	I-drug
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	B-drug
such	O
as	O
reserpine	B-drug
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and/or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
or	O
postural	O
hypotension	O
.	O

Patients	O
receiving	O
beta	B-drug
-	I-drug
adrenergic	I-drug
blocking	I-drug
agents	I-drug
along	O
with	O
either	O
oral	O
or	O
intravenous	O
calcium	B-drug
antagonists	O
should	O
be	O
monitored	O
for	O
possible	O
atrioventricular	O
conduction	O
disturbances	O
,	O
left	O
ventricular	O
failure	O
and	O
hypotension	O
.	O

In	O
patients	O
with	O
impaired	O
cardiac	O
function	O
,	O
simultaneous	O
use	O
should	O
be	O
avoided	O
altogether	O
.	O

The	O
concomitant	O
use	O
of	O
beta	B-drug
-	I-drug
adrenergic	I-drug
blocking	I-drug
agents	I-drug
with	O
digitalis	B-drug
and	O
calcium	B-drug
antagonists	O
may	O
have	O
additive	O
effects	O
on	O
prolonging	O
atrioventricular	O
conduction	O
time	O
.	O

Phenothiazine	B-drug
-	O
related	O
compounds	O
and	O
beta	B-drug
-	I-drug
adrenergic	I-drug
blocking	I-drug
agents	I-drug
may	O
have	O
additive	O
hypotensite	O
effects	O
due	O
to	O
the	O
inhibition	O
of	O
each	O
other?s	O
metabolism	O
.	O

Beta	B-drug
-	I-drug
adrenergic	I-drug
Blocking	I-drug
Agents	I-drug
:	O
Experience	O
in	O
over	O
1400	O
patients	O
in	O
a	O
non	O
-	O
comparative	O
clinical	O
trial	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
nifedipine	B-drug
and	O
beta	B-drug
-	I-drug
blocking	I-drug
agents	O
is	O
usually	O
well	O
tolerated	O
,	O
but	O
there	O
have	O
been	O
occasional	O
literature	O
reports	O
suggesting	O
that	O
the	O
combination	O
may	O
increase	O
the	O
likelihood	O
of	O
congestive	O
heart	O
failure	O
,	O
severe	O
hypotension	O
or	O
exacerbation	O
of	O
angina	O
.	O

Long	O
Acting	O
Nitrates	B-drug
:	O
Nifedipine	B-drug
may	O
be	O
safely	O
co	O
-	O
administered	O
with	O
nitrates	B-drug
,	O
but	O
there	O
have	O
been	O
no	O
controlled	O
studies	O
to	O
evaluate	O
the	O
antianginal	O
effectiveness	O
of	O
this	O
combination	O
.	O

Digitalis	B-drug
:	O
Immediate	O
Release	O
Capsules	O
:	O
Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	O
levels	O
,	O
and	O
there	O
is	O
a	O
possible	O
interaction	O
between	O
digoxin	B-drug
and	O
nifedipine	B-drug
,	O
it	O
is	O
recommended	O
that	O
digoxin	O
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	B-drug
to	O
avoid	O
possible	O
over-	O
or	O
under	O
-	O
digitalization	O
.	O

Extended	O
Release	O
Tablets	O
:	O
Administration	O
of	O
nifedipine	B-drug
with	O
digoxin	B-drug
increased	O
digoxin	O
levels	O
in	O
9	O
of	O
12	O
normal	O
volunteers	O
.	O

The	O
average	O
increase	O
was	O
45	O
%	O
.	O

Another	O
investigator	O
found	O
no	O
increase	O
in	O
digoxin	O
levels	O
in	O
13	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

In	O
an	O
uncontrolled	O
study	O
of	O
over	O
200	O
patients	O
with	O
congestive	O
heart	O
failure	O
during	O
which	O
digoxin	O
blood	O
levels	O
were	O
not	O
measured	O
,	O
digitalis	O
toxicity	O
was	O
not	O
observed	O
.	O

Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	O
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	O
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	B-drug
to	O
avoid	O
possible	O
over-	O
or	O
under	O
-	O
digitalization	O
.	O

Quinidine	B-drug
:	O
Immediate	O
Release	O
Capsules	O
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
an	O
interaction	O
between	O
quinidine	B-drug
and	O
nifedipine	B-drug
(	O
with	O
a	O
decreased	O
plasma	O
level	O
of	O
quinidine	B-drug
)	O
.	O

Coumarin	B-drug
Anticoagulants	O
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
increased	O
prothrombin	O
time	O
in	O
patients	O
taking	O
coumarin	B-drug
anticoagulants	O
to	O
whom	O
nifedipine	B-drug
was	O
administered	O
.	O

However	O
,	O
the	O
relationship	O
to	O
nifedipine	B-drug
therapy	O
is	O
uncertain	O
.	O

Cimetidine	B-drug
:	O
A	O
study	O
in	O
6	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
nifedipine	B-drug
plasma	O
levels	O
(	O
80	O
%	O
)	O
and	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
(	O
74	O
%	O
)	O
after	O
a	O
1	O
week	O
course	O
of	O
cimetidine	B-drug
at	O
1000	O
mg	O
per	O
day	O
and	O
nifedipine	B-drug
at	O
40	O
mg	O
per	O
day	O
.	O

Ranitidine	B-drug
produced	O
smaller	O
,	O
non	O
-	O
significant	O
increases	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
cimetidine	B-drug
on	O
hepatic	O
cytochrome	B-drug
P-450	I-drug
,	O
the	O
enzyme	O
system	O
probably	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
nifedipine	B-drug
.	O

If	O
nifedipine	B-drug
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B-drug
,	O
cautious	O
titration	O
is	O
advised	O
.	O

Zidovudine	B-drug
:	O
There	O
is	O
no	O
significant	O
pharmacokinetic	O
interaction	O
between	O
ZDV	B-drug
and	O
zalcitabine	B-drug
which	O
has	O
been	O
confirmed	O
clinically	O
.	O

Zalcitabine	B-drug
also	O
has	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
ZDV	B-drug
,	O
as	O
shown	O
in	O
vitro	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
in	O
two	O
other	O
cell	O
lines	O
(	O
U937	O
and	O
Molt-4	O
)	O
.	O

In	O
the	O
same	O
study	O
it	O
was	O
shown	O
that	O
didanosine	B-drug
and	O
stavudine	B-drug
had	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B-drug
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Lamivudine	B-drug
:	O
In	O
vitro	O
studies	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
U937	O
and	O
Molt-4	O
cells	O
revealed	O
that	O
lamivudine	B-drug
significantly	O
inhibited	O
zalcitabine	B-drug
phosphorylation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

Effects	O
were	O
already	O
seen	O
with	O
doses	O
corresponding	O
to	O
relevant	O
plasma	O
levels	O
in	O
humans	O
,	O
and	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B-drug
to	O
its	O
three	O
metabolites	B-drug
(	O
including	O
the	O
active	O
zalcitabine	B-drug
triphosphate	O
metabolite	O
)	O
was	O
significantly	O
inhibited	O
.	O

Zalcitabine	B-drug
inhibited	O
lamivudine	B-drug
phosphorylation	O
at	O
high	O
concentration	O
ratios	O
(	O
10	O
and	O
100	O
)	O
;	O

however	O
,	O
it	O
is	O
considered	O
to	O
be	O
unlikely	O
that	O
this	O
decrease	O
of	O
phosphorylated	O
lamivudine	B-drug
concentration	O
is	O
of	O
clinical	O
significance	O
,	O
as	O
lamivudine	B-drug
is	O
a	O
more	O
efficient	O
substrate	O
for	O
deoxycytidine	B-drug
kinase	I-drug
than	O
zalcitabine	B-drug
.	O

These	O
in	O
vitro	O
studies	O
suggest	O
that	O
concomitant	O
administration	O
of	O
zalcitabine	B-drug
and	O
lamivudine	B-drug
in	O
humans	O
may	O
result	O
in	O
sub	O
-	O
therapeutic	O
concentrations	O
of	O
active	O
phosphorylated	O
zalcitabine	B-drug
,	O
which	O
may	O
lead	O
to	O
a	O
decreased	O
antiretroviral	O
effect	O
of	O
zalcitabine	B-drug
.	O

It	O
is	O
unknown	O
how	O
the	O
effect	O
seen	O
in	O
these	O
in	O
vitro	O
studies	O
translates	O
into	O
clinical	O
consequences	O
.	O

Concomitant	O
use	O
of	O
zalcitabine	B-drug
and	O
lamivudine	B-drug
is	O
not	O
recommended	O
.	O

Saquinavir	B-drug
:	O
The	O
combination	O
of	O
HIVID	B-drug
,	O
saquinavir	B-drug
,	O
and	O
ZDV	B-drug
has	O
been	O
studied	O
(	O
as	O
triple	O
combination	O
)	O
in	O
adults	O
.	O

Pharmacokinetic	O
data	O
suggest	O
that	O
absorption	O
,	O
metabolism	O
,	O
and	O
elimination	O
of	O
each	O
of	O
these	O
drugs	B-drug
are	O
unchanged	O
when	O
they	O
are	O
used	O
together	O
.	O

Drugs	B-drug
Associated	O
With	O
Peripheral	O
Neuropathy	O
:	O
The	O
concomitant	O
use	O
of	O
HIVID	B-drug
with	O
drugs	B-drug
that	O
have	O
the	O
potential	O
to	O
cause	O
peripheral	O
neuropathy	O
should	O
be	O
avoided	O
where	O
possible	O
.	O

Drugs	B-drug
that	O
have	O
been	O
associated	O
with	O
peripheral	O
neuropathy	O
include	O
antiretroviral	B-drug
nucleoside	I-drug
analogues	I-drug
,	I-drug
chloramphenicol	B-drug
,	O
cisplatin	B-drug
,	O
dapsone	B-drug
,	O
disulfiram	B-drug
,	O
ethionamide	B-drug
,	O
glutethimide	B-drug
,	O
gold	B-drug
,	O
hydralazine	B-drug
,	O
iodoquinol	B-drug
,	O
isoniazid	B-drug
,	O
metronidazole	B-drug
,	O
nitrofurantoin	B-drug
,	O
phenytoin	B-drug
,	O
ribavirin	B-drug
,	O
and	O
vincristine	B-drug
.	O

Concomitant	O
use	O
of	O
HIVID	B-drug
with	O
didanosine	B-drug
is	O
not	O
recommended	O
.	O

Intravenous	O
Pentamidine	O
:	O
Treatment	O
with	O
HIVID	B-drug
should	O
be	O
interrupted	O
when	O
the	O
use	O
of	O
a	O
drug	B-drug
that	O
has	O
the	O
potential	O
to	O
cause	O
pancreatitis	O
is	O
required	O
.	O

Death	O
due	O
to	O
fulminant	O
pancreatitis	O
possibly	O
related	O
to	O
intravenous	O
pentamidine	O
and	O
HIVID	B-drug
has	O
been	O
reported	O
.	O

If	O
intravenous	O
pentamidine	O
is	O
required	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
,	O
treatment	O
with	O
HIVID	B-drug
should	O
be	O
interrupted	O
.	O

Amphotericin	B-drug
,	O
Foscarnet	B-drug
,	O
and	O
Aminoglycosides	B-drug
:	O
Drugs	B-drug
such	O
as	O
amphotericin	B-drug
,	O
foscarnet	B-drug
,	O
and	O
aminoglycosides	B-drug
may	O
increase	O
the	O
risk	O
of	O
developing	O
peripheral	O
neuropathy	O
or	O
other	O
HIVID	B-drug
-	O
associated	O
adverse	O
events	O
by	O
interfering	O
with	O
the	O
renal	O
clearance	O
of	O
zalcitabine	B-drug
(	O
thereby	O
raising	O
systemic	O
exposure	O
)	O
.	O

Patients	O
who	O
require	O
the	O
use	O
of	O
one	O
of	O
these	O
drugs	B-drug
with	O
HIVID	B-drug
should	O
have	O
frequent	O
clinical	O
and	O
laboratory	O
monitoring	O
with	O
dosage	O
adjustment	O
for	O
any	O
significant	O
change	O
in	O
renal	O
function	O
.	O

Probenecid	B-drug
or	O
Cimetidine	B-drug
:	O
Concomitant	O
administration	O
of	O
probenecid	B-drug
or	O
cimetidine	B-drug
decreases	O
the	O
elimination	O
of	O
zalcitabine	B-drug
,	O
most	O
likely	O
by	O
inhibition	O
of	O
renal	O
tubular	O
secretion	O
of	O
zalcitabine	B-drug
.	O

Patients	O
receiving	O
these	O
drugs	B-drug
in	O
combination	O
with	O
zalcitabine	B-drug
should	O
be	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
the	O
dose	O
of	O
zalcitabine	B-drug
reduced	O
if	O
warranted	O
.	O

Magnesium	B-drug
/	B-drug
Aluminum	I-drug
-	I-drug
containing	I-drug
Antacid	I-drug
Products	O
:	O
Absorption	O
of	O
zalcitabine	B-drug
is	O
moderately	O
reduced	O
(	O
approximately	O
25	O
%	O
)	O
when	O
coadministered	O
with	O
magnesium	B-drug
/	B-drug
aluminum	I-drug
-	I-drug
containing	I-drug
antacid	I-drug
products	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
reduction	O
is	O
not	O
known	O
,	O
hence	O
zalcitabine	B-drug
is	O
not	O
recommended	O
to	O
be	O
ingested	O
simultaneously	O
with	O
magnesium	B-drug
/	O
aluminum	B-drug
-	I-drug
containing	I-drug
antacids	I-drug
.	O

Metoclopramide	B-drug
:	O
Bioavailability	O
is	O
mildly	O
reduced	O
(	O
approximately	O
10	O
%	O
)	O
when	O
zalcitabine	B-drug
and	O
metoclopramide	B-drug
are	O
coadministered	O
.	O

Doxorubicin	B-drug
:	O
Doxorubicin	B-drug
caused	O
a	O
decrease	O
in	O
zalcitabine	B-drug
phosphorylation	O
(	O
50	O
%	O
inhibition	O
of	O
total	O
phosphate	O
formation	O
)	O
in	O
U937	O
/	O
Molt	O
4	O
cells	O
.	O

Although	O
there	O
may	O
be	O
decreased	O
zalcitabine	B-drug
activity	O
because	O
of	O
lessened	O
active	B-drug
metabolite	I-drug
formation	O
,	O
the	O
clinical	O
relevance	O
of	O
these	O
in	O
vitro	O
results	O
are	O
not	O
known	O
.	O

Clindamycin	B-drug
has	O
been	O
shown	O
to	O
have	O
neuromuscular	O
blocking	O
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B-drug
blocking	I-drug
agents	I-drug
.	O

Therefore	O
,	O
it	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
such	O
agents	O
.	O

Antagonism	O
has	O
been	O
demonstrated	O
between	O
clindamycin	B-drug
and	O
erythromycin	B-drug
in	O
vitro	O
.	O

Because	O
of	O
possible	O
clinical	O
significance	O
,	O
these	O
two	O
drugs	B-drug
should	O
not	O
be	O
administered	O
concurrently	O
.	O

When	O
atropine	B-drug
and	O
pralidoxime	B-drug
are	O
used	O
together	O
,	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
,	O
mydriasis	O
,	O
tachycardia	O
,	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
than	O
when	O
atropine	B-drug
is	O
used	O
alone	O
because	O
pralidoxime	B-drug
may	O
potentiate	O
the	O
effect	O
of	O
atropine	B-drug
.	O

The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
atropine	B-drug
and	O
pralidoxime	B-drug
.	O

Since	O
barbiturates	B-drug
are	O
potentiated	O
by	O
the	O
anticholinesterases	B-drug
,	O
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
.	O

Bentiromide	B-drug
may	O
interact	O
with	O
acetaminophen	B-drug
(	O
e.g.	O
,	O
Tylenol	B-drug
)	O
,	O
chloramphenicol	B-drug
(	O
e.g.	O
,	O
Chloromycetin	B-drug
)	O
,	O
local	B-drug
anesthetics	I-drug
(	O
e.g.	O
,	O
benzocaine	B-drug
and	O
lidocaine	B-drug
)	O
,	O
para	B-drug
-	I-drug
aminobenzoic	I-drug
acid	I-drug
(	O
PABA)-containing	O
preparations	O
(	O
e.g.	O
,	O
sunscreens	B-drug
and	O
some	O
multivitamins	B-drug
)	O
,	O
procainamide	B-drug
(	O
e.g.	O
,	O
Pronestyl	B-drug
)	O
,	O
sulfonamides	B-drug
(	O
sulfa	B-drug
medicines	O
)	O
,	O
thiazide	B-drug
diuretics	I-drug
(	O
use	O
of	O
these	O
medicines	B-drug
during	O
the	O
test	O
period	O
will	O
affect	O
the	O
test	O
results	O
)	O
,	O
and	O
pancreatic	O
supplements	O
(	O
use	O
of	O
pancreatic	B-drug
supplements	O
may	O
give	O
false	O
test	O
results	O
)	O
.	O

Aminosalicylic	B-drug
acid	I-drug
may	O
decrease	O
the	O
amount	O
of	O
digoxin	B-drug
(	O
Lanoxin	B-drug
,	I-drug
Lanoxicaps	B-drug
)	O
that	O
gets	B-drug
absorbed	O
into	O
your	O
body	O
.	O

In	O
the	O
case	O
that	O
you	O
are	O
taking	O
digoxin	B-drug
while	O
taking	O
aminosalicylic	B-drug
acid	I-drug
,	O
higher	O
doses	O
of	O
digoxin	B-drug
may	O
be	O
needed	O
.	O

Aminosalicylic	B-drug
acid	I-drug
may	O
also	O
decrease	O
the	O
absorption	O
of	O
vitamin	B-drug
B12	I-drug
,	O
which	O
can	O
lead	O
to	O
a	O
deficiency	O
.	O

Therefore	O
you	O
may	O
need	O
to	O
take	O
a	O
vitamin	O
B12	O
supplement	O
while	O
taking	O
aminosalicylic	B-drug
acid	I-drug
.	O

No	O
drug	O
-	O
drug	O
interaction	O
studies	O
in	O
human	O
subjects	O
have	O
been	O
conducted	O
.	O

Toxicologic	O
and	O
toxicokinetic	O
studies	O
in	O
rats	O
did	O
not	O
demonstrate	O
any	O
alterations	O
in	O
the	O
clearance	O
or	O
toxicologic	O
profile	O
of	O
either	O
methotrexate	B-drug
or	O
Kineret	O
?	O
when	O
the	O
two	O
agents	O
were	O
administered	O
together	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
Kineret	O
?	O
and	O
etanercept	B-drug
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
etanercept	B-drug
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
Kineret	O
?	O
and	O
etanercept	B-drug
developed	O
neutropenia	O
(	O
ANC	B-drug
 	I-drug
1	I-drug
x	I-drug
109	I-drug
/	I-drug
L	I-drug
)	I-drug
.	O

Oxcarbazepine	B-drug
can	O
inhibit	O
CYP2C19	B-drug
and	O
induce	O
CYP3A4/5	O
with	O
potentially	O
important	O
effects	O
on	O
plasma	O
concentrations	O
of	O
other	O
drugs	B-drug
.	O

In	O
addition	O
,	O
several	O
AED?s	O
that	O
are	O
cytochrome	B-drug
P450	I-drug
inducers	O
can	O
decrease	O
plasma	O
concentrations	O
of	O
oxcarbazepine	B-drug
and	O
MHD	O
.	O

Oxcarbazepine	B-drug
was	O
evaluated	O
in	O
human	O
liver	O
microsomes	O
to	O
determine	O
its	O
capacity	O
to	O
inhibit	O
the	O
major	O
cytochrome	B-drug
P450	I-drug
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
other	O
drugs	B-drug
.	O

Results	O
demonstrate	O
that	O
oxcarbazepine	B-drug
and	O
its	O
pharmacologically	O
active	B-drug
10-monohydroxy	I-drug
metabolite	I-drug
(	O
MHD	O
)	O
have	O
little	O
or	O
no	O
capacity	O
to	O
function	O
as	O
inhibitors	O
for	O
most	O
of	O
the	O
human	O
cytochrome	B-drug
P450	I-drug
enzymes	O
evaluated	O
(	O
CYP1A2	B-drug
,	O
CYP2A6	B-drug
,	O
CYP2C9	B-drug
,	O
CYP2D6	B-drug
,	O
CYP2E1	B-drug
,	O
CYP4A9	O
and	O
CYP4A11	B-drug
)	O
with	O
the	O
exception	O
of	O
CYP2C19	B-drug
and	O
CYP3A4/5	O
.	O

Although	O
inhibition	O
of	O
CYP	B-drug
3A4/5	O
by	O
OXC	O
and	O
MHD	O
did	O
occur	O
at	O
high	O
concentrations	O
,	O
it	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
inhibition	O
of	O
CYP-2C19	B-drug
by	O
OXC	O
and	O
MHD	O
,	O
however	O
,	O
is	O
clinically	O
relevant	O
.	O

In	O
vitro	O
,	O
the	O
UDP	B-drug
-	I-drug
glucuronyl	I-drug
transferase	I-drug
level	O
was	O
increased	O
,	O
indicating	O
induction	O
of	O
this	O
enzyme	O
.	O

Increases	O
of	O
22	O
%	O
with	O
MHD	O
and	O
47	O
%	O
with	O
oxcarbazepine	B-drug
were	O
observed	O
.	O

As	O
MHD	O
,	O
the	O
predominant	O
plasma	O
substrate	O
,	O
is	O
only	O
a	O
weak	O
inducer	O
of	O
UDP	B-drug
-	I-drug
glucuronyl	I-drug
transferase	I-drug
,	I-drug
it	O
is	O
unlikely	O
to	O
have	O
an	O
effect	O
on	O
drugs	B-drug
that	O
are	O
mainly	O
eliminated	O
by	O
conjugation	O
through	O
UDP	B-drug
-	I-drug
glucuronyl	I-drug
transferase	I-drug
(	O
e.g.	O
,	O
valproic	B-drug
acid	I-drug
,	O
lamotrigine	B-drug
)	O
.	O

In	O
addition	O
,	O
oxcarbazepine	B-drug
and	O
MHD	O
induce	O
a	O
subgroup	O
of	O
the	O
cytochrome	B-drug
P450	I-drug
3A	I-drug
family	O
(	O
CYP3A4	B-drug
and	O
CYP3A5	B-drug
)	O
responsible	O
for	O
the	O
metabolism	O
of	O
dihydropyridine	O
calcium	B-drug
antagonists	O
and	O
oral	B-drug
contraceptives	I-drug
,	O
resulting	O
in	O
a	O
lower	O
plasma	O
concentration	O
of	O
these	O
drugs	B-drug
.	O

As	O
binding	O
of	O
MHD	O
to	O
plasma	B-drug
proteins	I-drug
is	O
low	O
(	O
40	O
%	O
)	O
,	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	B-drug
through	O
competition	O
for	O
protein	B-drug
binding	O
sites	O
are	O
unlikely	O
.	O

Antiepileptic	B-drug
drugs	I-drug
Potential	O
interactions	O
between	O
Trileptal	B-drug
and	O
other	O
AEDs	O
were	O
assessed	O
in	O
clinical	O
studies	O
.	O

The	O
effect	O
of	O
these	O
interactions	O
on	O
mean	O
AUCs	O
and	O
Cmin	O
are	O
summarized	O
in	O
Table	O
2	O
:	O
Table	O
2	O
:	O
Summary	O
of	O
AED	O
interactions	O
with	O
Trileptal	B-drug

AED	O
Co	O
-	O
administered	O

Dose	O
of	O
AED	O
(	O
mg	O
/	O
day	O
)	O

Trileptal	B-drug
dose	O
(	O
mg	O
/	O
day	O
)	O

Influence	O
of	O
Trileptal	B-drug
on	O
AED	O
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O

Influence	O
of	O
AED	O
On	O
MHD	O
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O

Carbamazepine	B-drug

400	O
-	O
2000	O

900	O

nc1	O
40	O
%	O
decrease	O
[	O
CI	O
:	O
17	O
%	O
decrease	O
,	O
57	O
%	O
decrease	O
]	O

Phenobarbital	B-drug

100	O
-	O
150	O

600	O
-	O
1800	O

14	O
%	O
increase	O
[	O
CI	O
:	O
2	O
%	O
increase	O
,	O
24	O
%	O
increase	O
]	O
25	O
%	O
decrease	O
[	O
CI	O
:	O
12	O
%	O
decrease	O
,	O
51	O
%	O
decrease	O
]	O

Phenytoin	B-drug

250	O
-	O
500	O

600	O
-	O
1800	O

nc1,2	O
30	O
%	O
decrease	O
[	O
CI	O
:	O
3	O
%	O
decrease	O
,	O
48	O
%	O
decrease	O
]	O

1200	O
-	O
2400	O
up	O
to	O
40	O
%	O
increase3	O
[	O
CI	O
:	O
12	O
%	O
increase	O
,	O
60	O
%	O
increase	O
]	O

Valproic	B-drug
acid	I-drug

400	O
-	O
2800	O

600	O
-	O
1800	O

nc1	O
18	O
%	O
decrease	O
[	O
CI	O
:	O
13	O
%	O
decrease	O
,	O
40	O
%	O
decrease	O
]	O

1-	O
nc	O
denotes	O
a	O
mean	O
change	O
of	O
less	O
than	O
10	O
%	O
2-	O
Pediatrics	O
3-	O
Mean	O
increase	O
in	O
adults	O
at	O
high	O
Trileptal	B-drug
doses	O
In	O
vivo	O
,	O
the	O
plasma	O
levels	O
of	O
phenytoin	B-drug
increased	O
by	O
up	O
to	O
40	O
%	O
,	O
when	O
Trileptal	B-drug
was	O
given	O
at	O
doses	O
above	O
1200	O
mg	O
/	O
day	O
.	O

Therefore	O
,	O
when	O
using	O
doses	O
of	O
Trileptal	B-drug
greater	O
than	O
1200	O
mg	O
/	O
day	O
during	O
adjunctive	O
therapy	O
,	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
phenytoin	B-drug
may	O
be	O
required	O
.	O

The	O
increase	O
of	O
phenobarbital	O
level	O
,	O
however	O
,	O
is	O
small	O
(	O
15	O
%	O
)	O
when	O
given	O
with	O
Trileptal	B-drug
.	O

Strong	O
inducers	O
of	O
cytochrome	B-drug
P450	I-drug
enzymes	O
(	O
i.e.	O
carbamazepine	B-drug
,	O
phenytoin	B-drug
and	O
phenobarbital	B-drug
)	O
have	O
been	O
shown	O
to	O
decrease	O
the	O
plasma	O
levels	O
of	O
MHD	O
(	O
29	O
-	O
40	O
%	O
)	O
.	O

No	O
autoinduction	O
has	O
been	O
observed	O
with	O
Trileptal	B-drug
.	O

Hormonal	O
contraceptives	O
Co	O
-	O
administration	O
of	O
Trileptal	B-drug
with	O
an	O
oral	B-drug
contraceptive	I-drug
has	O
been	O
shown	O
to	O
influence	O
the	O
plasma	O
concentrations	O
of	O
the	O
two	O
hormonal	O
components	O
,	O
ethinylestradiol	B-drug
(	O
EE	O
)	O
and	O
levonorgestrel	B-drug
(	O
LNG	O
)	O
.	O

The	O
mean	O
AUC	O
values	O
of	O
EE	O
were	O
decreased	O
by	O
48	O
%	O
[	O
90	O
%	O
CI	O
:	O
22	O
-	O
65	O
]	O
in	O
one	O
study	O
and	O
52	O
%	O
[	O
90	O
%	O
CI	O
:	O
38	O
-	O
52	O
]	O
in	O
another	O
study	O
[	O
1,2	O
]	O
.	O

The	O
mean	O
AUC	O
values	O
of	O
LNG	O
were	O
decreased	O
by	O
32	O
%	O
[	O
90	O
%	O
CI	O
:	O
20	O
-	O
45	O
]	O
in	O
one	O
study	O
and	O
52	O
%	O
[	O
90	O
%	O
CI	O
:	O
42	O
-	O
52	O
]	O
in	O
another	O
study	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
Trileptal	B-drug
with	O
hormonal	O
contraceptives	B-drug
may	O
render	O
these	O
contraceptives	B-drug
less	O
effective	O
.	O

Studies	O
with	O
other	O
oral	O
or	O
implant	O
contraceptives	B-drug
have	O
not	O
been	O
conducted	O
.	O

Calcium	B-drug
Antagonists	O
After	O
repeated	O
co	O
-	O
administration	O
of	O
Trileptal	B-drug
,	O
the	O
AUC	O
of	O
felodipine	B-drug
was	O
lowered	O
by	O
28	O
%	O
[	O
90	O
%	O
CI	O
:	O
20	O
-	O
33	O
]	O
.	O

Verapamil	B-drug
produced	O
a	O
decrease	O
of	O
20	O
%	O
[	O
90	O
%	O
CI	O
:	O
18	O
-	O
27	O
]	O
of	O
the	O
plasma	O
levels	O
of	O
MHD	O
.	O

Other	O
drug	O
interactions	O
Cimetidine	B-drug
,	O
erythromycin	B-drug
and	O
dextropropoxyphene	B-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
MHD	O
.	O

Results	O
with	O
warfarin	B-drug
wshow	O
no	O
evidence	O
of	O
interaction	O
with	O
either	O
single	O
or	O
repeated	O
doses	O
of	O
Trileptal	B-drug
.	O

Inhibitors	O
of	O
CYP2D6	B-drug
;	O

poor	O
metabolizers	O
of	O
debrisoquin	B-drug
:	O
Interactions	O
of	O
carvedilol	B-drug
with	O
strong	O
inhibitors	O
of	O
CYP2D6	B-drug
(	O
such	O
as	O
quinidine	B-drug
,	O
fluoxetine	B-drug
,	O
paroxetine	B-drug
,	O
and	O
propafenone	B-drug
)	O
have	O
not	O
been	O
studied	O
,	O
but	O
these	O
drugs	B-drug
would	O
be	O
expected	O
to	O
increase	O
blood	O
levels	O
of	O
the	O
R(+	O
)	O
enantiomer	B-drug
of	O
carvedilol	B-drug
.	O

Retrospective	O
analysis	O
of	O
side	O
effects	O
in	O
clinical	O
trials	O
showed	O
that	O
poor	O
2D6	O
metabolizers	O
had	O
a	O
higher	O
rate	O
of	O
dizziness	O
during	O
up	O
-	O
titration	O
,	O
presumably	O
resulting	O
from	O
vasodilating	O
effects	O
of	O
the	O
higher	O
concentrations	O
of	O
the	O
a	O
-	O
blocking	O
R(+	O
)	O
enantiomer	B-drug
.	O

Catecholamine	O
-	O
depleting	O
Agents	O
:	O
Patients	O
taking	O
both	O
agents	O
with	O
b	O
-	O
blocking	O
properties	O
and	O
a	O
drug	B-drug
that	O
can	O
deplete	O
catecholamines	O
(	O
e.g.	O
,	O
reserpine	B-drug
and	O
monoamine	B-drug
oxidase	I-drug
inhibitors	I-drug
)	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
hypotension	O
and/or	O
severe	O
bradycardia	O
.	O

Clonidine	B-drug
:	O
Concomitant	O
administration	O
of	O
clonidine	B-drug
with	O
agents	O
with	O
b	O
-	O
blocking	O
properties	O
may	O
potentiate	O
blood	O
-	O
pressure-	O
and	O
heart	O
-	O
rate	O
-	O
lowering	O
effects	O
.	O

When	O
concomitant	O
treatment	O
with	O
agents	O
with	O
b	O
-	O
blocking	O
properties	O
and	O
clonidine	B-drug
is	O
to	O
be	O
terminated	O
,	O
the	O
b	O
-	O
blocking	O
agent	O
should	O
be	O
discontinued	O
first	O
.	O

Clonidine	B-drug
therapy	O
can	O
then	O
be	O
discontinued	O
several	O
days	O
later	O
by	O
gradually	O
decreasing	O
the	O
dosage	O
.	O

Cyclosporine	B-drug
:	O
Modest	O
increases	O
in	O
mean	O
trough	O
cyclosporine	B-drug
concentrations	O
were	O
observed	O
following	O
initiation	O
of	O
carvedilol	B-drug
treatment	O
in	O
21	O
renal	O
transplant	O
patients	O
suffering	O
from	O
chronic	O
vascular	O
rejection	O
.	O

In	O
about	O
30	O
%	O
of	O
patients	O
,	O
the	O
dose	O
of	O
cyclosporine	B-drug
had	O
to	O
be	O
reduced	O
in	O
order	O
to	O
maintain	O
cyclosporine	B-drug
concentrations	O
within	O
the	O
therapeutic	O
range	O
,	O
while	O
in	O
the	O
remainder	O
no	O
adjustment	O
was	O
needed	O
.	O

On	O
the	O
average	O
for	O
the	O
group	O
,	O
the	O
dose	O
of	O
cyclosporine	B-drug
was	O
reduced	O
about	O
20	O
%	O
in	O
these	O
patients	O
.	O

Due	O
to	O
wide	O
interindividual	O
variability	O
in	O
the	O
dose	O
adjustment	O
required	O
,	O
it	O
is	O
recommended	O
that	O
cyclosporine	B-drug
concentrations	O
be	O
monitored	O
closely	O
after	O
initiation	O
of	O
carvedilol	B-drug
therapy	O
and	O
that	O
the	O
dose	O
of	O
cyclosporine	B-drug
be	O
adjusted	O
as	O
appropriate	O
.	O

Digoxin	B-drug
:	O
Digoxin	B-drug
concentrations	O
are	O
increased	O
by	O
about	O
15	O
%	O
when	O
digoxin	B-drug
and	O
carvedilol	B-drug
are	O
administered	O
concomitantly	O
.	O

Both	O
digoxin	B-drug
and	O
COREG	B-drug
slow	O
AV	O
conduction	O
.	O

Therefore	O
,	O
increased	O
monitoring	O
of	O
digoxin	B-drug
is	O
recommended	O
when	O
initiating	O
,	O
adjusting	O
,	O
or	O
discontinuing	O
COREG	B-drug
.	O

Inducers	O
and	O
Inhibitors	O
of	O
Hepatic	O
Metabolism	O
:	O
Rifampin	B-drug
reduced	O
plasma	O
concentrations	O
of	O
carvedilol	B-drug
by	O
about	O
70	O
%	O
.	O

Cimetidine	B-drug
increased	O
AUC	O
by	O
about	O
30	O
%	O
but	O
caused	O
no	O
change	O
in	O
Cmax	O
.	O

Calcium	B-drug
Channel	I-drug
Blockers	I-drug
:	O
Isolated	O
cases	O
of	O
conduction	O
disturbance	O
(	O
rarely	O
with	O
hemodynamic	O
compromise	O
)	O
have	O
been	O
observed	O
when	O
COREG	B-drug
is	O
co	O
-	O
administered	O
with	O
diltiazem	B-drug
.	O

As	O
with	O
other	O
agents	O
with	O
b	O
-	O
blocking	O
properties	O
,	O
if	O
COREG	B-drug
is	O
to	O
be	O
administered	O
orally	O
with	O
calcium	B-drug
channel	I-drug
blockers	I-drug
of	O
the	O
verapamil	B-drug
or	O
diltiazem	B-drug
type	O
,	O
it	O
is	O
recommended	O
that	O
ECG	O
and	O
blood	O
pressure	O
be	O
monitored	O
.	O

Insulin	B-drug
or	O
Oral	B-drug
Hypoglycemics	I-drug
:	O
Agents	O
with	O
b	O
-	O
blocking	O
properties	O
may	O
enhance	O
the	O
blood	O
-	O
sugar	O
-	O
reducing	O
effect	O
of	O
insulin	B-drug
and	O
oral	B-drug
hypoglycemics	I-drug
.	O

Therefore	O
,	O
in	O
patients	O
taking	O
insulin	B-drug
or	O
oral	B-drug
hypoglycemics	I-drug
,	O
regular	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
.	O

Oral	B-drug
Contraceptives	I-drug
Multiple	O
doses	O
of	O
cefditoren	B-drug
pivoxil	I-drug
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B-drug
estradiol	I-drug
,	O
the	O
estrogenic	B-drug
component	O
in	O
most	O
oral	B-drug
contraceptives	I-drug
.	O

Antacids	B-drug
Co	O
-	O
administration	O
of	O
a	O
single	O
dose	O
of	O
an	O
antacid	B-drug
which	O
contained	O
both	O
magnesium	B-drug
(	O
800	O
mg	O
)	O
and	O
aluminum	O
(	O
900	O
mg	O
)	O
hydroxides	O
reduced	O
the	O
oral	O
absorption	O
of	O
a	O
single	O
400	O
mg	O
dose	O
of	O
cefditoren	B-drug
pivoxil	I-drug
administered	O
following	O
a	O
meal	O
,	O
as	O
evidenced	O
by	O
a	O
14	O
%	O
decrease	O
in	O
mean	O
Cmax	O
and	O
an	O
11	O
%	O
decrease	O
in	O
mean	O
AUC	O
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-drug
pivoxil	I-drug
be	O
taken	O
concomitantly	O
with	O
antacids	B-drug
.	O

H2-Receptor	B-drug
Antagonists	I-drug
Co	O
-	O
administration	O
of	O
a	O
single	O
dose	O
of	O
intravenously	O
administered	O
famotidine	B-drug
(	O
20	O
mg	O
)	O
reduced	O
the	O
oral	O
absorption	O
of	O
a	O
single	O
400	O
mg	O
dose	O
of	O
cefditoren	B-drug
pivoxil	I-drug
administered	O
following	O
a	O
meal	O
,	O
as	O
evidenced	O
by	O
a	O
27	O
%	O
decrease	O
in	O
mean	O
Cmax	O
and	O
a	O
22	O
%	O
decrease	O
in	O
mean	O
AUC	O
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B-drug
pivoxil	I-drug
be	O
taken	O
concomitantly	O
with	O
H2	B-drug
receptor	I-drug
antagonists	O
.	O

Probenecid	B-drug
As	O
with	O
other	O
b	B-drug
-	I-drug
lactam	I-drug
antibiotics	I-drug
,	O
co	O
-	O
administration	O
of	O
probenecid	B-drug
with	O
cefditoren	B-drug
pivoxil	I-drug
resulted	O
in	O
an	O
increase	O
in	O
the	O
plasma	O
exposure	O
of	O
cefditoren	B-drug
,	O
with	O
a	O
49	O
%	O
increase	O
in	O
mean	O
Cmax	O
,	O
a	O
122	O
%	O
increase	O
in	O
mean	O
AUC	O
,	O
and	O
a	O
53	O
%	O
increase	O
in	O
half	O
-	O
life	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
Cephalosporins	B-drug
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

A	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	B-drug
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	O
reduction	O
tests	O
(	O
Benedicts	O
or	O
Fehlings	O
solution	O
or	O
with	O
CLINITEST	O
tablets	O
)	O
,	O
but	O
not	O
with	O
enzyme	O
-	O
based	O
tests	O
for	O
glycosuria	O
(	O
e.g.	O
,	O
CLINISTIX	O
,	O
TES	O
-	O
TAPE	O
)	O
.	O

As	O
a	O
false	O
-	O
negative	O
result	O
may	O
occur	O
in	O
the	O
ferricyanide	O
test	O
,	O
it	O
is	O
recommended	O
that	O
either	O
the	O
glucose	B-drug
oxidase	I-drug
or	O
hexokinase	B-drug
method	O
be	O
used	O
to	O
determine	O
blood	O
/	O
plasma	O
glucose	O
levels	O
in	O
patients	O
receiving	O
cefditoren	B-drug
pivoxil	I-drug
.	O

The	O
renal	O
effects	O
of	O
nephrotoxic	O
compounds	O
may	O
be	O
potentiated	O
by	O
Carboplatin	B-drug
.	O

There	O
have	O
been	O
no	O
formal	O
clinical	O
studies	O
to	O
evaluate	O
the	O
drug	O
interactions	O
of	O
TAXOTERE	B-drug
with	O
other	B-drug
medications	I-drug
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
metabolism	O
of	O
docetaxel	B-drug
may	O
be	O
modified	O
by	O
the	O
concomitant	O
administration	O
of	O
compounds	O
that	O
induce	O
,	O
inhibit	O
,	O
or	O
are	O
metabolized	O
by	O
cytochrome	B-drug
P450	I-drug
3A4	I-drug
,	O
such	O
as	O
cyclosporine	B-drug
,	O
terfenadine	B-drug
,	O
ketoconazole	B-drug
,	O
erythromycin	B-drug
,	O
and	O
troleandomycin	B-drug
.	O

Caution	O
should	O
be	O
exercised	O
with	O
these	O
drugs	B-drug
when	O
treating	O
patients	O
receiving	O
TAXOTERE	B-drug
as	O
there	O
is	O
a	O
potential	O
for	O
a	O
significant	O
interaction	O
.	O

Folic	B-drug
acid	I-drug
in	O
large	O
amounts	O
may	O
counteract	O
the	O
antiepileptic	B-drug
effect	O
of	O
phenobarbital	B-drug
,	O
phenytoin	B-drug
and	O
primidone	B-drug
,	O
and	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
susceptible	O
pediatric	B-drug
patients	O
.	O

Preliminary	O
animal	O
and	O
human	O
studies	O
have	O
shown	O
that	O
small	O
quantities	O
of	O
systemically	O
administered	O
leucovorin	B-drug
enter	O
the	O
CSF	O
primarily	O
as	O
5-methyltetrahydro	O
-	O
folate	O
and	O
,	O
in	O
humans	O
,	O
remain	O
1	O
to	O
3	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
usual	O
methotrexate	B-drug
concentrations	O
following	O
intrathecal	O
administration	O
.	O

However	O
,	O
high	O
doses	O
of	O
leucovorin	B-drug
may	O
reduce	O
the	O
efficacy	O
of	O
intrathecally	O
administered	O
methotrexate	B-drug
.	O

Leucovorin	B-drug
may	O
enhance	O
the	O
toxicity	O
of	O
5-fluorouracil	O
.	O

1	O
.	O

Drugs	B-drug
Metabolized	O
by	O
P450	B-drug
2D6	I-drug
:	I-drug
The	O
biochemical	O
activity	O
of	O
the	O
drug	B-drug
metabolizing	O
isozyme	O
cytochrome	O
P450	O
2D6	O
(	O
debrisoquin	B-drug
hydroxylase	I-drug
)	I-drug
is	O
reduced	O
in	O
a	O
subset	O
of	O
the	O
caucasian	O
population	O
(	O
about	O
7	O
to	O
10	O
%	O
of	O
caucasians	O
are	O
so	O
called	O
poor	O
metabolizers	O
)	O
;	O

reliable	O
estimates	O
of	O
the	O
prevalence	O
of	O
reduced	O
P450	B-drug
2D6	I-drug
isozyme	I-drug
activity	O
among	O
Asian	O
,	O
African	O
and	O
other	O
populations	O
are	O
not	O
yet	O
available	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B-drug
antidepressants	I-drug
(	O
TCAs	O
)	O
when	O
given	O
usual	O
doses	O
.	O

Depending	O
on	O
the	O
traction	O
of	O
drug	B-drug
metabolized	O
by	O
P450	B-drug
2D6	I-drug
,	I-drug
the	O
increase	O
in	O
plasma	O
concentration	O
may	O
be	O
small	O
,	O
or	O
quite	O
large	O
(	O
8	O
fold	O
increase	O
in	O
plasma	O
AUC	O
of	O
the	O
TCA	O
)	O
.	O

In	O
addition	O
,	O
certain	O
drugs	B-drug
inhibit	O
the	O
activity	O
of	O
this	O
isozyme	B-drug
and	O
make	O
normal	O
metabolizers	O
resemble	O
p.o	O
.	O

metabolizers	O
.	O

An	O
individual	O
who	O
is	O
stable	O
on	O
a	O
given	O
dose	O
of	O
TCA	O
may	O
become	O
abruptly	O
toxic	O
when	O
given	O
one	O
of	O
these	O
inhibiting	O
drugs	B-drug
as	O
concomitant	O
therapy	O
.	O

The	O
drugs	B-drug
that	O
inhibit	O
cytochrome	B-drug
P450	I-drug
2D6	I-drug
include	O
some	O
that	O
are	O
not	O
metabolized	O
by	O
the	O
enzyme	O
(	O
quinidine	B-drug
;	O

cimetidine	B-drug
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	B-drug
2D6	I-drug
(	O
many	O
other	O
antidepressants	B-drug
,	O
phenothiazines	B-drug
,	O
and	O
the	O
Type	O
1C	O
antiarrhythrnics	O
propatenone	O
and	O
flecainide	B-drug
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	B-drug
reuptake	I-drug
inhibitors	I-drug
(	O
SSRIs	O
)	O
,	O
e.g.	O
,	O
fluoxetine	B-drug
,	O
seriraline	O
,	O
and	O
paroxetine	B-drug
,	O
inhibit	O
P450	B-drug
2D6	I-drug
,	I-drug
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	O
-	O
TCA	O
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	O
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
co	O
-	O
administration	O
of	O
T.A.	O
with	O
any	O
of	O
the	O
SSRIs	O
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Of	O
particular	O
importance	O
,	O
sufficient	O
time	O
must	O
elapse	O
before	O
initiating	O
TCA	O
treatment	O
in	O
a	O
patient	O
being	O
withdrawn	O
from	O
fluoxetine	B-drug
,	O
given	O
the	O
long	O
half	O
-	O
life	O
of	O
the	O
parent	O
and	O
active	B-drug
metabolite	I-drug
(	O
at	O
least	O
5	O
weeks	O
may	O
be	O
necessary	O
)	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B-drug
antidepressants	I-drug
with	O
drugs	B-drug
that	O
can	O
inhibit	O
cytochrome	B-drug
P450	I-drug
2D6	I-drug
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B-drug
antidepressant	I-drug
or	O
the	O
other	O
drug	B-drug
.	O

Furthermore	O
,	O
whenever	O
one	O
of	O
these	O
other	O
drugs	B-drug
is	O
withdrawn	O
from	O
co	O
-	O
therapy	O
,	O
an	O
increased	O
dose	O
of	O
tricyclic	B-drug
antidepressant	I-drug
may	O
be	O
required	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	O
plasma	O
levels	O
whenever	O
a	O
TCA	O
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	B-drug
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	B-drug
2D6	I-drug
.	I-drug

2	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosage	O
are	O
required	O
when	O
this	O
drug	B-drug
is	O
given	O
concomitantly	O
with	O
anticholinergic	B-drug
or	O
sympathomimetic	B-drug
drugs	I-drug
.	O

3	O
.	O

Clinical	O
experience	O
in	O
the	O
concurrent	O
administration	O
of	O
ECT	O
and	O
antidepressant	B-drug
drugs	I-drug
is	O
limited	O
.	O

Thus	O
,	O
if	O
such	O
treatment	O
is	O
essential	O
,	O
the	O
possibility	O
of	O
increased	O
risk	O
relative	O
to	O
benefits	O
should	O
be	O
considered	O
.	O

4	O
.	O

If	O
desipramine	B-drug
hydrochloride	I-drug
is	O
to	O
be	O
combined	O
with	O
other	O
psychotropic	B-drug
agents	I-drug
such	O
as	O
tranquilizers	B-drug
or	O
sedative	B-drug
/	O
hypnotics	B-drug
,	O
careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
pharmacology	O
of	O
the	O
agents	O
employed	O
since	O
the	O
sedative	B-drug
effects	O
of	O
desipramine	B-drug
and	O
benzodiazepines	B-drug
(	O
e.g.	O
,	O
chlordiazepoxide	B-drug
or	O
diazepam	B-drug
)	O
are	O
additive	O
.	O

Both	O
the	O
sedative	B-drug
and	O
anticholinergic	B-drug
effects	O
of	O
the	O
major	B-drug
tranquilizers	I-drug
are	O
also	O
additive	O
to	O
those	O
of	O
desipramine	B-drug
.	O

5	O
.	O

Concurrent	O
administration	O
of	O
cimetidine	B-drug
and	O
tricyclic	B-drug
antidepressants	I-drug
can	O
produce	O
clinically	O
significant	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
the	O
tricyclic	B-drug
antidepressants	I-drug
.	O

Conversely	O
,	O
decreases	O
in	O
plasma	O
levels	O
of	O
the	O
tricyclic	B-drug
antidepressants	I-drug
have	O
been	O
reported	O
upon	O
discontinuation	O
of	O
cimetidine	B-drug
which	O
may	O
result	O
in	O
the	O
loss	O
of	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
tricyclic	B-drug
antidepressant	I-drug
6	O
.	O

There	O
have	O
been	O
greater	O
than	O
two	O
-	O
fold	O
increases	O
of	O
previously	O
stable	O
plasma	O
levels	O
of	O
tricyclic	B-drug
antidepressants	I-drug
when	O
fluoxetine	B-drug
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

Interactions	O
may	O
occur	O
with	O
the	O
following	O
:	O
adrenocorticoids	O
(	O
cortisone	B-drug
-	O
like	O
medicine	B-drug
)	O
,	O
anticoagulants	B-drug
(	O
blood	B-drug
thinners	O
)	O
,	O
carbamazepine	B-drug
,	O
corticotropin	B-drug
(	O
barbiturates	B-drug
may	O
decrease	O
the	O
effects	O
of	O
these	O
medicines	B-drug
)	O
,	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depressants	O
(	O
using	O
these	O
medicines	B-drug
with	O
barbiturates	B-drug
may	O
result	O
in	O
increased	O
CNS	B-drug
depressant	I-drug
effects	O
)	O
,	O
divalproex	B-drug
sodium	I-drug
,	O
valproic	B-drug
acid	I-drug
(	O
using	O
these	O
medicines	B-drug
with	O
barbiturates	B-drug
may	O
change	O
the	O
amount	O
of	O
either	O
medicine	B-drug
that	O
you	O
need	O
to	O
take	O
)	O
,	O
and	O
oral	B-drug
contraceptives	I-drug
containing	O
estrogens	B-drug
(	O
barbiturates	B-drug
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
oral	B-drug
contraceptives	I-drug
,	O
and	O
you	O
may	O
need	O
to	O
change	O
to	O
a	O
different	O
type	O
of	O
birth	B-drug
control	I-drug
)	O
.	O

Drug	B-drug
/	O
Laboratory	O
Interactions	O
No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
performed	O
with	O
Campath	B-drug
.	O

An	O
immune	O
response	O
to	O
Campath	B-drug
may	O
interfere	O
with	O
subsequent	O
diagnostic	O
serum	O
tests	O
that	O
utilize	O
antibodies	B-drug

.	O

?	O
?	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B-drug
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	B-drug
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	B-drug
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
quinolones	B-drug
and	O
theophylline	B-drug
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B-drug
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	O
adjusted	O
,	O
as	O
required	O
.	O

Quinolones	B-drug
have	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B-drug
.	O

This	O
may	O
lead	O
to	O
reduced	O
clearance	O
of	O
caffeine	B-drug
and	O
the	O
prolongation	O
of	O
its	O
plasma	O
half	O
-	O
life	O
.	O

Quinolones	B-drug
,	O
including	O
nalidixic	B-drug
acid	I-drug
,	O
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	B-drug
anticoagulant	I-drug
warfarin	I-drug
or	O
its	O
derivatives	B-drug
.	O

When	O
these	O
products	O
are	O
administered	O
concomitantly	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
.	O

Nitrofurantoin	B-drug
interferes	O
with	O
the	O
therapeutic	O
action	O
of	O
nalidixic	B-drug
acid	I-drug
.	O

Antacids	B-drug
containing	O
magnesium	B-drug
,	O
aluminum	O
,	O
or	O
calcium	B-drug
;	O

sucralfate	B-drug
or	O
divalent	O
or	O
trivalent	O
cations	B-drug
such	O
as	O
iron	B-drug
;	O

multivitamins	B-drug
containing	O
zinc	B-drug
;	O

and	O
Videx	O
?	O
,	O
(	O
Didanosine	B-drug
)	O
,	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	B-drug
powder	O
for	O
oral	O
solution	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	B-drug
,	O
resulting	O
in	O
systemic	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

These	O
agents	O
should	O
not	O
be	O
taken	O
within	O
the	O
two	O
hour	O
period	O
before	O
or	O
within	O
the	O
two	O
-	O
hour	O
period	O
after	O
nalidixic	B-drug
acid	I-drug
administration	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	B-drug
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
some	O
quinolones	B-drug
and	O
cyclosporine	B-drug
.	O

Therefore	O
,	O
cyclosporine	B-drug
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B-drug
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	B-drug
are	O
used	O
concomitantly	O
.	O

)	O

?	O

?	O
Clinical	O
Laboratory	O

?	O

increased	O
creatine	B-drug

positive	O
antinuclear	O

?	O

phosphokinase	B-drug

antibody	B-drug

?	O

increased	O
bilirubin	B-drug

?	O

?	O

increased	O
liver	B-drug

?	O

?	O

transaminases	B-drug
(	O
AST	B-drug

?	O

?	O

(	O
SGOT	O
)	O
,	O
ALT	O
(	O
SGPT	O
)	O

?	O

?	O

increased	O
alkaline	O

?	O

?	O

phophatase	O

?	O

?	O
Hematopoietic	O

anemia	O

thrombocytopenia	O

?	O

leukopenia	O

?	O

?	O

bone	O
marrow	O
hypoplasia	O

?	O

?	O

eosinophilia	O

?	O

?	O
Immunologic	O

angioedema	O

anaphylaxis	O

?	O

laryngeal	O
edema	O

Lupus	O
-	O
like	O
syndrome	O

?	O

urticaria	O

vasculitis	O

?	O
Integumentary	O

exfoliative	O
dermatitis	O

alopecia	O

?	O

rash	O

?	O

?	O

dermatitis	O

?	O

?	O

pruritus	O

?	O

The	O
adverse	O
effects	O
of	O
CAMPTOSAR	B-drug
,	O
such	O
as	O
myelosuppression	O
and	O
diarrhea	O
,	O
would	O
be	O
expected	O
to	O
be	O
exacerbated	O
by	O
other	B-drug
antineoplastic	I-drug
agents	I-drug
having	O
similar	O
adverse	O
effects	O
.	O

Patients	O
who	O
have	O
previously	O
received	O
pelvic/	O
abdominal	O
irradiation	O
are	O
at	O
increased	O
risk	O
of	O
severe	O
myelosuppression	O
following	O
the	O
administration	O
of	O
CAMPTOSAR	B-drug
.	O

The	O
concurrent	O
administration	O
of	O
CAMPTOSAR	B-drug
with	O
irradiation	O
has	O
not	O
been	O
adequately	O
studied	O
and	O
is	O
not	O
recommended	O
.	O

Lymphocytopenia	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B-drug
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
administration	O
of	O
dexamethasone	B-drug
as	O
antiemetic	B-drug
prophylaxis	O
may	O
have	O
enhanced	O
the	O
likelihood	O
of	O
this	O
effect	O
.	O

However	O
,	O
serious	O
opportunistic	O
infections	O
have	O
not	O
been	O
observed	O
,	O
and	O
no	O
complications	O
have	O
specifically	O
been	O
attributed	O
to	O
lymphocytopenia	O
.	O

Hyperglycemia	O
has	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B-drug
.	O

Usually	O
,	O
this	O
has	O
been	O
observed	O
in	O
patients	O
with	O
a	O
history	O
of	O
diabetes	O
mellitus	O
or	O
evidence	O
of	O
glucose	O
intolerance	O
prior	O
to	O
administration	O
of	O
CAMPTOSAR	B-drug
.	O

It	O
is	O
probable	O
that	O
dexamethasone	B-drug
,	O
given	O
as	O
antiemetic	B-drug
prophylaxis	O
,	O
contributed	O
to	O
hyperglycemia	O
in	O
some	O
patients	O
.	O

The	O
incidence	O
of	O
akathisia	O
in	O
clinical	O
trials	O
of	O
the	O
weekly	O
dosage	O
schedule	O
was	O
greater	O
(	O
8.5	O
%	O
,	O
4/47	O
patients	O
)	O
when	O
prochlorperazine	B-drug
was	O
administered	O
on	O
the	O
same	O
day	O
as	O
CAMPTOSAR	B-drug
than	O
when	O
these	O
drugs	B-drug
were	O
given	O
on	O
separate	O
days	O
(	O
1.3	O
%	O
,	O
1/80	O
patients	O
)	O
.	O

The	O
8.5	O
%	O
incidence	O
of	O
akathisia	O
,	O
however	O
,	O
is	O
within	O
the	O
range	O
reported	O
for	O
use	O
of	O
prochlorperazine	B-drug
when	O
given	O
as	O
a	O
premedication	O
for	O
other	O
chemotherapies	O
.	O

It	O
would	O
be	O
expected	O
that	O
laxative	B-drug
use	O
during	O
therapy	O
with	O
CAMPTOSAR	B-drug
would	O
worsen	O
the	O
incidence	O
or	O
severity	O
of	O
diarrhea	O
,	O
but	O
this	O
has	O
not	O
been	O
studied	O
.	O

In	O
view	O
of	O
the	O
potential	O
risk	O
of	O
dehydration	O
secondary	O
to	O
vomiting	O
and/or	O
diarrhea	O
induced	O
by	O
CAMPTOSAR	B-drug
,	O
the	O
physician	O
may	O
wish	O
to	O
withhold	O
diuretics	B-drug
during	O
dosing	O
with	O
CAMPTOSAR	B-drug
and	O
,	O
certainly	O
,	O
during	O
periods	O
of	O
active	O
vomiting	O
or	O
diarrhea	O
.	O

Drug	O
-	O
Laboratory	O
Test	O
Interactions	O
There	O
are	O
no	O
known	O
interactions	O
between	O
CAMPTOSAR	B-drug
and	O
laboratory	O
tests	O
.	O

Colchicine	B-drug
is	O
inhibited	O
by	O
acidifying	B-drug
agents	I-drug
.	O

The	O
action	O
of	O
colchicine	B-drug
is	O
potentiated	O
by	O
alkalinizing	B-drug
agents	I-drug
.	O

Colchicine	B-drug
may	O
increase	O
sensitivity	O
to	O
the	O
CNS	B-drug
depressants	I-drug
.	O

Response	O
to	O
sympathomimetic	B-drug
agents	I-drug
may	O
be	O
enhanced	O
by	O
colchicine	B-drug
.	O

No	O
significant	O
drug	O
interactions	O
have	O
been	O
reported	O
in	O
studies	O
of	O
candesartan	B-drug
cilexetil	I-drug
given	O
with	O
other	O
drugs	B-drug
such	O
as	O
glyburide	B-drug
,	O
nifedipine	B-drug
,	O
digoxin	B-drug
,	O
warfarin	B-drug
,	O
hydrochlorothiazide	B-drug
,	O
and	O
oral	B-drug
contraceptives	I-drug
in	O
healthy	O
volunteers	O
,	O
or	O
given	O
with	O
enalapril	B-drug
to	O
patients	O
with	O
heart	O
failure	O
(	O
NYHA	O
class	O
II	O
and	O
III	O
)	O
.	O

Because	O
candesartan	B-drug
is	O
not	O
significantly	O
metabolized	O
by	O
the	O
cytochrome	B-drug
P450	I-drug
system	O
and	O
at	O
therapeutic	O
concentrations	O
has	O
no	O
effects	O
on	O
P450	B-drug
enzymes	O
,	O
interactions	O
with	O
drugs	B-drug
that	O
inhibit	O
or	O
are	O
metabolized	O
by	O
those	O
enzymes	O
would	O
not	O
be	O
expected	O
.	O

Lithium	O
?	O
Reversible	O
increases	O
in	O
serum	O
lithium	B-drug
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-drug
with	O
ACE	B-drug
inhibitors	I-drug
,	O
and	O
with	O
some	O
angiotensin	B-drug
II	I-drug
receptor	I-drug
antagonists	I-drug
.	O

An	O
increase	O
in	O
serum	O
lithium	B-drug
concentration	O
has	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B-drug
with	O
ATACAND	B-drug
,	O
so	O
careful	O
monitoring	O
of	O
serum	O
lithium	O
levels	O
is	O
recommended	O
during	O
concomitant	O
use	O
.	O

Use	O
of	O
Cerubidine	B-drug
in	O
a	O
patient	O
who	O
has	O
previously	O
received	O
doxorubicin	B-drug
increases	O
the	O
risk	O
of	O
cardiotoxicity	O
.	O

Cerubidine	B-drug
should	O
not	O
be	O
used	O
in	O
patients	O
who	O
have	O
previously	O
received	O
the	O
recommended	O
maximum	O
cumulative	O
doses	O
of	O
doxorubicin	B-drug
or	O
Cerubidine	B-drug
.	O

Cyclophosphamide	B-drug
used	O
concurrently	O
with	O
Cerubidine	B-drug
may	O
also	O
result	O
in	O
increased	O
cardiotoxicity	O
.	O

Dosage	O
reduction	O
of	O
Cerubidine	B-drug
may	O
be	O
required	O
when	O
used	O
concurrently	O
with	O
other	O
myelosuppressive	O
agents	O
.	O

Hepatotoxic	O
medications	B-drug
,	O
such	O
as	O
high	O
-	O
dose	O
methotrexate	B-drug
,	O
may	O
impair	O
liver	O
function	O
and	O
increase	O
the	O
risk	O
of	O
toxicity	O
.	O

The	O
use	O
of	O
codeine	B-drug
may	O
result	O
in	O
additive	O
CNS	B-drug
depressant	I-drug
effects	O
when	O
coadministered	O
with	O
alcohol	B-drug
,	O
antihistamines	B-drug
,	O
psychotropics	O
or	O
other	O
drugs	B-drug
that	O
produce	O
CNS	O
depression	O
.	O

Serious	O
toxicity	O
may	O
result	O
if	O
dextromethorphan	B-drug
is	O
coadministered	O
with	O
monoamine	B-drug
oxidase	I-drug
inhibitors	I-drug
(	O
MAOIs	O
)	O
.	O

The	O
use	O
of	O
dextromethorphan	B-drug
hydrobromide	I-drug
may	O
result	O
in	O
additive	O
CNS	B-drug
depressant	I-drug
effects	O
when	O
coadministered	O
with	O
alcohol	B-drug
,	O
antihistamines	B-drug
,	O
psychotropics	O
or	O
other	O
drugs	B-drug
that	O
produce	O
CNS	O
depression	O
.	O

Known	O
drug	O
interactions	O
include	O
barbiturates	B-drug
,	O
tranquilizers	B-drug
,	O
and	O
alcohol	B-drug
.	O

Diphenoxylate	B-drug
HCl	I-drug
and	O
atropine	B-drug
sulfate	I-drug
may	O
interact	O
with	O
MAO	B-drug
inhibitors	I-drug
In	O
studies	O
with	O
male	O
rats	O
,	O
diphenoxylate	B-drug
hydrochloride	I-drug
was	O
found	O
to	O
inhibit	O
the	O
hepatic	O
microsomal	B-drug
enzyme	I-drug
system	O
at	O
a	O
dose	O
of	O
2	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Therefore	O
,	O
diphenoxylate	B-drug
has	O
the	O
potential	O
to	O
prolong	O
the	O
biological	O
half	O
-	O
lives	O
of	O
drugs	B-drug
for	O
which	O
the	O
rate	O
of	O
elimination	O
is	O
dependent	O
on	O
the	O
microsomal	B-drug
drug	I-drug
metabolizing	O
enzyme	O
system	O
.	O

No	O
formal	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
with	O
Cyanokit	O
.	O

Catecholamine	O
-	O
depleting	O
drugs	B-drug
,	O
such	O
as	O
reserpine	B-drug
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	B-drug
-	I-drug
blocking	I-drug
agents	O
.	O

Patients	O
treated	O
with	O
acebutolol	B-drug
plus	O
catecholamine	O
depletors	O
should	O
,	O
therefore	O
,	O
be	O
observed	O
closely	O
for	O
evidence	O
of	O
marked	O
bradycardia	O
or	O
hypotension	O
which	O
may	O
present	O
as	O
vertigo	O
,	O
syncope	O
/	O
presyncope	O
,	O
or	O
orthostatic	O
changes	O
in	O
blood	O
pressure	O
without	O
compensatory	O
tachycardia	O
.	O

Exaggerated	O
hypertensive	O
responses	O
have	O
been	O
reported	O
from	O
the	O
combined	O
use	O
of	O
beta	B-drug
-	I-drug
adrenergic	I-drug
antagonists	O
and	O
alpha	O
-	O
adrenergic	O
stimulants	B-drug
,	O
including	O
those	O
contained	O
in	O
proprietary	O
cold	O
remedies	O
and	O
vasoconstrictive	O
nasal	O
drops	O
.	O

Patients	O
receiving	O
beta	B-drug
-	I-drug
blockers	I-drug
should	O
be	O
warned	O
of	O
this	O
potential	O
hazard	O
.	O

Blunting	O
of	O
the	O
antihypertensive	B-drug
effect	O
of	O
beta	B-drug
-	I-drug
adrenoceptor	I-drug
blocking	I-drug
agents	O
by	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drugs	I-drug
has	O
been	O
reported	O
.	O

No	O
significant	O
interactions	O
with	O
digoxin	B-drug
,	O
hydrochlorothiazide	B-drug
,	O
hydralazine	B-drug
,	O
sulfinpyrazone	B-drug
,	O
oral	B-drug
contraceptives	I-drug
,	O
tolbutamide	B-drug
,	O
or	O
warfarin	B-drug
have	O
been	O
observed	O
.	O

Efavirenz	B-drug
has	O
been	O
shown	O
in	O
vivo	O
to	O
induce	O
CYP3A4	B-drug
.	O

Other	O
compounds	O
that	O
are	O
substrates	O
of	O
CYP3A4	B-drug
may	O
have	O
decreased	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
SUSTIVA	B-drug
(	O
efavirenz	B-drug
)	O
.	O

In	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
efavirenz	B-drug
inhibits	O
2C9	O
,	O
2C19	O
,	O
and	O
3A4	O
isozymes	B-drug
in	O
the	O
range	O
of	O
observed	O
efavirenz	B-drug
plasma	O
concentrations	O
.	O

Coadministration	O
of	O
efavirenz	B-drug
with	O
drugs	B-drug
primarily	O
metabolized	O
by	O
these	O
isozymes	B-drug
may	O
result	O
in	O
altered	O
plasma	O
concentrations	O
of	O
the	O
coadministered	O
drug	B-drug
.	O

Therefore	O
,	O
appropriate	O
dose	O
adjustments	O
may	O
be	O
necessary	O
for	O
these	O
drugs	B-drug
.	O

Drugs	B-drug
which	O
induce	O
CYP3A4	B-drug
activity	O
(	O
eg	O
,	O
phenobarbital	B-drug
,	O
rifampin	B-drug
,	O
rifabutin	B-drug
)	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
efavirenz	B-drug
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
.	O

Drug	O
interactions	O
with	O
SUSTIVA	B-drug
are	O
summarized	O
in	O
Table	O
5	O
.	O

Table	O
5a	O
:	O
Drugs	B-drug
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
SUSTIVA	B-drug

Drug	B-drug
Class	O

Drugs	B-drug
Within	O
Class	O
Not	O
To	O
Be	O
Coadministered	O
With	O
SUSTIVA	B-drug

Antihistamines	B-drug
Benzodiazepines	O
GI	O
Motility	O
Agents	O
Anti	O
-	O
Migraine	O
Antifungal	O

astemizole	B-drug
midazolam	O
,	O
triazolam	B-drug
cisapride	O
ergot	O
derivatives	O
voriconazole	B-drug

Established	O
Drug	O
Interactions	O

?	O

Drug	B-drug
Name	O

Effect	O

Clinical	O
Comment	O

Atazanavir	B-drug

?	O
atazanavir	O

When	O
coadministered	O
with	O
SUSTIVA	B-drug
in	O
treatment	O
-	O
naive	O
patients	O
,	O
the	O
recommended	O
dose	O
of	O
atazanavir	B-drug
is	O
300	O
mg	O
with	O
ritonavir	B-drug
100	I-drug
mg	I-drug
and	O
SUSTIVA	B-drug
600	O
mg	O
(	O
all	O
once	O
daily	O
)	O
.	O

Dosing	O
recommendations	O
for	O
SUSTIVA	B-drug
and	O
atazanavir	B-drug
in	O
treatment	O
-	O
experienced	O
patients	O
have	O
not	O
been	O
established	O
.	O

Established	O
Drug	O
Interactions	O
(	O
continued	O
)	O

Drug	B-drug
Name	O

Effect	O

Clinical	O
Comment	O

Clarithromycin	B-drug

?	O
?	O
clarithromycin	B-drug
concentration	O

Plasma	O
concentrations	O
decreased	O
by	O
SUSTIVA	B-drug
;	O

clinical	O
significance	O
unknown	O
.	O

In	O
uninfected	O
volunteers	O
,	O
46	O
%	O
developed	O
rash	O
while	O
receiving	O
SUSTIVA	B-drug
and	O
clarithromycin	B-drug
.	O

No	O
dose	O
adjustment	O
of	O
SUSTIVA	B-drug
is	O
recommended	O
when	O
given	O
with	O
clarithromycin	B-drug
.	O

Alternatives	O
to	O
clarithromycin	B-drug
,	O
such	O
as	O
azithromycin	B-drug
,	O
should	O
be	O
considered	O
.	O

Other	O
macrolide	B-drug
antibiotics	I-drug
,	O
such	O
as	O
erythromycin	B-drug
,	O
have	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B-drug
.	O

?	O
?	O

14-OH	O
metabolite	O
concentration	O

Indinavir	B-drug

?	O
?	O
indinavir	B-drug
concentration	O

The	O
optimal	O
dose	O
of	O
indinavir	B-drug
,	O
when	O
given	O
in	O
combination	O
with	O
SUSTIVA	B-drug
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	B-drug
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-drug
metabolism	O
due	O
to	O
SUSTIVA	B-drug
.	O

When	O
indinavir	B-drug
at	O
an	O
increased	O
dose	O
(	O
1000	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
with	O
SUSTIVA	B-drug
(	O
600	O
mg	O
once	O
daily	O
)	O
,	O
the	O
indinavir	B-drug
AUC	O
and	O
Cmin	O
were	O
decreased	O
on	O
average	O
by	O
33	O
-	O
46	O
%	O
and	O
39	O
-	O
57	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
when	O
indinavir	B-drug
(	O
800	O
mg	O
every	O
8	O
hours	O
)	O
was	O
given	O
alone	O
.	O

Lopinavir	B-drug
/	O
ritonavir	B-drug

?	O
?	O
lopinavir	B-drug
concentration	O

A	O
dose	O
increase	O
of	O
lopinavir	B-drug
/	O
ritonavir	B-drug
to	O
533/133	O
mg	O
(	O
4	O
capsules	O
or	O
6.5	O
mL	O
)	O
twice	O
daily	O
taken	O
with	O
food	O
is	O
recommended	O
when	O
used	O
in	O
combination	O
with	O
SUSTIVA	B-drug
.	O

Methadone	B-drug

?	O
?	O
methadone	B-drug
concentration	O

Coadministration	O
in	O
HIV	O
-	O
infected	O
individuals	O
with	O
a	O
history	O
of	O
injection	O
drug	O
use	O
resulted	O
in	O
decreased	O
plasma	O
levels	O
of	O
methadone	B-drug
and	O
signs	O
of	O
opiate	B-drug
withdrawal	O
.	O

Methadone	O
dose	O
was	O
increased	O
by	O
a	O
mean	O
of	O
22	O
%	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O

Patients	O
should	O
be	O
monitored	O
for	O
signs	O
of	O
withdrawal	O
and	O
their	O
methadone	O
dose	O
increased	O
as	O
required	O
to	O
alleviate	O
withdrawal	O
symptoms	O
.	O

Ethinyl	B-drug
estradiol	I-drug

?	O
?	O
ethinyl	B-drug
estradiol	I-drug
concentration	O

Plasma	O
concentrations	O
increased	O
by	O
SUSTIVA	B-drug
(	O
efavirenz	B-drug
)	O
;	O

clinical	O
significance	O
unknown	O
.	O

Because	O
the	O
potential	O
interaction	O
of	O
efavirenz	B-drug
with	O
oral	B-drug
contraceptives	I-drug
has	O
not	O
been	O
fully	O
characterized	O
,	O
a	O
reliable	O
method	O
of	O
barrier	O
contraception	O
should	O
be	O
used	O
in	O
addition	O
to	O
oral	B-drug
contraceptives	I-drug
.	O

Rifabutin	B-drug

?	O
?	O
rifabutin	B-drug
concentration	O

Increase	O
daily	O
dose	O
of	O
rifabutin	B-drug
by	O
50	O
%	O
.	O

Consider	O
doubling	O
the	O
rifabutin	B-drug
dose	O
in	O
regimens	O
where	O
rifabutin	B-drug
is	O
given	O
2	O
or	O
3	O
times	O
a	O
week	O
.	O

Rifampin	B-drug

?	O
?	O
efavirenz	B-drug
concentration	O

Clinical	O
significance	O
of	O
reduced	O
efavirenz	B-drug
concentrations	O
unknown	O
.	O

Ritonavir	B-drug

?	O
?	O
ritonavir	B-drug
concentration	O

Combination	O
was	O
associated	O
with	O
a	O
higher	O
frequency	O
of	O
adverse	O
clinical	O
experiences	O
(	O
eg	O
,	O
dizziness	O
,	O
nausea	O
,	O
paresthesia	O
)	O
and	O
laboratory	O
abnormalities	O
(	O
elevated	O
liver	O
enzymes	O
)	O
.	O

Monitoring	O
of	O
liver	B-drug
enzymes	I-drug
is	O
recommended	O
when	O
SUSTIVA	B-drug
is	O
used	O
in	O
combination	O
with	O
ritonavir	B-drug
.	O

?	O
?	O
efavirenz	B-drug
concentration	O

Saquinavir	B-drug

?	O
?	O
saquinavir	B-drug
concentration	O

Should	O
not	O
be	O
used	O
as	O
sole	O
protease	B-drug
inhibitor	I-drug
in	O
combination	O
with	O
SUSTIVA	B-drug
.	O

Sertraline	B-drug

?	O
?	O
sertraline	B-drug
concentration	O

Increases	O
in	O
sertraline	O
dose	O
should	O
be	O
guided	O
by	O
clinical	O
response	O
.	O

Other	O
Potentially	O
Clinically	O
Significant	O
Drug	B-drug
or	O
Herbal	O
Product	O
Interactions	O
With	O
SUSTIVAb	O

Anticoagulants	B-drug
:	O
Warfarin	B-drug

Plasma	O
concentrations	O
and	O
effects	O
potentially	O
increased	O
or	O
decreased	O
by	O
SUSTIVA	B-drug
.	O

Anticonvulsants	B-drug
:	O
Phenytoin	O
Phenobarbital	B-drug
Carbamazepine	O

Potential	O
for	O
reduction	O
in	O
anticonvulsant	B-drug
and/or	O
efavirenz	B-drug
plasma	O
levels	O
;	O

periodic	O
monitoring	O
of	O
anticonvulsant	B-drug
plasma	O
levels	O
should	O
be	O
conducted	O
.	O

Antifungals	B-drug
:	O
Itraconazole	B-drug
Ketoconazole	O

Drug	O
interaction	O
studies	O
with	O
SUSTIVA	B-drug
and	O
these	O
imidazole	B-drug
and	O
triazole	B-drug
antifungals	I-drug
have	O
not	O
been	O
conducted	O
.	O

SUSTIVA	B-drug
has	O
the	O
potential	O
to	O
decrease	O
plasma	O
concentrations	O
of	O
itraconazole	B-drug
and	O
ketoconazole	B-drug
.	O

Anti	B-drug
-	I-drug
HIV	I-drug
protease	I-drug
inhibitors	I-drug
:	O
Saquinavir	B-drug
/	O
ritonavir	B-drug
combination	O

No	O
pharmacokinetic	O
data	O
are	O
available	O
.	O

Amprenavir	B-drug

SUSTIVAhas	O
the	O
potential	O
to	O
decrease	O
serum	O
concentrations	O
of	O
amprenavir	B-drug
.	O

Non	B-drug
-	I-drug
nucleoside	I-drug
reverse	I-drug
transcriptase	I-drug
inhibitors	I-drug

No	O
studies	O
have	O
been	O
performed	O
with	O
other	O
NNRTIs	O
.	O

St.	O
John?s	O
wort	O
(	O
Hypericum	B-drug
perforatum	I-drug
)	O

Expected	O
to	O
substantially	O
decrease	O
plasma	O
levels	O
of	O
efavirenz;has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
SUSTIVA	B-drug
.	O

a	O
See	O
Tables	O
1	O
and	O
2	O
.	O

b	O
This	O
table	O
is	O
not	O
all	O
-	O
inclusive	O
.	O

Other	O
Drugs	B-drug
:	O
Based	O
on	O
the	O
results	O
of	O
drug	O
interaction	O
studies	O
,	O
no	O
dosage	O
adjustment	O
is	O
recommended	O
when	O
SUSTIVA	B-drug
(	O
efavirenz	B-drug
)	O
is	O
given	O
with	O
the	O
following	O
:	O
aluminum	O
/	O
magnesium	B-drug
hydroxide	I-drug
antacids	O
,	O
azithromycin	B-drug
,	O
cetirizine	B-drug
,	O
famotidine	B-drug
,	O
fluconazole	B-drug
,	O
lamivudine	B-drug
,	O
lorazepam	B-drug
,	O
nelfinavir	B-drug
,	O
paroxetine	B-drug
,	O
and	O
zidovudine	B-drug
.	O

Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
performed	O
with	O
SUSTIVA	B-drug
and	O
NRTIs	O
other	O
than	O
lamivudine	B-drug
and	O
zidovudine	B-drug
.	O

Clinically	O
significant	O
interactions	O
would	O
not	O
be	O
expected	O
since	O
the	O
NRTIs	O
are	O
metabolized	O
via	O
a	O
different	O
route	O
than	O
efavirenz	B-drug
and	O
would	O
be	O
unlikely	O
to	O
compete	B-drug
for	O
the	O
same	O
metabolic	O
enzymes	O
and	O
elimination	O
pathways	O
.	O

Many	O
other	O
medicines	B-drug
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
glimepiride	B-drug
or	O
affect	O
your	O
condition	O
.	O

Before	O
taking	O
glimepiride	B-drug
,	O
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
medicines	B-drug
:	O
-	O
aspirin	B-drug
or	O
another	O
salicylate	B-drug
such	O
as	O
magnesium	B-drug
/	O
choline	B-drug
salicylate	I-drug
(	O
Trilisate	B-drug
)	O
,	O
salsalate	B-drug
(	O
Disalcid	B-drug
,	O
others	O
)	O
,	O
choline	B-drug
salicylate	I-drug
(	O
Arthropan	B-drug
)	O
,	O
magnesium	B-drug
salicylate	I-drug
(	O
Magan	B-drug
)	O
,	O
or	O
bismuth	B-drug
subsalicylate	I-drug
(	O
Pepto	B-drug
-	I-drug
Bismol	I-drug
)	O
;	O

-	O
a	O
nonsteroidal	B-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
drug	I-drug
(	O
NSAID	B-drug
)	O
such	O
as	O
ibuprofen	B-drug
(	O
Motrin	B-drug
,	O
Advil	B-drug
,	O
Nuprin	B-drug
,	O
others	O
)	O
,	O
ketoprofen	B-drug
(	O
Orudis	B-drug
,	O
Orudis	B-drug
KT	I-drug
,	O
Oruvail	B-drug
)	O
,	O
diclofenac	B-drug
(	O
Voltaren	B-drug
,	O
Cataflam	B-drug
)	O
,	O
etodolac	B-drug
(	O
Lodine	B-drug
)	O
,	O
indomethacin	B-drug
(	O
Indocin	B-drug
)	O
,	O
nabumetone	B-drug
(	O
Relafen	B-drug
)	O
,	O
oxaprozin	B-drug
(	O
Daypro	B-drug
)	O
,	O
and	O
naproxen	B-drug
(	O
Anaprox	B-drug
,	O
Naprosyn	B-drug
,	O
Aleve	B-drug
)	O
;	O

-	O
a	O
sulfa	B-drug
-	I-drug
based	I-drug
drug	I-drug
such	O
as	O
sulfamethoxazole	B-drug
-	I-drug
trimethoprim	I-drug
(	O
Bactrim	B-drug
,	O
Septra	B-drug
)	O
,	O
sulfisoxazole	B-drug
(	O
Gantrisin	B-drug
)	O
,	O
or	O
sulfasalazine	B-drug
(	O
Azulfidine	B-drug
)	I-drug
;	O

-	O
a	O
monoamine	B-drug
oxidase	I-drug
inhibitor	I-drug
(	O
MAOI	O
)	O
such	O
as	O
isocarboxazid	B-drug
(	O
Marplan	B-drug
)	O
,	O
tranylcypromine	B-drug
(	O
Parnate	B-drug
)	O
,	O
or	O
phenelzine	B-drug
(	O
Nardil	B-drug
)	O
;	O

-	O
a	O
beta	B-drug
-	I-drug
blocker	I-drug
such	O
as	O
propranolol	B-drug
(	O
Inderal	B-drug
)	O
,	O
atenolol	B-drug
(	O
Tenormin	B-drug
)	O
,	O
acebutolol	B-drug
(	O
Sectral	B-drug
)	O
,	O
metoprolol	B-drug
(	O
Lopressor	B-drug
)	O
,	O
and	O
others	O
;	O

-	O
a	O
diuretic	B-drug
(	O
water	B-drug
pill	O
)	O
such	O
as	O
hydrochlorothiazide	B-drug
(	O
HCTZ	B-drug
,	O
Hydrodiuril	B-drug
)	O
,	O
chlorothiazide	B-drug
(	O
Diuril	B-drug
)	O
,	O
and	O
others	O
;	O

-	O
a	O
steroid	B-drug
medicine	I-drug
such	O
as	O
prednisone	B-drug
(	O
Deltasone	B-drug
,	O
Orasone	B-drug
,	O
others	O
)	O
,	O
methylprednisolone	B-drug
(	O
Medrol	B-drug
,	O
others	O
)	O
,	O
prednisolone	B-drug
(	O
Prelone	B-drug
,	O
Pediapred	B-drug
,	O
others	O
)	O
,	O
and	O
others	O
;	O

-	O
a	O
phenothiazine	B-drug
such	O
as	O
chlorpromazine	B-drug
(	O
Thorazine	B-drug
)	O
,	O
fluphenazine	B-drug
(	O
Prolixin	B-drug
,	O
Permitil	B-drug
)	O
,	O
prochlorperazine	B-drug
(	O
Compazine	B-drug
)	O
,	O
promethazine	B-drug
(	O
Phenergan	B-drug
)	O
,	O
and	O
others	O
;	O

-	O
phenytoin	B-drug
(	O
Dilantin	B-drug
)	O
;	O

-	O
isoniazid	B-drug
(	O
Nydrazid	B-drug
)	O
;	O

-	O
rifampin	B-drug
(	O
Rifadin	B-drug
,	O
Rifamate	B-drug
)	O
;	O

or	O
-	O
over	O
-	O
the	O
-	O
counter	O
cough	O
,	O
cold	O
,	O
allergy	O
,	O
or	O
weight	O
loss	O
medications	B-drug
.	O

You	O
may	O
require	O
a	O
dosage	O
adjustment	O
or	O
special	O
monitoring	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
medicines	B-drug
listed	O
above	O
.	O

Drugs	B-drug
other	O
than	O
those	O
listed	O
here	O
may	O
also	O
interact	O
with	O
glimepiride	B-drug
or	O
affect	O
your	O
condition	O
.	O

Talk	O
to	O
your	O
doctor	O
and	O
pharmacist	O
before	O
taking	O
any	O
prescription	O
or	O
over	B-drug
-	I-drug
the	I-drug
-	I-drug
counter	I-drug
medicines	I-drug
,	O
including	O
herbal	O
products	O
.	O

Specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ENBREL	O
?	O
.	O

However	O
,	O
it	O
was	O
observed	O
that	O
the	O
pharmacokinetics	O
of	O
ENBREL	O
?	O
was	O
unaltered	O
by	O
concomitant	O
methotrexate	B-drug
in	O
rheumatoid	O
arthritis	O
patients	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
ENBREL	O
?	O
and	O
anakinra	B-drug
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
ENBREL	O
?	O
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
ENBREL	O
?	O
and	O
anakinra	B-drug
developed	O
neutropenia	O
(	O
ANC	B-drug
  	I-drug
1	I-drug
x	I-drug
109	I-drug
/	I-drug
L	I-drug
)	I-drug
.	O

Patients	O
in	O
a	O
clinical	O
study	O
who	O
were	O
on	O
established	O
therapy	O
with	O
sulfasalazine	B-drug
,	O
to	O
which	O
ENBREL	B-drug
was	O
added	O
,	O
were	O
noted	O
to	O
develop	O
a	O
mild	O
decrease	O
in	O
mean	O
neutrophil	O
counts	O
in	O
comparison	O
to	O
groups	O
treated	O
with	O
either	O
ENBREL	B-drug
CI	O
or	O
sulfasalazine	B-drug
alone	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
observation	O
is	O
unknown	O
.	O

Androgens	B-drug
may	O
increase	O
sensitivity	O
to	O
oral	O
anticoagulahts	O
.	O

Dosage	O
of	O
the	O
anticoagulant	B-drug
may	O
require	O
reduction	O
in	O
order	O
to	O
maintain	O
satisfactory	O
therapeutic	O
hypoprothrombinemia	O
.	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	B-drug
and	O
androgens	B-drug
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B-drug
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	B-drug
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
,	O
insulin	B-drug
requirements	O
.	O

No	O
information	O
available	O

.	O

?	O

The	O
CNS	O
effects	O
of	O
butalbital	B-drug
may	O
be	O
enhanced	O
by	O
monoamine	B-drug
oxidase	I-drug
(	O
MAO	O
)	O
inhibitors	O
.	O

Butalbital	B-drug
,	O
acetaminophen	O
and	O
caffeine	B-drug
may	O
enhance	O
the	O
effects	O
of	O
:	O
other	B-drug
narcotic	I-drug
analgesics	O
,	O
alcohol	B-drug
,	O
general	B-drug
anesthetics	I-drug
,	O
tranquilizers	B-drug
such	O
as	O
chlordiazepoxide	B-drug
,	O
sedative	B-drug
-	I-drug
hypnotics	I-drug
,	O
or	O
other	O
CNS	B-drug
depressants	I-drug
,	O
causing	O
increased	O
CNS	O
depression	O
.	O

Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
Acetaminophen	B-drug
may	O
produce	O
false	O
-	O
positive	O
test	O
results	O
for	O
urinary	B-drug
5-hydroxyindoleacetic	I-drug
acid	I-drug
.	I-drug

Tablet	O
If	O
a	O
patient	O
receiving	O
clonidine	B-drug
hydrochloride	I-drug
is	O
also	O
taking	O
tricyclic	B-drug
antidepressants	I-drug
,	O
the	O
effect	O
of	O
clonidine	B-drug
may	O
be	O
reduced	O
,	O
thus	O
necessitating	O
an	O
increase	O
in	O
dosage	O
.	O

Clonidine	B-drug
hydrochloride	I-drug
may	O
enhance	O
the	O
CNS	O
-	O
depressive	O
effects	O
of	O
alcohol	B-drug
,	O
barbiturates	B-drug
or	O
other	O
sedatives	B-drug
.	O

Amitriptyline	B-drug
in	O
combination	O
with	O
clonidine	B-drug
enhances	O
the	O
manifestation	O
of	O
corneal	O
lesions	O
in	O
rats	O
Epidural	O
Injection	O
Clonidine	B-drug
may	O
potentiate	O
the	O
CNS	O
-	O
depressive	O
effect	O
of	O
alcohol	B-drug
,	O
barbiturates	B-drug
or	O
other	O
sedating	O
drugs	B-drug
.	O

Narcotic	B-drug
analgesics	I-drug
may	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B-drug
.	O

Tricyclic	B-drug
antidepressants	I-drug
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
clonidine	B-drug
.	O

The	O
effects	O
of	O
tricyclic	B-drug
antidepressants	I-drug
on	O
clonidines	O
analgesic	B-drug
actions	O
are	O
not	O
known	O
.	O

Beta	B-drug
blockers	I-drug
may	O
exacerbate	O
the	O
hypertensive	O
response	O
seen	O
with	O
clonidine	B-drug
withdrawl	O
.	O

Also	O
,	O
due	O
to	O
the	O
potential	O
for	O
additive	O
effects	O
such	O
as	O
bradycardia	O
and	O
AV	O
block	O
,	O
caution	O
is	O
warranted	O
in	O
patients	O
receiving	O
clonidine	B-drug
with	O
agents	O
known	O
to	O
affect	O
sinus	O
node	O
function	O
or	O
AV	O
nodal	O
conduction	O
(	O
e.g.	O
,	O
digitalis	B-drug
,	O
calcium	B-drug
channel	I-drug
blockers	I-drug
,	O
and	O
beta	B-drug
-	I-drug
blockers	I-drug
.	I-drug
)	O

There	O
is	O
one	O
reported	O
case	O
of	O
a	O
patient	O
with	O
acute	O
delirium	O
associated	O
with	O
the	O
simultaneous	O
use	O
of	O
fluphenazine	B-drug
and	O
oral	O
clonidine	B-drug
.	O

Symptoms	O
resolved	O
when	O
clonidine	B-drug
was	O
withdrawn	O
and	O
recurred	O
when	O
the	O
patient	O
was	O
rechallenged	O
with	O
clonidine	B-drug
.	O

Epidural	O
clonidine	B-drug
may	O
prolong	O
the	O
duration	O
of	O
pharmacologic	O
effects	O
of	O
epidural	O
local	B-drug
anesthetics	I-drug
,	O
including	O
both	O
sensory	O
and	O
motor	O
blockade	O
.	O

Because	O
alosetron	B-drug
is	O
metabolized	O
by	O
a	O
variety	O
of	O
hepatic	O
CYP	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
of	O
alosetron	B-drug
.	O

Fluvoxamine	B-drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP1A2	B-drug
and	O
also	O
inhibits	O
CYP3A4	B-drug
,	O
CYP2C9	B-drug
,	O
and	O
CYP2C19	B-drug
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
40	O
healthy	O
female	O
subjects	O
received	O
fluvoxamine	B-drug
in	O
escalating	O
doses	O
from	O
50	O
to	O
200	O
mg	O
per	O
day	O
for	O
16	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B-drug
1	I-drug
mg	I-drug
on	O
the	O
last	O
day	O
.	O

Fluvoxamine	B-drug
increased	O
mean	O
alosetron	B-drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
approximately	O
6-fold	O
and	O
prolonged	O
the	O
half	O
-	O
life	O
by	O
approximately	O
3-fold	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B-drug
and	O
fluvoxamine	B-drug
is	O
contraindicated	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B-drug
and	O
moderate	O
CYP1A2	B-drug
inhibitors	O
,	O
including	O
quinolone	B-drug
antibiotics	O
and	O
cimetidine	B-drug
,	O
has	O
not	O
been	O
evaluated	O
,	O
but	O
should	O
be	O
avoided	O
unless	O
clinically	O
necessary	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

Ketoconazole	B-drug
is	O
a	O
known	O
strong	O
inhibitor	O
of	O
CYP3A4	B-drug
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
38	O
healthy	O
female	O
subjects	O
received	O
ketoconazole	B-drug
200	I-drug
mg	I-drug
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B-drug
1	I-drug
mg	I-drug
on	O
the	O
last	O
day	O
.	O

Ketoconazole	B-drug
increased	O
mean	O
alosetron	B-drug
plasma	O
concentrations	O
(	O
AUC	O
)	O
by	O
29	O
%	O
.	O

Caution	O
should	O
be	O
used	O
when	O
alosetron	B-drug
and	O
ketoconazole	B-drug
are	O
administered	O
concomitantly	O
.	O

Coadministration	O
of	O
alosetron	B-drug
and	O
strong	O
CYP3A4	B-drug
inhibitors	O
,	O
such	O
as	O
clarithromycin	B-drug
,	O
telithromycin	B-drug
,	O
protease	B-drug
inhibitors	I-drug
,	O
voriconazole	B-drug
,	O
and	O
itraconazole	B-drug
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
undertaken	O
with	O
caution	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

The	O
effect	O
of	O
induction	O
or	O
inhibition	O
of	O
other	O
pathways	O
on	O
exposure	O
to	O
alosetron	B-drug
and	O
its	O
metabolites	B-drug
is	O
not	O
known	O
.	O

In	O
vitro	O
human	O
liver	O
microsome	O
studies	O
and	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
demonstrated	O
that	O
alosetron	B-drug
did	O
not	O
inhibit	O
CYP	B-drug
enzymes	O
2D6	O
,	O
3A4	O
,	O
2C9	O
,	O
or	O
2C19	O
.	O

In	O
vitro	O
,	O
at	O
total	O
drug	O
concentrations	O
27-fold	O
higher	O
than	O
peak	O
plasma	O
concentrations	O
observed	O
with	O
the	O
1-mg	O
dosage	O
,	O
alosetron	B-drug
inhibited	O
CYP	B-drug
enzymes	O
1A2	O
(	O
60	O
%	O
)	O
and	O
2E1	O
(	O
50	O
%	O
)	O
.	O

In	O
an	O
in	O
vivo	O
metabolic	O
probe	O
study	O
,	O
alosetron	B-drug
did	O
not	O
inhibit	O
CYP2E1	B-drug
but	O
did	O
produce	O
30	O
%	O
inhibition	O
of	O
both	O
CYP1A2	B-drug
and	O
N	B-drug
-	I-drug
acetyltransferase	I-drug
.	O

Although	O
not	O
studied	O
with	O
alosetron	B-drug
,	O
inhibition	O
of	O
N	O
-	O
acetyltransferase	B-drug
may	O
have	O
clinically	O
relevant	O
consequences	O
for	O
drugs	B-drug
such	O
as	O
isoniazid	B-drug
,	O
procainamide	B-drug
,	O
and	O
hydralazine	B-drug
.	O

The	O
effect	O
on	O
CYP1A2	B-drug
was	O
explored	O
further	O
in	O
a	O
clinical	O
interaction	O
study	O
with	O
theophylline	B-drug
and	O
no	O
effect	O
on	O
metabolism	O
was	O
observed	O
.	O

Another	O
study	O
showed	O
that	O
alosetron	B-drug
had	O
no	O
clinically	O
significant	O
effect	O
on	O
plasma	O
concentrations	O
of	O
the	O
oral	B-drug
contraceptive	I-drug
agents	O
ethinyl	O
estradiol	O
and	O
levonorgestrel	B-drug
(	O
CYP3A4	B-drug
substrates	O
)	O
.	O

A	O
clinical	O
interaction	O
study	O
was	O
also	O
conducted	O
with	O
alosetron	B-drug
and	O
the	O
CYP3A4	O
substrate	O
cisapride	B-drug
.	O

No	O
significant	O
effects	O
on	O
cisapride	B-drug
metabolism	O
or	O
QT	O
interval	O
were	O
noted	O
.	O

The	O
effect	O
of	O
alosetron	B-drug
on	O
monoamine	B-drug
oxidases	I-drug
and	O
on	O
intestinal	O
first	O
pass	O
secondary	O
to	O
high	O
intraluminal	O
concentrations	O
have	O
not	O
been	O
examined	O
.	O

Based	O
on	O
the	O
above	O
data	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
alosetron	B-drug
will	O
inhibit	O
the	O
hepatic	O
metabolic	O
clearance	O
of	O
drugs	B-drug
metabolized	O
by	O
the	O
major	O
CYP	B-drug
enzyme	O
3A4	O
,	O
as	O
well	O
as	O
the	O
CYP	B-drug
enzymes	O
2D6	O
,	O
2C9	O
,	O
2C19	O
,	O
2E1	O
,	O
or	O
1A2	O
.	O

Alosetron	B-drug
does	O
not	O
appear	O
to	O
induce	O
the	O
major	O
cytochrome	B-drug
P450	I-drug
(	O
CYP	B-drug
)	O
drug	B-drug
metabolizing	O
enzyme	O
3A.	O

Alosetron	B-drug
also	O
does	O
not	O
appear	O
to	O
induce	O
CYP	B-drug
enzymes	O
2E1	O
or	O
2C19	O
.	O

It	O
is	O
not	O
known	O
whether	O
alosetron	B-drug
might	O
induce	O
other	O
enzymes	O
.	O

Corticotropin	B-drug
may	O
accentuate	O
the	O
electrolyte	O
loss	O
associated	O
with	O
diuretic	O
therapy	O
.	O

Disulfiram	B-drug
appears	O
to	O
decrease	O
the	O
rate	O
at	O
which	O
certain	O
drugs	B-drug
are	O
metabolized	O
and	O
therefore	O
may	O
increase	O
the	O
blood	O
levels	O
and	O
the	O
possibility	O
of	O
clinical	O
toxicity	O
of	O
drugs	B-drug
given	O
concomitantly	O
.	O

DISULFIRAM	B-drug
SHOULD	O
BE	O
USED	O
WITH	O
CAUTION	O
IN	O
THOSE	O
PATIENTS	O
REVEIVING	O
PHENYTOIN	B-drug
AND	O
ITS	O
CONGENERS	O
.	O

SINCE	O
THE	O
CONCOMITANT	O
ADMINISTRATION	O
OF	O
THESE	O
TWO	O
DRUGS	B-drug
CAN	O
LEAD	O
TO	O
PHENYTOIN	O
INTOXICATION	O
,	O
PRIOR	O
TO	O
ADMINISTERING	O
DISULFIRAM	B-drug
TO	O
A	O
PATIENT	O
ON	O
PHENYTOIN	B-drug
THERAPY	O
,	O
A	O
BASELINE	O
PHENYTOIN	O
SERUM	O
LEVEL	O
SHOULD	O
BE	O
OBTAINED	O
.	O

SUBSEQUENT	O
TO	O
INITIATION	O
OF	O
DISULFIRAM	O
THERAPY	O
.	O

SERUM	O
LEVELS	O
OF	O
PHENYTOIN	B-drug
SHOULD	O
BE	O
DETERMINED	O
ON	O
DIFFERENT	O
DAYS	O
FOR	O
EVIDENCE	O
OF	O
AN	O
INCREASE	O
OR	O
FOR	O
A	O
CONTINUING	O
RISE	O
IN	O
LEVELS	O
.	O

INCREASED	O
PHENYTOIN	O
LEVELS	O
SHOULD	O
BE	O
TREATED	O
WITH	O
APPROPRIATE	O
DOSAGE	O
ADJUSTMENT	O
.	O

It	O
may	O
be	O
necessary	O
to	O
adjust	O
the	O
dosage	O
of	O
oral	B-drug
anticoagulants	I-drug
upon	O
beginning	O
or	O
stopping	O
disulfiram	B-drug
.	O
since	O
disulfiram	B-drug
may	O
prolong	O
prothrombin	O
time	O
.	O

Patients	O
taking	O
isoniazid	B-drug
when	O
disulfiram	B-drug
is	O
given	O
should	O
be	O
observed	O
for	O
the	O
appearance	O
of	O
unsteady	O
gait	O
or	O
marked	O
changes	O
in	O
mental	O
status	O
;	O

the	O
disulfiram	B-drug
should	O
be	O
discontinued	O
if	O
such	O
signs	O
appear	O
.	O

In	O
rats	O
,	O
simultaneous	O
ingestion	O
of	O
disulfiram	B-drug
and	O
nitrite	B-drug
in	O
the	O
diet	O
for	O
78	O
weeks	O
has	O
been	O
reported	O
to	O
cause	O
tumors	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
disulfiram	B-drug
may	O
react	O
with	O
nitrites	B-drug
in	O
the	O
rat	O
stomach	O
to	O
form	O
a	O
nitrosamine	O
,	O
which	O
is	O
tumorigenic	O
.	O

Disulfiram	B-drug
alone	O
in	O
the	O
rat?s	O
diet	O
did	O
not	O
lead	O
to	O
such	O
tumors	O
.	O

The	O
relevance	O
of	O
this	O
finding	O
to	O
humans	O
is	O
not	O
known	O
at	O
this	O
time	O
.	O

In	O
a	O
Phase	O
I	O
trial	O
using	O
escalating	O
doses	O
of	O
TAXOL	B-drug
(	O
110	O
-	O
200	O
mg	O
/	O
m2	O
)	O
and	O
cisplatin	B-drug
(	O
50	O
or	O
75	O
mg	O
/	O
m2	O
)	O
given	O
as	O
sequential	O
infusions	O
,	O
myelosuppression	O
was	O
more	O
profound	O
when	O
TAXOL	B-drug
was	O
given	O
after	O
cisplatin	B-drug
than	O
with	O
the	O
alternate	O
sequence	O
(	O
ie	O
,	O
TAXOL	B-drug
before	O
cisplatin	B-drug
)	O
.	O

Pharmacokinetic	O
data	O
from	O
these	O
patients	O
demonstrated	O
a	O
decrease	O
in	O
paclitaxel	B-drug
clearance	O
of	O
approximately	O
33	O
%	O
when	O
TAXOL	B-drug
was	O
administered	O
following	O
cisplatin	B-drug
.	O

The	O
metabolism	O
of	O
TAXOL	B-drug
is	O
catalyzed	O
by	O
cytochrome	B-drug
P450	I-drug
isoen	O
-	O
zymes	O
CYP2C8	O
and	O
CYP3A4	B-drug
.	O

In	O
the	O
absence	O
of	O
formal	O
clinical	O
drug	O
interaction	O
studies	O
,	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	B-drug
concomitantly	O
with	O
known	O
substrates	O
or	O
inhibitors	O
of	O
the	O
cytochrome	B-drug
P450	I-drug
isoenzymes	O
CYP2C8	O
and	O
CYP3A4	B-drug
.	O

Potential	O
interactions	O
between	O
TAXOL	B-drug
,	O
a	O
substrate	O
of	O
CYP3A4	B-drug
,	O
and	O
protease	B-drug
inhibitors	I-drug
(	O
ritonavir	B-drug
,	O
saquinavir	B-drug
,	O
indinavir	B-drug
,	O
and	O
nelfinavir	B-drug
)	O
,	O
which	O
are	O
substrates	O
and/or	O
inhibitors	O
of	O
CYP3A4	B-drug
,	O
have	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Reports	O
in	O
the	O
literature	O
suggest	O
that	O
plasma	O
levels	O
of	O
doxorubicin	B-drug
(	O
and	O
its	O
active	B-drug
metabolite	I-drug
doxorubicinol	O
)	O
may	O
be	O
increased	O
when	O
paclitaxel	B-drug
and	O
doxorubicin	B-drug
are	O
used	O
in	O
combination	O
.	O

Hematology	O
:	O
TAXOL	B-drug
therapy	O
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
baseline	O
neutrophil	O
counts	O
of	O
less	O
than	O
1,500	O
cells	O
/	O
mm3	O
.	O

In	O
order	O
to	O
monitor	O
the	O
occurrence	O
of	O
myelotoxicity	O
,	O
it	O
is	O
recommended	O
that	O
frequent	O
peripheral	O
blood	O
cell	O
counts	O
be	O
performed	O
on	O
all	O
patients	O
receiving	O
TAXOL	B-drug
.	O

Patients	O
should	O
not	O
be	O
re	O
-	O
treated	O
with	O
subsequent	O
cycles	O
of	O
TAXOL	B-drug
until	O
neutrophils	O
recover	O
to	O
a	O
level	O
 	O
1500	O
cells	O
/	O
mm3	O
and	O
platelets	O
recover	O
to	O
a	O
level	O
 	O
100,000	O
cells	O
/	O
mm3	O
.	O

In	O
the	O
case	O
of	O
severe	O
neutropenia	O
(	O
500	O
cells	O
/	O
mm3	O
for	O
seven	O
days	O
or	O
more	O
)	O
during	O
a	O
course	O
of	O
TAXOL	B-drug
therapy	O
,	O
a	O
20	O
%	O
reduction	O
in	O
dose	O
for	O
subsequent	O
courses	O
of	O
therapy	O
is	O
recommended	O
.	O

For	O
patients	O
with	O
advanced	O
HIV	B-drug
disease	O
and	O
poor	O
-	O
risk	O
AIDS	O
-	O
related	O
Kaposi?s	O
sarcoma	O
,	O
TAXOL	B-drug
,	O
at	O
the	O
recommended	O
dose	O
for	O
this	O
disease	O
,	O
can	O
be	O
initiated	O
and	O
repeated	O
if	O
the	O
neutrophil	O
count	O
is	O
at	O
least	O
1000	O
cells	O
/	O
mm3	O
.	O

Hypersensitivity	O
Reactions	O
:	O
Patients	O
with	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
products	O
containing	O
Cremophor	O
?	O
EL	O
(	O
eg	O
,	O
cyclosporin	B-drug
for	O
injection	O
concentrate	O
and	O
teniposide	B-drug
for	O
injection	O
concentrate	O
)	O
should	O
not	O
be	O
treated	O
with	O
TAXOL	B-drug
.	O

In	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
severe	O
hypersensitivity	O
reactions	O
,	O
all	O
patients	O
treated	O
with	O
TAXOL	B-drug
should	O
be	O
premedicated	O
with	O
corticosteroids	B-drug
(	O
such	O
as	O
dexamethasone	B-drug
)	O
,	O
diphen	B-drug
-	O
hydramine	O
and	O
H2	O
antagonists	O
(	O
such	O
as	O
cimetidine	B-drug
or	O
ranitidine	B-drug
)	O
.	O

Minor	O
symptoms	O
such	O
as	O
flushing	O
,	O
skin	O
reactions	O
,	O
dyspnea	O
,	O
hypotension	O
,	O
or	O
tachycardia	O
do	O
not	O
require	O
interruption	O
of	O
therapy	O
.	O

However	O
,	O
severe	O
reactions	O
,	O
such	O
as	O
hypotension	O
requiring	O
treatment	O
,	O
dyspnea	O
requiring	O
bronchodilators	B-drug
,	O
angioedema	O
,	O
or	O
generalized	O
urticaria	O
require	O
immediate	O
discontinuation	O
of	O
TAXOL	B-drug
and	O
aggressive	O
symptomatic	O
therapy	O
.	O

Patients	O
who	O
have	O
developed	O
severe	O
hypersensitivity	O
reactions	O
should	O
not	O
be	O
rechallenged	O
with	O
TAXOL	B-drug
.	O

Cardiovascular	O
:	O
Hypotension	O
,	O
bradycardia	O
,	O
and	O
hypertension	O
have	O
been	O
observed	O
during	O
administration	O
of	O
TAXOL	B-drug
,	O
but	O
generally	O
do	O
not	O
require	O
treatment	O
.	O

Occasionally	O
TAXOL	B-drug
infusions	O
must	O
be	O
interrupted	O
or	O
discontinued	O
because	O
of	O
initial	O
or	O
recurrent	O
hypertension	O
.	O

Frequent	O
vital	O
sign	O
monitoring	O
,	O
particularly	O
during	O
the	O
first	O
hour	O
of	O
TAXOL	B-drug
infusion	O
,	O
is	O
recommended	O
.	O

Continuous	O
cardiac	O
monitoring	O
is	O
not	O
required	O
except	O
for	O
patients	O
with	O
serious	O
conduction	O
abnormalities	O
.	O

Nervous	O
System	O
:	O
Although	O
the	O
occurrence	O
of	O
peripheral	O
neuropathy	O
is	O
frequent	O
,	O
the	O
development	O
of	O
severe	O
symptomatology	O
is	O
unusual	O
and	O
requires	O
a	O
dose	O
reduction	O
of	O
20	O
%	O
for	O
all	O
subsequentcourses	O
of	O
TAXOL	B-drug
.	O

TAXOL	B-drug
contains	O
dehydrated	B-drug
alcohol	I-drug
USP	I-drug
,	I-drug
396	O
mg	O
/	O
mL	O
;	O

consideration	O
should	O
be	O
given	O
to	O
possible	O
CNS	O
and	O
other	O
effects	O
of	O
alcohol	B-drug
.	O

Hepatic	O
:	O
There	O
is	O
limited	O
evidence	O
that	O
the	O
myelotoxicity	O
of	O
TAXOL	B-drug
may	O
be	O
exacerbated	O
in	O
patients	O
with	O
serum	O
total	O
bilirubin	O
 	O
2	O
times	O
ULN	O
.	O

Extreme	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
TAXOL	B-drug
to	O
such	O
patients	O
,	O
with	O
dose	O
reduction	O
as	O
recommended	O
in	O
DOSAGE	O
AND	O
ADMINISTRATION	O
,	O
Table	O
17	O
.	O

InjectionSite	O
Reaction	O
:	O
Injection	O
site	O
reactions	O
,	O
including	O
reactions	O
secondary	O
to	O
extravasation	O
,	O
were	O
usually	O
mild	O
and	O
consisted	O
of	O
erythema	O
,	O
tenderness	O
,	O
skin	O
discoloration	O
,	O
or	O
swelling	O
at	O
the	O
injection	O
site	O
.	O

These	O
reactions	O
have	O
been	O
observed	O
more	O
frequently	O
with	O
the	O
24-hour	O
infusion	O
than	O
with	O
the	O
3-hour	O
infusion	O
.	O

Recurrence	O
of	O
skin	O
reactions	O
at	O
a	O
site	O
of	O
previous	O
extravasation	O
following	O
administration	O
of	O
TAXOL	B-drug
at	O
a	O
different	O
site	O
,	O
ie	O
,	O
recall	O
,	O
has	O
been	O
reported	O
rarely	O
.	O

Rare	O
reports	O
of	O
more	O
severe	O
events	O
such	O
as	O
phlebitis	O
,	O
cellulitis	O
,	O
induration	O
,	O
skin	O
exfoliation	O
,	O
necrosis	O
,	O
and	O
fibrosis	O
have	O
been	O
received	O
as	O
part	O
of	O
the	O
continuing	O
surveillance	O
of	O
TAXOL	B-drug
safety	O
.	O

In	O
some	O
cases	O
the	O
onset	O
of	O
the	O
injection	O
site	O
reaction	O
either	O
occurred	O
during	O
a	O
prolonged	O
infusion	O
or	O
was	O
delayed	O
by	O
a	O
week	O
to	O
ten	O
days	O
.	O

A	O
specific	O
treatment	O
for	O
extravasation	O
reactions	O
is	O
unknown	O
at	O
this	O
time	O
.	O

Given	O
the	O
possibility	O
of	O
extravasation	O
,	O
it	O
is	O
advisable	O
to	O
closely	O
monitor	O
the	O
infusion	O
site	O
for	O
possible	O
infiltration	O
during	O
drug	O
administration	O
.	O

When	O
given	O
concurrently	O
the	O
following	O
drugs	B-drug
may	O
interact	O
with	O
thiazide	B-drug
diuretics	I-drug
.	O

-	O
Alcohol	B-drug
,	O
barbiturates	B-drug
,	O
or	O
narcotics	B-drug
:	O
Potentiation	O
of	O
otthostatic	O
hypotension	O
may	O
occur	O

.	O

-	O
Antidiabetic	B-drug
drugs	I-drug
:	O
(	O
Oral	O
agents	O
and	O
insulin	B-drug
)	O
Dosage	O
adjustment	O
of	O
the	O
antidiabetic	B-drug
drug	I-drug
may	O
be	O
required	O

.	O

-	O
Other	O
antihypertensive	B-drug
drugs	I-drug
:	O
Additive	O
effect	O
or	O
potentiation	O

.	O

-	O
Cholestyramine	B-drug
and	O
colestipol	B-drug
resins	O
:	O
Cholestytamine	O
and	O
colestipol	B-drug
resins	O
have	O
the	O
potential	O
of	O
binding	O
thiazide	B-drug
diuretics	I-drug
and	O
reducing	O
diuretic	B-drug
absorption	O
from	O
the	O
gastrointestinal	O
tract	O

.	O

-	O
Corticosteroids	B-drug
,	O
ACTH	B-drug
:	O
Intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O

.	O

-	O
Pressor	B-drug
amines	I-drug
(	O
e.g.	O
,	O
norepinephrine	B-drug
)	O
:	O
Possible	O
decreased	O
response	O
to	O
pressor	B-drug
amines	I-drug
but	O
not	O
sufficient	O
to	O
preclude	O
their	O
use	O

.	O

-	O
Skeletal	B-drug
muscle	I-drug
relaxants	I-drug
,	O
nondepolarizing	O
(	O
e.g.	O
,	O
tubocurarine	B-drug
)	O
:	O
Possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B-drug
relaxant	I-drug

.	O

-	O
Lithium	B-drug
:	O
Generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B-drug
.	O

Diuretic	B-drug
agents	O
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-drug
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	O
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B-drug
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
chlorothiazide	B-drug

.	O

-	O
Non	B-drug
-	I-drug
steroidal	I-drug
Anti	I-drug
-	I-drug
inflammatory	I-drug
Drugs	I-drug
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	B-drug
-	I-drug
steroidal	I-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
agent	I-drug
can	O
reduce	O
the	O
diuretic	B-drug
,	O
natriuretic	O
,	O
and	O
antihypertensive	B-drug
effects	O
of	O
loop	O
,	O
potassium	B-drug
-	O
sparing	O
and	O
thiazide	B-drug
diuretics	I-drug
.	O

Therefore	O
,	O
when	O
chlorothiazide	B-drug
and	O
non	B-drug
-	I-drug
steroidal	I-drug
anti	I-drug
-	I-drug
inflammatory	I-drug
agents	I-drug
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B-drug
is	O
obtained	O

.	O

-	O
Drug	B-drug
/	O
Laboratory	O
Test	O
Interactions	O
:	O
Thiazides	B-drug
should	O
be	O
discontinued	O
before	O
carrying	O
out	O
tests	O
for	O
parathyroid	B-drug
function	O
.	O

A	O
30	O
to	O
45	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
of	O
nisoldipine	B-drug
was	O
observed	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B-drug
400	I-drug
mg	I-drug
twice	O
daily	O
.	O

Ranitidine	B-drug
150	I-drug
mg	I-drug
twice	O
daily	O
did	O
not	O
interact	O
significantly	O
with	O
nisoldipine	B-drug
(	O
AUC	O
was	O
decreased	O
by	O
15	O
-	O
20	O
%	O
)	O
.	O

No	O
pharmacodynamic	O
effects	O
of	O
either	O
histamine	B-drug
H2	I-drug
receptor	I-drug
antagonist	I-drug
were	O
observed	O
.	O

Coadministration	O
of	O
phenytoin	B-drug
with	O
40	O
mg	O
SULAR	B-drug
tablets	O
in	O
epileptic	O
patients	O
lowered	O
the	O
nisoldipine	B-drug
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
SULAR	B-drug
with	O
phenytoin	B-drug
or	O
any	O
known	O
CYP3A4	B-drug
inducer	O
should	O
be	O
avoided	O
and	O
alternative	O
antihypertensive	B-drug
therapy	O
should	O
be	O
considered	O
.	O

Pharmacokinetic	O
interactions	O
between	O
nisoldipine	B-drug
and	O
beta	B-drug
-	I-drug
blockers	I-drug
(	O
atenolol	B-drug
,	O
propranolol	B-drug
)	O
were	O
variable	O
and	O
not	O
significant	O
.	O

Propranolol	B-drug
attenuated	O
the	O
heart	O
rate	O
increase	O
following	O
administration	O
of	O
immediate	O
release	O
nisoldipine	B-drug
.	O

The	O
blood	O
pressure	O
effect	O
of	O
SULAR	B-drug
tended	O
to	O
be	O
greater	O
in	O
patients	O
on	O
atenolol	B-drug
than	O
in	O
patients	O
on	O
no	O
other	O
antihypertensive	B-drug
therapy	O
.	O

Quinidine	B-drug
at	O
648	O
mg	O
bid	B-drug
decreased	O
the	O
bioavailability	O
(	O
AUC	O
)	O
of	O
nisoldipine	B-drug
by	O
26	O
%	O
,	O
but	O
not	O
the	O
peak	O
concentration	O
.	O

The	O
immediate	O
release	O
,	O
but	O
not	O
the	O
coat	O
-	O
core	O
formulation	O
of	O
nisoldipine	B-drug
increased	O
plasma	O
quinidine	O
concentrations	O
by	O
about	O
20	O
%	O
.	O

This	O
interaction	O
was	O
not	O
accompanied	O
by	O
ECG	O
changes	O
and	O
its	O
clinical	O
significance	O
is	O
not	O
known	O
.	O

No	O
significant	O
interactions	O
were	O
found	O
between	O
nisoldipine	B-drug
and	O
warfarin	B-drug
or	O
digoxin	B-drug
.	O

The	O
pharmacokinetic	O
interactions	O
listed	O
below	O
are	O
potentially	O
clinically	O
important	O
.	O

Drugs	B-drug
that	O
induce	O
hepatic	O
enzymes	O
such	O
as	O
phenobarbital	B-drug
,	O
phenytoin	B-drug
and	O
rifampin	B-drug
may	O
increase	O
the	O
clearance	O
of	O
corticosteroids	B-drug
and	O
may	O
require	O
increases	O
in	O
corticosteroid	B-drug
dose	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Drugs	B-drug
such	O
as	O
troleandomycin	B-drug
and	O
ketoconazole	B-drug
may	O
inhibit	O
the	O
metabolism	O
of	O
corticosteroids	B-drug
and	O
thus	O
decrease	O
their	O
clearance	O
.	O

Therefore	O
,	O
the	O
dose	O
of	O
corticosteroid	B-drug
should	O
be	O
titrated	O
to	O
avoid	O
steroid	O
toxicity	O
.	O

Corticosteroids	B-drug
may	O
increase	O
the	O
clearance	O
of	O
chronic	O
high	O
dose	O
aspirin	B-drug
.	O

This	O
could	O
lead	O
to	O
decreased	O
salicylate	O
serum	O
levels	O
or	O
increase	O
the	O
risk	O
of	O
salicylate	O
toxicity	O
when	O
corticosteroid	B-drug
is	O
withdrawn	O
.	O

Aspirin	B-drug
should	O
be	O
used	O
cautiously	O
in	O
conjunction	O
with	O
cortico	B-drug
-	I-drug
steroids	I-drug
in	O
patients	O
suffering	O
from	O
hypopro	O
-	O
thrombinemia	O
.	O

The	O
effect	O
of	O
corticosteroids	B-drug
on	O
oral	B-drug
anticoagulants	I-drug
is	O
variable	O
.	O

There	O
are	O
reports	O
of	O
enhanced	O
as	O
well	O
as	O
diminished	O
effects	O
of	O
anticoagulants	B-drug
when	O
given	O
concurrently	O
with	O
corticosteroids	B-drug
.	O

Therefore	O
,	O
coagulation	O
indices	O
should	O
be	O
monitored	O
to	O
maintain	O
the	O
desired	O
anticoagulant	O
effect	O
.	O

The	O
interaction	O
of	O
Activase	B-drug
with	O
other	O
cardioactive	O
or	O
cerebroactive	O
drugs	B-drug
has	O
not	O
been	O
studied	O
.	O

In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	B-drug
and	O
vitamin	O
K	O
antagonists	O
,	O
drugs	B-drug
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B-drug
acid	I-drug
,	O
dipyridamole	B-drug
and	O
Abciximab	B-drug
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
Activase	B-drug
therapy	O
.	O

Use	O
of	O
Antithrombotics	O
Aspirin	B-drug
and	O
heparin	B-drug
have	O
been	O
administered	O
concomitantly	O
with	O
and	O
following	O
infusions	O
of	O
Activase	B-drug
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
or	O
pulmonary	O
embolism	O
.	O

Because	O
heparin	B-drug
,	O
aspirin	B-drug
,	O
or	O
Activase	B-drug
may	O
cause	O
bleeding	O
complications	O
,	O
careful	O
monitoring	O
for	O
bleeding	O
is	O
advised	O
,	O
especially	O
at	O
arterial	O
puncture	O
sites	O
.	O

The	O
concomitant	O
use	O
of	O
heparin	B-drug
or	O
aspirin	B-drug
during	O
the	O
first	O
24	O
hours	O
following	O
symptom	O
onset	O
were	O
prohibited	O
in	O
The	O
NINDS	O
t	O
-	O
PA	O
Stroke	O
Trial	O
.	O

The	O
safety	O
of	O
such	O
concomitant	O
use	O
with	O
Activase	B-drug
for	O
the	O
management	O
of	O
acute	O
ischemic	O
stroke	O
is	O
unknown	O
.	O

